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Abstract 
Introduction 
The global burden of chronic kidney disease (CKD) is significant, and largely fuelled by the 
epidemics of diabetes and hypertension. CKD is a major risk factor for end-stage kidney 
disease (ESKD), cardiovascular disease (CVD) and premature death. In Australia, data on the 
prevalence of CKD are limited, and the best available evidence to estimate the CKD burden is 
drawn from renal replacement therapy (RRT) data. At the end of 2015, the number of patients 
receiving RRT was 968 per million population and continuing to rise. Evidence suggests 
that progression and adverse outcomes of CKD can be prevented or delayed by detecting and 
treating the disease in its initial stages. Unfortunately, CKD is asymptomatic until the kidney 
function declines by up to 90%; this makes it essential to detect the disease early. Hence, many 
clinical practice guidelines recommend that individuals with risk factors should be screened 
for CKD. In light of this evidence, globally, several targeted screening programs have been 
implemented in various community settings. However, the overall success of these programs 
is uncertain. Therefore, the aim of Project I was to conduct a systematic review of the literature 
to determine whether targeted screening programs are effective in identification of early stages 
of CKD. 
 Despite advancements in the early detection and prevention of CKD, availability of clinical 
practice guidelines, and development of risk stratification tools, 17% of new patients were 
referred late to nephrologists for the management of ESKD in Australia. Pharmacists are highly 
accessible and in a good position to engage people within the community who are not aware 
of their risks and less likely to access general practice care. Thus, a pharmacist-initiated CKD 
risk assessment service could help to identify at-risk patients and refer them to general 
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practitioners (GP) for further evaluation and management. Therefore, the aim of Project II was 
to implement and evaluate a CKD risk assessment service in community pharmacies.  
 Public awareness of CKD is an important determinant of the uptake of screening programs, 
which may help to address the CKD burden. However, there is a lack of understanding amongst 
the Australian community about the preventability of major health conditions. Additionally, 
even amongst sub-group of Australian cohorts with the greatest risk of CKD, the knowledge 
of CKD risk factors and the recall of kidney function testing were found to be limited. Hence, 
a final Project III to determine the Australian public knowledge about CKD was conducted. 
Aim of the thesis 
The overall aim of this thesis was to identify and implement strategies that could help to 
improve the early detection and management of CKD in Australia. 
Methods 
Project I 
All observational studies of targeted screening programs implemented in any community-based 
setting were systematically identified and analysed. The main outcome measures were the 
percentage of participants with positive screening results and diagnosed with CKD at follow-
up, and screening tests used to detect evidence of CKD.  
Project II 
A prospective cohort study in 24 Tasmanian community pharmacies was conducted. Prior to 
implementation, community pharmacists were trained to perform the CKD risk assessment 
service. Pharmacists were required to identify people with CKD risk factors and recruit them 
for risk assessment. The QKidney® risk calculator was used to estimates the eligible 
participants’ five-year percentage risk of developing moderate-severe CKD. Participants 
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identified with ≥ 3% risk were referred to their GP and followed-up after nine months. Next, 
laboratory data were collected from the pathology provider. The main outcome measures were 
rates of GP referral uptake and of participants who underwent estimated glomerular filtration 
rate (eGFR) and urine albumin creatinine ratio (ACR) measurement. Community pharmacists’ 
qualitative interviews were conducted, post-intervention, to explore the challenges faced by 
them during the implementation of the CKD service. Lastly, patient satisfaction with the CKD 
service was evaluated using a nine-item satisfaction survey which also included an additional 
question on willingness to pay. 
Project III 
A 24-item CKD knowledge questionnaire was developed, validated and used to conduct an 
online cross-sectional survey of the Australian public. Participants could achieve a maximum 
score of 24 on the questionnaire. Next, a standard multiple regression analysis was performed 
to identify predictors of the public knowledge of CKD. 
Results and discussion 
Project I 
Out of nine studies included in the systematic review analysis, eight reported the percentage of 
participants with positive screening test results, which ranged from 7% to 60.3%. The 
percentage of participants diagnosed with CKD at follow-up was reported by only two studies, 
which was 17.1% and 20.5%. The most commonly used screening tests were ACR (≥ 3.4 
mg/mmol) and eGFR (< 60 mL/min/1.73m2).  
 Our analysis showed that although a considerable percentage of participants are being 
identified with positive screening test results, follow-up diagnostic tests for these participants 
was either not reported or performed by many studies. In general, this review indicated that 
screening programs should appropriately use the clinical guidelines in order to detect CKD. 
Early detection and prevention of CKD 
15 
These steps are vital to determine the actual effectiveness of targeted screening and prevent 
over-diagnosis. 
Project II 
A total of 389 participants were recruited by the pharmacies, 203 (52.1%) of whom had ≥ 3% 
five-year risk of developing moderate-severe CKD and were referred to their GP. Follow-up 
was successful for 126 participants and showed low (27%) GP referral uptake. Analysis of the 
pathology data revealed suboptimal kidney testing in participants with ≥ 3% risk, with eGFR 
and ACR tests performed for only 52.7% and 25.1% of these participants, respectively. Thus, 
although the in-pharmacy CKD risk assessment service, with its targeting, identified a high 
proportion of people at ≥ 3% risk of developing moderate-severe CKD within five years, the 
low GP referral uptake was a major hindrance to the efficacy of the service.  
 The qualitative analysis showed that pharmacists found the CKD service to be efficient, 
user-friendly and of significant benefit to their customers. However, several pharmacists 
observed that customers lacked interest in disease prevention, and had limited understanding 
of CKD. More importantly, pharmacists perceived the scope of pharmacy practice to be 
significantly dependent on the inter-professional collaboration between pharmacists and 
general practitioners (GPs), and customers’ acknowledgement of the role of pharmacists in 
disease prevention.  
 Responses to the satisfaction survey (n = 143) revealed that the majority of the participants 
agreed that the time required to undergo the risk assessment process was justified (90.2%), 
overall they were satisfied with the CKD risk assessment service (90.0%), and they felt 
comfortable with the pharmacist referring their results to their doctor (88.9%). Of 136 
participants who answered the question on willingness to pay, 62.9% indicated that they would 
pay for the CKD service. 
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Project III 
A total of 934 participants (Australian public ≥ 18 years) provided complete responses to the 
CKD knowledge questionnaire. The mean (SD) knowledge score of the Australian public was 
10.3 (± 5.0) out of 24. In the multivariate analysis, the statistically significant predictors of the 
knowledge score were level of education, marital status (lower scores in those who were 
single/never married), a family history of kidney failure and a personal history of diabetes. The 
results of this survey showed that the Australian public knowledge of CKD was relatively poor. 
Conclusion 
Overall, the projects described in this thesis identified some effective strategies which could 
help to improve the early detection and management of CKD, and consequently, reduce its 
burden in Australia. Primarily, it was established that any targeted CKD screening program 
must adhere to the clinical practice guidelines on early CKD detection, prevention and 
management. Next, it was determined there is a significant scope for improving the public 
awareness of CKD and its early detection via implementation of a community pharmacy-based 
CKD risk assessment service. However, there is a need to explore effective strategies which 
would help to improve the inter-professional collaboration between community pharmacists 
and GPs. Additionally, integrating the CKD service with other pharmacy services, such as 
medication review, and providing verbal education to participants during risk assessment may 
help to improve its feasibility. Lastly, it was ascertained that there is a need to improve the 
public understanding of kidneys and knowledge on CKD through nationwide awareness 
programs. 
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General Introduction 
Epidemiology of chronic kidney disease 
The global health burden of chronic kidney disease (CKD) is significant.1 As per the 2013 
‘Global Burden of Disease Study’, between 2005 and 2013, the global age-standardised 
mortality rate for CKD increased by approximately 37%, over that period, making it one of the 
five main causes of reduced life expectancy worldwide.2 Based on the 2013 ‘Australian Health 
Survey: Biomedical results for Chronic Diseases’ data, approximately 1 in 10 adults (≥ 18 years) 
in Australia have clinical evidence of CKD such as reduced kidney function and/or 
albuminuria.3 Interestingly, less than 10% are aware that they have this condition.3 
CKD is defined as damage to the kidney or decline in the kidney function present for ≥ 3 
months.4, 5 The decline in the kidney function is indicated by a reduction in the estimated 
glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. The structural damage to the 
kidneys is indicated by excessive amounts of protein (mainly albumin) in the urine, and CKD 
is diagnosed when the urine albumin creatinine ratio (ACR) is > 2.5 mg/mmol for males and > 
3.5 mg/mmol for females.5 CKD is classified into 5 stages by combining both eGFR and 
albuminuria categories, irrespective of the underlying cause (Table A).4, 6  
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Table A. Chronic kidney disease classification by eGFR and albuminuria categories4, 5 
Albuminuria categories (urine ACR mg/mmol) 
Normal Microalbuminuria Macroalbuminuria 
Male: < 2.5 
Female: < 3.5 
Male: 2.5-25 
Female: 3.5-35 
Male: > 25 
Female: > 35 
eG
FR
 c
at
eg
or
ie
s 
(m
L/
m
in
/1
.7
3m
2 ) Stage 1 ≥90 
Stage 2 60-89
Stage 3a 45-59
Stage 3b 30-44
Stage 4 15-29
Stage 5 <15 
eGFR estimated glomerular filtration rate; ACR albumin creatinine ratio 
Green – Low risk (if no other markers of kidney disease, no CKD); Yellow – Moderately increased risk; 
Orange – High risk; Red – Very high risk. 
CKD causes a huge economic burden on the healthcare system and is associated with 
significant morbidity and mortality.7, 8 It is a major risk factor for end-stage kidney disease 
(ESKD) or stage 5 CKD, cardiovascular disease (CVD) and premature death.9 Advanced stages 
(4-5) of CKD can cause several health complications such as sodium retention, volume 
overload, hyperkalaemia, metabolic acidosis, hypertension, CKD-related mineral and bone 
disorder (CKD-MBD) and anaemia (Figure A).5, 10  
CKD is generally asymptomatic in nature until the kidney function declines by up to 90%.5, 
11 Therefore, patients with CKD may not notice any symptoms until they reach ESKD. General 
symptoms of ESKD include: lethargy, nocturia, anorexia, nausea, vomiting, malaise, pruritus, 
restless legs, and dyspnoea.10, 12 
Early detection and prevention of CKD 
26 
Figure A. Complications associated with chronic kidney disease. 
CKD chronic kidney disease NSAIDS Non-steroidal anti-inflammatory drugs ESA Erythropoietin stimulating agents.
CKD         
 Complications 
Treatment and  
Management 
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People with CKD require extensive hospital services, particularly those individuals with 
ESKD who need regular renal replacement therapies (RRT), such as dialysis or transplantation, 
for survival.13 Additionally, in patients with stage 4 CKD, death prior to RRT is more than 
twice as likely as progression to ESKD.14  
In Australia, kidney disease contributes towards approximately 15% of all hospitalisations. 
As per the Australian Institute of Health and Welfare, the number of new patients commencing 
RRT has more than doubled between 1991-2010, and Australia has already spent over $760 
million on RRT.13 Moreover, the estimated costs to the Australian government for treating 
ESKD, between 2009-2020, is between approximately $11.3 billion and $12 billion AUD.15  
The prevalence of CKD increases disproportionately in older people because of the age-
related decline in the GFR of an average 8 mL/min/1.73m2 per decade, after the age of 30 
years.16 Additionally, the increase in CKD prevalence is fuelled by the rising rates of diabetes 
and hypertension, which are its principal risk factors.1, 17 Of high concern is the analysis from 
a recent systematic review which reported that the prevalence of estimated impaired kidney 
function (particularly eGFR 30-59 mL/min/1.73m2) in the adult general population was 
common and similar to that of diabetes mellitus.18 In Australia, the primary causes of ESKD 
are diabetes (36%), glomerulonephritis (23%) and hypertension (14%). Also, the mean age of 
new patients commencing RRT, in 2014, was 57.7 and 60.9 years, for female and male, 
respectively.  
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Early detection and prevention of CKD 
The risks of CKD progression and CVD can be reduced by up to 50% if CKD is detected in its 
initial stages (1-3), and appropriate management strategies are implemented.5, 6 These strategies 
include better management of comorbidities such as hypertension and diabetes, and 
discontinuation of medications that are nephrotoxic or considered problematic in renal 
impairment.19-22 Previous studies23-27 have reported medication errors in CKD patients ranging 
from 23.5 to 69.6% in inpatients, long-term care and ambulatory settings, and that the majority 
of these problems are preventable if such medications are avoided or dosages appropriately 
adjusted in this population.  
Patients with impaired kidney function are at an increased risk of adverse drug events 
(ADE).28 ADE in turn may increase the risk of poor outcomes in patients with CKD, including 
accelerated kidney function loss, and increase the frequency or length of hospitalisation and 
death.28 A recent study reported that >10% of community dwelling older people used drugs 
that required dose adjustment in renal impairment and this exposure was independently 
associated with a 40% increased mortality in people with impaired kidney function.29  
 Thus, clinical practice guidelines such as the ‘Kidney Health Australia’s – Caring for 
Australasians with Renal Impairment’ (KHA-CARI) guideline on ‘Early CKD: Detection, 
prevention and management’, and ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) 
guideline for the ‘Evaluation and Management of Chronic Kidney Disease’ were developed.4, 
6 The KHA-CARI guideline6 recommends screening of people with established CKD risk 
factors as an effective strategy to reduce the increasing CKD burden in Australia.  
As per the KHA-CARI guideline,6 testing for CKD is recommended in individuals aged ≥ 
60 years, with the following risk factors: 
• Smoker,  
• Diabetes,  
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• Hypertension,
• Obesity,
• Established CVD (includes previous diagnosis of coronary heart disease,
cerebrovascular disease or peripheral vascular disease), and
• Family history of CKD.
A ‘Kidney Health Check’, which includes urine ACR, eGFR, and blood pressure 
measurement, is indicated every 12 months in these individuals. Also, repeated testing is 
indicated in individuals with initial abnormal eGFR and urine ACR test results over several 
weeks to confirm the CKD diagnosis. Figure B shows the algorithm recommended by KHA-
CARI for the initial detection of CKD.  
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Figure B. Algorithm for initial detection of chronic kidney disease5 
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Despite these advancements, the disease still remains underdiagnosed worldwide; and in 
Australia, the data on its prevalence and determinants is extrapolated merely from records of 
patients commencing RRT.11, 30 Individuals with stage 1-4 of CKD may not be identified 
because of a failure to use laboratory measurements of renal function in high-risk patients and 
the asymptomatic nature of early CKD.28 Although the implementation of automated GFR 
reporting, when a serum creatinine level is requested, has helped to identify CKD early, studies 
have reported that practitioners may not take appropriate action or tailor their care in patients 
with impaired kidney function.31-33According to the KHA’s CKD management in general 
practice recommendations, referral to a nephrologist is indicated when the eGFR is < 30 
mL/min/1.73m2, the persistent urine ACR is ≥ 30 mg/mmol or there is a consistent decline in 
eGFR from a baseline of < 60 mL/min/1.73m2.5 However, at the end of 2014, approximately 
17% of new patients were referred late to nephrologists for the management of ESKD in 
Australia.17 In addition, the median eGFR in new patients commencing RRT was low at 7.4 
mL/min/1.73m2.  
CKD among Australian older adults within primary care settings is common, and drastically 
under-recognised and under-treated.12 The AusHEART study which aimed to determine the 
prevalence of CKD in the Australian primary care settings showed that out of 37% patients 
with abnormal kidney function, < 18% were appropriately identified with CKD.12 Similarly, a 
retrospective study found that despite the increasing prevalence of CKD in the state of 
Tasmania, Australia, testing for kidney disease (i.e. serum creatinine and albuminuria) in at-
risk people was suboptimal.34  
All the above evidence indicates significant practice gaps and the need to improve early 
CKD detection in Australia. Thus, the Electronic Diagnosis and Management Assistance to 
Primary Care in Chronic Kidney Disease (eMAP:CKD) program was developed and 
implemented within 22 primary care settings located in the north west Melbourne, in the state 
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of Victoria, Australia.35 The aim of the eMAP:CKD program was to identify patients at risk of 
CKD and provide guidance to general practitioners (GPs) for appropriate further testing, 
diagnosis and management. This study showed a significant improvement in urine ACR testing 
and CKD documentation after 15 months of program implementation; however, this study did 
not perform repeated testing in at-risk patients to confirm the CKD diagnosis. Hence, effective 
alert strategies to identify patients at risk, and promote collaboration between health care 
practitioners to improve outcomes especially in individuals at risk for continuous kidney 
function loss are essential. Collaboration with community pharmacists has been identified as 
an essential step in improving patient safety in CKD.28 
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Community pharmacists’ role in health promotion and disease prevention 
Although it has been established that targeted screening can help to reduce the burden of CKD,6 
currently, screening for CKD is not practised in Australia.11 Only one Australian screening 
program performed in community settings suggested that implementation of targeted 
‘opportunistic’ screening within primary care settings might be a sustainable approach.36 
However, owing to the rise in the prevalence of several chronic diseases, most (GPs) give 
priority to interventions for management of patients with established chronic diseases.37-39 
Subsequently, the high patient workload makes it difficult for GPs to participate in 
interventions for health promotion and disease prevention.37-39 A recent qualitative study 
investigating the barriers and facilitators of CKD screening by general practice nurses showed 
that currently the decision to conduct screening was determined by GPs, who perceived the 
nurses’ time to be financially imperative.40 Lack of funding and inter-professional conflicts in 
the workplace were additionally identified as barriers to nurse initiated CKD screening. 
Community pharmacists’ role in the provision of screening services for various chronic 
diseases such as diabetes,41-43 CVD,44 osteoporosis45, 46 and atrial fibrillation47 has recently 
gained attention. Most of these studies indicated that pharmacists can make a noteworthy 
contribution in the early diagnosis and disease prevention strategies by conducting screening 
or risk assessment services. This is because community pharmacists are highly accessible 
healthcare professionals, and more likely to identify those people within the community who 
do not regularly access general practice care.48  
In France, a community pharmacist-initiated intervention in patients at risk of, or suffering 
from, CKD has been shown to identify and alert GPs of inappropriate prescribing of drugs 
which need dosage adjustment, or are contraindicated, in renal impairment.49 In this study, 
pharmacists underwent a four-hour course on general knowledge of CKD and prescription 
adjustment for renal impairment. Eligible patients’ serum creatinine value was measured with 
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the help of a medical biologist, and eGFR was also calculated. This study identified renal 
impairment (<60 mL/min/1.73m2) in 24.5% of its participants; however, repeated testing was 
not performed to confirm CKD diagnosis.  Another study determining the feasibility of point-
of-care creatinine testing in community pharmacy settings identified > 50% participants with 
mild (50-80 mL/min/1.73m2) to moderate (30-49 mL/min/1.73m2) CKD.50 In the western 
province of Canada, Alberta, the community pharmacists’ scope of practice has expanded, 
allowing them access to order and view patient laboratory data.51 These pharmacists applied 
the clinical guidelines for the screening and identification of CKD, and detected 39% 
participants with CKD, out of which 40% were previously undiagnosed cases of CKD. These 
findings indicate that pharmacist-initiated targeted CKD screening intervention could provide 
significant patient benefit and help to improve the early CKD detection. 
At present, community pharmacists in Australia do not have access to order or retrieve 
patient laboratory data. This might change with the increased uptake of the online health 
information recording system called ‘My Health Record’, initiated by the Australian 
government.52 ‘My Health Record’ allows patient details such as allergies, current conditions 
and treatments, medicine details, pathology reports or diagnostic imaging scan reports to be 
digitally stored in one place. Use of this recording system will allow greater patient information 
sharing amongst healthcare professionals in Australia. However, this system was developed 
recently and hence, it might take some time before its use becomes commonplace within 
routine practice and accepted by both consumers and health professionals.  
Currently, the lack of Australian community pharmacists’ access to laboratory data, 
prevents them from directly implementing the KHA-CARI clinical guidelines for early CKD 
detection and prevention. However, community pharmacists can still play an essential role by 
performing risk assessment and referring people at high risk of developing CKD to their GP 
for further diagnostic evaluation.  
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Risk assessment interventions for other diseases in community pharmacy settings have 
shown potential.42, 44, 53, 54 Similarly, implementation of a CKD risk assessment service in 
community pharmacy settings could also prove to be beneficial. In recent years, several risk 
stratification tools that can identify individuals at a higher risk for future CKD have been 
developed worldwide.55-60 One such tool recommended by the KHA is an online QKidney® 
risk calculator.55, 56, 58, 61 This calculator is a validated algorithm which estimates a person’s 
risk of developing moderate-severe CKD (eGFR < 45mL/min/1.73m2) over the next five years. 
Implementation of the QKidney® risk calculator within community pharmacy setting, and its 
evaluation will help to determine whether this would be an effective approach to identify 
undetected cases of early CKD within the community. These findings may possibly influence 
the public health policy for the primary prevention of CKD in Australia. 
Aim of thesis 
The research presented in this thesis covers three separate, but largely related, investigations. 
The overall aim of this thesis was to explore, implement and evaluate strategies which could 
help to improve the early detection and prevention of CKD in Australia. 
 
The three main projects were as follows: 
Project I Effectiveness of targeted screening programs for detection, prevention and 
management of CKD in community settings: A systematic review. 
Project II  
(A)  Impact of a web-based training program on pharmacists’ knowledge and skills 
associated with CKD risk assessment. 
(B) Evaluation of a CKD risk assessment service in community pharmacies. 
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(C) Community pharmacists’ experience of implementing a chronic kidney disease 
risk assessment service: A qualitative study 
(D) Patient satisfaction with a CKD risk assessment service in community 
pharmacies. 
Project III  Evaluation of the Australian public knowledge about CKD. 
 
Each project is presented as a separate chapter in the thesis. 
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PROJECT I 
CHAPTER 1. Effectiveness of Targeted Screening Programs for Detection, 
Prevention and Management of Early Chronic Kidney Disease in community-
settings: A Systematic Review 
1.1 Abstract 
1.1.1 Background 
Targeted screening interventions for chronic kidney disease (CKD) are increasingly being 
implemented in various community settings. However, the overall success of these programs 
is uncertain. Therefore, the aim of this review is to determine whether targeted screening is 
effective in detecting people with undiagnosed CKD.  
1.1.2 Methods 
Targeted screening program was defined as the implementation of test/s in patients with known 
risk factors for CKD. We performed a systematic literature review, and included observational 
studies of targeted screening programs implemented in any community-based setting. Studies 
were required to have targeted people aged ≥ 18 years, and multiple CKD risk factors from the 
following: diabetes, hypertension, cardiovascular disease and family history of kidney disease. 
The outcome measures were percentages of participants with positive screening test results and 
diagnosed with CKD at follow-up, and screening tests used to detect evidence of CKD 
including: proteinuria, albuminuria, urine albumin creatinine ratio (ACR), serum creatinine, 
creatinine clearance, or estimated glomerular filtration rate (eGFR) 
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1.1.3 Results 
Nine studies met the inclusion criteria. Eight studies reported the percentage of participants 
with positive screening test results, which ranged from 7% to 60.3%. The percentage of 
participants diagnosed with CKD at follow-up was reported by 2 studies, which was 17.1% 
and 20.5%. The most commonly used screening tests were ACR (≥ 3.4 mg/mmol), and eGFR 
(< 60 mL/min/1.73m2). All studies classified CKD stage 3 and above based on eGFR alone. 
Characteristics of the interventions responsible for inconsistencies in the outcome measures 
include CKD risk factors targeted, and screening tests used to detect CKD.  
1.1.4 Conclusion  
This systematic review found significant variation in the methods that were used to detect 
CKD, and identified that majority studies reported results based on only single albuminuria or 
eGFR values. Data on the percentage of participants, for whom follow-up was successful and 
who were diagnosed with CKD at follow-up were either unclear or not reported in many 
studies. Future targeted screening programs should appropriately use the clinical guideline for 
‘Early CKD: Detection, prevention and management’ in order to detect CKD, which is 
necessary to determine the benefit of these programs when implemented in community settings.  
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1.2 Introduction 
Chronic kidney disease (CKD) causes a significant economic burden on the healthcare system 
and is associated with reduced life expectancy and increased mortality.8 Evidence suggests that 
progression and adverse outcomes of CKD can be prevented or delayed by detecting and 
treating the disease in its initial stages (i.e. 1-3).8 More specifically, this involves treatment of 
co-existing co-morbidities, such as diabetes and hypertension, and application of measures to 
slow progression of early CKD, which should be initiated in stage 1 and 2 of CKD. Also, CKD 
is asymptomatic until kidney function deteriorates by approximately 90%, which makes it 
challenging to detect the disease early.11 Furthermore, failure to identify a patient in stages 1-
3 of CKD may result in an escalation of CKD complications and kidney failure, often leaving 
the patient inadequately prepared to commence renal replacement therapies (RRTs) for 
survival. This is crucial, as early referral and consultation with a nephrologist can enable better 
uptake of different dialysis procedures and reduce the rate of hospitalisation and mortality.62 
Hence, many clinical practice guidelines recommend that individuals with risk factors, such as 
hypertension, diabetes, cardiovascular disease (CVD) and a family history of kidney disease, 
should be screened for CKD.63   
Current literature indicates that screening and risk stratification for CKD can be carried out 
by measurement of estimated glomerular filtration rate (eGFR) (which indicates level of kidney 
function) and/or assessment of proteinuria (marker of kidney damage).64 Additionally, simple 
tests, such as dipstick urinalysis, point-of-care testing (POCT) for serum creatinine (SCr)64 and 
various risk assessment tools56, 57, 59, 65 can facilitate the early identification of patients with 
undiagnosed CKD in a community setting. At present, evidence exists that mass screening for 
CKD can result in: over-estimation of prevalence of stage 3 CKD based on eGFR, inefficient 
use of resources and needless anxiety in the general population.66 Instead, screening was found 
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to be cost-effective and more capable of identifying unrecognised cases of CKD when 
performed in people at increased risk.64 
Globally, targeted screening programs36, 51, 67-76 have been implemented in various 
community settings to identify patients with early stage CKD and refer them to specialists for 
further diagnosis and management. However, no data synthesis has been performed to 
determine the overall success of these screening programs. Therefore, the aim of this systematic 
review was to evaluate whether targeted screening is effective in identification of people with 
undiagnosed CKD, and to identify characteristics that were responsible for the more effective 
screening interventions.  
1.3 Methods 
We conducted a systematic review according to a pre-specified protocol (PROSPERO 
[International Prospective Register of Systematic Reviews] number: CRD42016037204) as 
shown in Appendix 1.1 and reported in accordance with published guidelines (PRISMA).77 
1.3.1 Selection criteria 
For the purpose of this review, targeted screening was defined as the implementation of test/s 
in patients with known risk factors for CKD. We included observational studies (cross-
sectional, case-control and prospective cohort) of targeted screening interventions that were 
implemented in a community-based setting, specifically aimed to identify people with 
undiagnosed CKD. For inclusion in this review, the screening program was required to have 
targeted adults (≥ 18 years) and multiple CKD risk factors from the following: diabetes, 
hypertension, CVD and family history of kidney disease. Screening programs could have been 
implemented in any community setting and performed by any healthcare professional. There 
were no restrictions imposed based on the length of follow-up of outcomes. No publication 
date restrictions were applied and articles in a language other than English were not included. 
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Studies that were retrospective in nature and of epidemiological design were excluded from 
this review. Articles that were conference abstracts, editorials, literature reviews, news, 
ongoing studies and case reports were excluded. 
1.3.2 Data Sources and Search Strategy 
An electronic search of four databases: EMBASE, PubMed, Cochrane Central Register of 
Controlled Trials (CENTRAL) and Scopus was conducted in February 2016, and an updated 
search, was performed in July 2016. Three layers of search terms (chronic kidney disease, 
screening and community) were piloted by using the Emtree thesaurus and Medical Subject 
Headings (MeSH) of EMBASE and PubMed, respectively. Wherever possible, the terms were 
exploded to broaden the search or searched as a keyword in titles and abstracts of articles. Text 
word searching was also conducted to identify any articles that may not have been indexed 
appropriately. The search terms were modified for use across individual databases, due to the 
differences in their functionality. Search strategy for individual database is shown in Appendix 
1.2. 
The search strategy was used to retrieve citations into EndNote X7.4. Duplicate articles were 
removed, and titles were screened to identify studies relevant to this review. Screening of 
abstracts of all retained articles was then performed, and full-texts were obtained of all articles 
that appeared to be potentially relevant for inclusion. Two reviewers (P.A.G. and R.L.C.) 
independently assessed the full-text articles for inclusion and any disagreements were resolved 
after consultation with third and fourth reviewers (S.T.Z. and G.M.P.). Reference lists of 
included studies or relevant reviews identified through the electronic search were screened to 
identify any potential articles.  
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1.3.3 Data extraction and synthesis 
Data extracted from each study included: (1) Study characteristics: study design, year of 
publication, country of origin; (2) Participant characteristics: mean age, gender, CKD risk 
factors targeted; (3) Intervention type: healthcare professional involved, community setting 
type, length of follow-up, screening tests used to detect evidence of CKD (including 
proteinuria, microalbuminuria (MAU), albumin/creatinine ratio (ACR), SCr or eGFR), 
threshold used for positive screening test result and equation used to calculate renal function; 
(4) Outcome measures: percentage of participants with positive screening test results, 
percentage of participants for whom follow-up was successful and percentage of participants 
diagnosed with CKD at follow-up. We contacted two authors74, 75 for further information. Both 
responded and one74 provided unpublished numerical data.  
Due to the heterogeneity in the eligibility criteria of participants, and in the screening tests 
and thresholds used to detect CKD, a quantitative meta-analysis was not appropriate. Study 
characteristics, screening program characteristics and outcome measures of the included 
studies are presented in the form of texts, tables, and/or figures. We also explored relationships 
in data i.e. considered factors that might explain observed differences between studies and the 
potential facilitators or barriers to successful implementation of different screening programs.  
1.3.4 Risk-of-Bias Assessment 
The quality of the included studies was assessed by using the Cochrane Risk of Bias 
Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI).78 This 
tool covers seven domains through which bias might be introduced into quantitative studies. 
The first two domains assessed the risk of bias that can occur before initiation of the 
intervention; the third domain assessed the intervention itself; and the final four domains 
assessed the risk of bias that can arise after the intervention has been initiated. Each domain 
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includes signalling questions which aim to facilitate judgement about the risk of bias. If the 
answers to the signalling questions for a domain were “yes” or “probably yes”, then the risk of 
bias was judged low. If the answers to the signalling questions were “no” or “probably no”, 
then the potential for bias was likely; a judgement was then made on the extent to which the 
results of the study are at risk of bias (i.e. low, moderate, serious or critical).  
1.4 Results 
1.4.1 Study selection 
The electronic search strategy retrieved a total of 512 unique citations, from which we 
identified 17 articles for full-text review. Of these nine articles were eligible for inclusion. We 
excluded the other eight articles because five did not meet the eligibility criteria, one was a 
review article, 1 was mass screening and 1 was a retrospective analysis. Four articles67-70 were 
primary, follow-up and secondary reports on the same study. Therefore, we retrieved the final 
report on this study from their nominated website and extracted data from it.73 We additionally 
identified one article74 by scanning the references of included studies and by searching for 
studies that had cited these papers. The study selection process is outlined in Figure 1.1. One 
study published by Obrador72 was conducted at two different locations (Mexico City and 
Jalisco state), and the outcome measures and descriptive data of the participants screened at 
these locations were reported separately (under one publication). Therefore, we have included 
these separately in our analysis. The updated search in PubMed identified one relevant study75, 
which met the eligibility criteria and was included in the final analysis. 
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Figure 1.1 Study selection process 
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1.4.2 Study characteristics  
Screening programs were conducted in the United States71, 73, 76, Iran74, Canada51, 75, Australia36 
and Mexico72. Five studies 36, 72, 73, 75, 76  were of prospective cohort design and the remaining 
three51, 71, 74 were cross-sectional in nature. Most studies were conducted in the past 10 years 
except the study by Brown et al.76 which was conducted almost 20 years ago. The number of 
people at risk who participated in all included studies ranged from 40236 to 1,50,97273. The 
mean age of participants ranged between 4672 and 65.3 years75 across six studies that reported 
these data. Six studies71-74, 76 recruited a higher proportion (> 65%) of female participants. The 
follow-up period across studies ranged from half to three months. The screening programs were 
conducted in various community settings and utilised a range of healthcare professionals (Table 
1.1). 
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Table 1.1 Characteristics of the included studies 
First Author 
and year 
Study 
design 
Risk of bias 
assessment 
Setting 
Healthcare 
Professional 
Involved 
N 
Mean 
Age 
(SD) 
% 
Female 
Follow-up 
(months) 
Brown et al.,76 
2003 
Prospective 
cohort 
Serious 
Multiple settings~, 
United States 
Physician 889 NR 67 1 and 3 
Harward et 
al.,71 2009 
Cross-
sectional 
Moderate 
Multiple settings~, 
United States 
Multidisciplinary* 1,742# 54 70.1 NA 
Matthew et 
al.,36 2010 
Prospective 
cohort 
Moderate 
Community venue and 
company workplace,  
Australia 
Renal nurse or 
scientist 
402 58 (11.1) 47 3 
Obrador et al. 
(a),72 2010+ 
Prospective 
cohort 
Moderate 
Unclear, 
Mexico 
Multidisciplinary* 
519 
 
46 (15) 
72 
 
3 
Obrador et al. 
(b),72 2010+ 
Prospective 
cohort 
Moderate 
Mobile screening units, 
Mexico 
Multidisciplinary* 2,020 53 (13) 74 NR 
NKF-KEEP,73 
2012 
Prospective 
cohort 
Moderate 
Multiple settings~, 
United States 
Multidisciplinary* 1,50,972 NR 68 Approx. 2 
Barahimi et 
al.,74 2014 
Cross-
sectional 
Moderate Specialised clinics, Iran Multidisciplinary* 1,228 NR >70 3 
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First Author 
and year 
Study 
design 
Risk of bias 
assessment 
Setting 
Healthcare 
Professional 
Involved 
N 
Mean 
Age 
(SD) 
% 
Female 
Follow-up 
(months) 
Al Hamarneh et 
al.,51 2016 
Cross-
sectional 
Moderate 
Community pharmacy, 
Canada 
Community 
pharmacists 
720 63` 43 3 
Galbraith et 
al.,75 2016 
Prospective 
cohort 
Moderate 
Multiple settings, 
Canada 
Registered nurse or 
pharmacist 
6329^ 
58.5 
(15.9) 
65.3 0.5 to 1 
NKF-KEEP National Kidney Foundation’s Kidney Early Evaluation Program, SD standard deviation, NR not reported, NA not applicable, Approx. approximately;  
+ Data of the studies Obrador (a) and (b) were presented under one publication; * Physicians, nurses, educators, social workers, research/lab technicians, 
internists, executive authorities, nephrologists, dietitians and trained volunteers (medical students, nursing students, citizens); ~ Churches, hospitals, health 
centres, schools, community centers, friendship centers, religious centers, senior’s residence, Safeway (supermarket), grocery stores, health center buildings, 
community colleges, senior citizen centers, correctional institutions and dialysis units; # Data is calculated from participants who completed the questionnaire. 
Proteinuria was conducted on 1706 participants and MAU on 1497; ^ Data is calculated from all people who participated in the screening event. eGFR was 
calculated only for 5144 participants who provided complete data; ` median age. 
Early detection and prevention of CKD 
49 
 
1.4.3 Targeted screening program characteristics 
Table 1.2 shows the targeted screening program characteristics, such as CKD risk factors 
targeted, screening tests used to detect CKD, equations used to calculate renal function and 
thresholds used for positive screening test results.  
1.4.4 CKD risk factors targeted 
Screening interventions screened participants with the age of ≥ 18,71-73, 75, 76 ≥ 20,36 and > 3074 
years. Risk factors targeted by the screening programs included diabetes36, 51, 71-76 high blood 
pressure,36, 51, 71-76 first-degree relative with diabetes and high blood pressure, 72, 73, 76 vascular 
disease,51, 71, 75 high-risk ethnic population (e.g. Aboriginal, Hispanic, South Asian, Asian, or 
African descent),36, 75 current tobacco use51, 75 and high cholesterol level.51 
1.4.5 Screening tests and thresholds used 
Included studies used different screening tests for CKD detection. Four studies71, 72, 75, 76 
included dipstick urinalysis, five36, 51, 72-74 performed ACR measurement, one76 used SCr 
measurement alone and seven36, 51, 72-75 reported eGFR. All studies36, 51, 72-76 except one71 used 
both kidney damage and kidney function tests for CKD screening. Three studies73-75 used the 
Chronic kidney disease-Epidemiology Collaboration (CKD-EPI) formula and four used the 
Modification of Diet in Renal Disease (MDRD) formula36, 72, 73 to calculate the eGFR.  
The threshold values used for positive screening test results also varied across the screening 
programs. One study used a proteinuria value of  ≥ 150 mg/L,72 one used a value of ≥ 300 
mg/L71 and one did not report the threshold value used 75. One study used a MAU value of ≥ 
20 mg/L71 and one 76 did not report the MAU value used. Three studies72-74 used an ACR value 
of ≥ 3.4 mg/mmol, one36 used a value of > 2.5 mg/mmol for male or > 3.5 mg/mmol for female 
and one used51 ACR value of ≥ 3 mg/mmol or ≥ 30 mg/mmol. Seven studies36, 51, 72-75 used an 
eGFR value of < 60 mL/min/1.73m2.  
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Table 1.2 Characteristics of the targeted screening programs 
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CKD risk factors targeted 
 High blood pressure • • • • • • • • • 
 Diabetes • • • • • • • • • 
 Family history of kidney disease • • • • • •  • • 
 First degree relative with diabetes •   • • •    
 First degree relative with high blood pressure •   • • •    
 Vascular disease  •*      •# • 
 High-risk ethnic population   •~      •^ 
 Tobacco use        • • 
 High cholesterol level        •  
Screening tests used to detect CKD 
 Dipstick urinalysis • •   •    • 
 Albumin/creatinine ratio   • •  • • •  
 Serum creatinine •         
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 Estimated glomerular filtration rate   • • • • • • • 
Equations used to calculate renal function 
 MDRD   • • • •  -  
 CKD-EPI      • • - • 
Thresholds used for positive screening test results 
 Microalbuminuria          
 Not reported •         
 ≥ 20 mg/L  •        
 Proteinuria          
 Not reported         • 
 ≥ 150 mg/L     •     
 ≥ 300 mg/L  •        
 Albumin/creatinine ratio          
 > 3.5 mg/mmol, F; > 2.5 mg/mmol, M   •       
 ≥ 3 mg/mmol        •  
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 ≥ 30 mg/mmol        •  
 ≥ 3.4 mg/mmol    •  • •   
 Serum creatinine          
 > 1.2 mg/dL, F; > 1.4 mg/dL, M •         
 Estimated glomerular filtration rate          
 < 60 mL/min/1.73m2   • • • • • • • 
NKF-KEEP National Kidney Foundation’s Kidney Early Evaluation Program, CKD chronic kidney disease, MDRD Modification of Diet in Renal Disease, CKD-
EPI Chronic Kidney Disease Epidemiology Collaboration, NR not reported; + Data of the studies Obrador (a) and (b) were presented under one publication; * 
Heart disease; # prior diagnosis of cardiovascular disease, stroke, transient ischaemic attack or peripheral vascular disease; ~ Aboriginal; ^ Aboriginal, Hispanic, 
South Asian, Asian, or African descent. 
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1.4.6 Outcome measures 
A total of 8 studies36, 71-76 reported the percentage of participants with positive screening results. 
Figure 1.2 shows the percentage of participants with positive screening test results as per the 
screening tests and thresholds used to detect. The percentage of participants with positive 
results of kidney damage were inconsistent and ranged from 11.4%71 to 60.3%71 by dipstick 
test, and 8%36 to 35%74 by ACR measurement. The percentage of participants with positive 
results of a decline in kidney function was 12.8% by SCr measurement and 7%72 to 26.1%74 
by eGFR.  
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Figure 1.2 Percentage of participants with positive screening test results as per the screening tests and 
thresholds used to detect CKD. 
Studies with data (i.e. percentage of participants with positive screening results) either not reported or 
unclear are not shown in this figure. NKF-KEEP National Kidney Foundation’s Kidney Early Evaluation 
Program. + Data of the studies Obrador (a) and (b) were presented under one publication; * Data are 
calculated after excluding participants with self-reported “kidney problems” 
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The combined positive screening test results were reported by 4 studies.36, 51, 74, 76 Figure 1.3 
shows the percentage of participants with combined (i.e. kidney damage and kidney function) 
positive screening test results and CKD diagnosis at follow-up. The percentage ranged from 
20.4%36 to 56%.74 Al Hamarneh et al.51 and Brahimi et al.74 confirmed a diagnosis of CKD in 
20.5% and 17.1% of screened participants, respectively. Brown et al.76 reported a CKD 
diagnosis in 9 participants at follow-up; however, the overall percentage of this and tests used 
for diagnosis was unclear. 
 
 
Figure 1.3 Percentage of participants with combined (i.e. kidney damage and kidney function) positive 
screening test results and CKD diagnosis at follow-up. 
NKF-KEEP National Kidney Foundation’s Kidney Early Evaluation Program. ~Data on percentage of 
participants diagnosed with CKD were either unclear or not reported. *Data on percentage of 
participants with positive screening results were not reported, and data on percentage of participants 
diagnosed with CKD are calculated after excluding participants with known CKD. 
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1.4.7 Risk-of-bias within studies 
Overall, screening interventions of the included studies were well defined. All studies were at 
moderate risk of bias due to confounding at pre-intervention stage. Two studies51, 75 recruited 
participants with CKD and kidney problems; however, these studies also reported results 
obtained using statistical analysis that adjusted for these confounding variables. One study76 
was at serious risk of bias due to missing data, and 8 studies36, 51, 71-75 were at low risk of bias 
in selection of the reported results. The risk of bias assessment for all studies is shown in Table 
1.3. 
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Table 1.3 Risk-of-bias assessment of studies included in this review 
Bias criteria 
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Bias due to confounding Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate 
Bias in selection of participants 
into this study 
Low Low Low Low Low Low Low Low Low 
Bias in measurement of 
interventions 
Low Low Low Low Low Low Moderate Low Low 
Bias due to departures from 
intended interventions 
No 
information 
No 
Information 
No 
Information 
No 
Information 
No 
Information 
No 
Information 
No 
Information 
No 
Information 
No 
Information 
Bias due to missing data Serious Low Low Low Low Moderate Low Low Low 
Bias in measurement of 
outcomes 
Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate 
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Bias criteria 
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Bias in selection of the 
reported results 
Moderate Low Low Low Low Low Low Low Low 
Overall Serious Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate 
NKF-KEEP National Kidney Foundation’s Kidney Early Evaluation Program; + Data of the studies Obrador (a) and (b) were presented under one publication. 
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1.5 Discussion 
We identified a broad range of targeted screening interventions that detected a considerable but 
inconsistent number of people with markers of kidney disease. We found that the screening 
programs varied with respect to the screening tests and thresholds used to detect CKD. A 
possible explanation could be the inconsistencies between various guidelines’ 
recommendations for proteinuria, albuminuria, ACR and protein/creatinine ratio (PCR) and 
diagnostic cut-off values.63 We also found inconsistencies in the percentage of participants with 
positive screening results. This is most likely because studies that had higher positive screening 
results of dipstick test, i.e. 31% and 60.3%, used lower threshold values of proteinuria (≥ 150 
mg/L)72 and MAU (≥ 20 mg/L),71 respectively. Dipstick tests are well known as the most 
feasible method for screening in community settings, although there is evidence that “false 
positive” and “false negative” results are quite common.79, 80 Albuminuria can be transient or 
persistent and positive results of the dipstick tests should be confirmed by quantitative 
laboratory measurements, such as ACR or PCR, for diagnostic evaluation.80 We found that 
none of the screening programs that used the dipstick method evaluated or reported the CKD 
diagnosis at follow-up. Hence, no conclusions could be made about the validity of this method 
for targeted screening. 
Another possible explanation for inconsistencies is the participant eligibility criteria. The 
age cut-off for the study74 with the highest test result (i.e. 35%) by the eGFR measurement was 
> 30 years whereas other studies screened participants who were ≥ 18 years72, 73, 75, 76 and ≥ 20 
years.36 Moreover, the study with the highest test result looked at participants only with a 
personal history of diabetes and hypertension. The remaining studies included a broader range 
of participants, such as first-degree relative with diabetes, hypertension or kidney disease, 
vascular diseases, high-risk ethnic population, current tobacco user and high cholesterol level, 
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which may have resulted in the lower percentage of participants with positive screening test 
results.  
Screening interventions conducted more recently used the CKD-EPI formula51, 73-75 whereas 
older studies used the MDRD formula.36, 72, 73 This could be because the CKD-EPI equation is 
associated with lower false positives and is more accurate in estimating eGFR between 60 and 
120 mL/min/1.73m2.81 However, it is important to note that both equations have limitations 
because the results are normalised to the body surface area of 1.73 m2, and the lack of 
representation of racial and ethnic minorities in the development or validation of the 
equations.82, 83 Also, both equations use serum creatinine which is influenced by muscle mass, 
diet, medications and unstable co-morbid conditions. Hence, it is important to view each 
participant’s result as an estimate and not an actual GFR. 
Two51, 74 studies reported CKD diagnosis rate of 20.5% and 17.1% by 2 consecutive ACR 
and eGFR measurements over a period of 3 months. However, the participants screened in the 
Canadian study51 were recruited from another randomised controlled study of pharmacist-led 
cardiovascular risk reduction intervention, suggesting that these participants were at higher risk 
when compared with other participants of the included studies. Nevertheless, these data suggest 
that even with a robust healthcare system in place, it is likely that a significant proportion of 
patients at risk are not being routinely monitored for CKD.  
The Kidney Disease Improving Global Outcomes (KDIGO) 2012 clinical practice guideline 
for the Evaluation and Management of CKD clearly states that a person needs to have 
persistence of either decreased kidney function (eGFR < 60 mL/min/1.73m2) or kidney damage 
(ACR > 3 mg/mmol) for at least three months for a diagnosis of CKD.4 Hence, a systematic 
approach for initial detection of CKD is essential, which means repeating diagnostic evaluation 
of both ACR and eGFR, two to three times over the next several months before a person can 
be labelled as having CKD.80  A recent cross-sectional study found false-positive results in 
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67.5% of participants with mild proteinuria. In case of absence of proof of chronicity of a 
decreased eGFR, a false positivity of 32% with stage 3A and 7.4% participants with stage 3B 
CKD was found. Repeated measurements for confirmation of proteinuria and chronicity of 
eGFR (conducted after a period of 3, 6 and 12 months) resulted in an almost 50% decrease in 
the CKD prevalence.84 This data suggests that there is a very high risk of CKD over-diagnosis, 
when diagnostic tests are not repeated. Many studies36, 71-73, 75, 76 included in this review 
reported results only from the one-time tests that were performed during the intervention, and 
participant follow-up data were either not evaluated or reported. Similarly, Bruck et al. found 
that none of the studies conducted to determine the prevalence of CKD in the general 
population had evaluated the chronicity of eGFR and/or albuminuria.85  
Most36, 72-76 screening programs used simultaneous testing (i.e. measurements of both 
kidney damage and decline in kidney function) to detect CKD; however, all defined CKD 
stages 3 and above, based on eGFR alone. The current CKD classification used by KDIGO is 
based on both eGFR and albuminuria category. The use of albuminuria together with eGFR 
has been shown to greatly enhance the ability to detect and quantify the risk of progressive 
CKD, particularly at CKD stage 3 or above.86 On the other hand, the use of eGFR alone to 
categorise CKD stage 3 has been shown to cause false positive categorisation and over-
diagnosis in as many as 30% of people.87 Labelling several people as having CKD without 
diagnostic confirmation and appropriate CKD staging, increases the chances of over-diagnosis 
and further negates the benefit of screening in the targeted population.  
A major issue with observational studies is the potential for confounding bias. Confounding 
is most likely to occur due to the presence of existing co-morbidities other than those being 
recorded during the intervention and participants’ awareness of his/her previous diagnosis of 
CKD. Although the included studies controlled for confounding by restricting the eligibility of 
participants based on known CKD risk factors, these were generally self-reported. Bias in the 
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implementation of screening programs in community settings can also occur as participants 
who agree to undergo screening are likely to be volunteers, more educated and health-
conscious individuals.88  
1.6 Conclusion 
Our analysis shows that a considerable percentage of participants are being identified with 
CKD by targeted screening. However, data on the percentage of participants for whom follow-
up was successful and who were diagnosed with CKD at follow-up, as well as data on loss to 
follow-up, were either unclear or not reported in many studies. Hence, it is difficult to draw 
definitive conclusions on the effectiveness of targeted screening.  We recommend that future 
studies should be designed such that follow-up of screened participants is conducted and 
reported at regular intervals to allow interpretation of the effectiveness of screening programs. 
Furthermore, screening programs should use simultaneous testing approaches, and CKD 
should be classified using both eGFR and albuminuria categories. This will help prevent over-
diagnosis and labelling the healthy as diseased in the community.  
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PROJECT II (A) 
 
CHAPTER 2. A Web-based Training Program to Support Chronic Kidney 
Disease Screening by Community Pharmacists 
 
2.1Abstract 
2.1.1 Background 
Owing to the increase in the global health burden of CKD, community pharmacists’ role in the 
early CKD detection and prevention could be beneficial. Hence, a web-based training program 
was developed to enhance community pharmacists’ abilities to perform a CKD risk assessment 
service in community pharmacy settings. The aim of this study was to evaluate the impact of a 
web-based training program on pharmacists’ knowledge and skills associated with CKD risk 
assessment. As a secondary measure, pharmacists’ satisfaction with the training program was 
assessed. 
2.1.2 Methods 
A web-based training program was developed by academic pharmacists and a nephrologist. 
Quantitative data were collected by employing a self-administered, web-based questionnaire, 
which comprised a set of five multiple-choice knowledge questions and one clinical vignette 
to assess skills. A nine-item Likert scale was used to determine pharmacists’ satisfaction with 
the training program. The outcome measures were (1) Pharmacists’ knowledge and skills 
scores at pre- and post-training, (2) Reliability of the Likert scale, and (3) Proportion of 
responses to the individual nine items of the satisfaction survey.  
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2.1.3 Results 
Fifty pharmacists participated in the pre-questionnaire and 38 pharmacists completed the web-
based training and post-questionnaire. Significant differences were observed in the knowledge 
scores (p < 0.001) and skills scores (p < 0.001) at pre- and post-training. Cronbach’s alpha for 
the nine-item satisfaction scale was 0.73, and the majority of pharmacists (92.1% - 100%) were 
satisfied with the various aspects of the training program. 
2.1.4 Conclusion 
The web-based training program positively enhanced pharmacists’ knowledge and skills 
associated with CKD risk assessment. These findings support further development and 
widespread implementation of the training program to facilitate health promotion and early 
identification of CKD in a community setting. 
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2.2 Introduction 
Community pharmacists are commonly presented with patients who are on several medications 
for the management of their chronic diseases. Given their training and accessibility, community 
pharmacists are well placed to play a key role in providing health promotion and screening 
services to the general population.89 In Australia, pharmacists have successfully implemented, 
within their normal daily practice, many interventional programs such as for asthma 
management,90 home-based post discharge warfarin management,91 detecting and resolving 
drug-related problems,92 and CVD risk screening.44 The delivery of these high-quality and 
evidence-based interventions provides pharmacists with an opportunity to improve overall 
consumer health outcomes.93 
Evidence suggests that early identification and management of CKD has enormous potential 
to prevent or delay the disease progression and associated adverse outcomes, such as kidney 
failure, CVD and premature death.15 Numerous guidelines recommend regular screening of 
patients with established risk factors such as hypertension, diabetes, CVD and a family history 
of kidney disease, particularly as in the majority of patients with early stage CKD (Stages 1-
3), the progression is asymptomatic.63 
Community pharmacists’ potential to improve the quality use of medications in patients 
with CKD has been widely explored. Also, pharmacists’ interventions in patients with CKD, 
improved management of blood pressure and lipid profile, and reduced all-cause 
hospitalisations and the incidence of ESKD or death.94 So far, no quantitative study has been 
performed to investigate the role of community pharmacists in early CKD detection and 
prevention. Only a qualitative analysis identified the need for pharmacists to participate in 
continuing education workshops on ‘early CKD detection’, and increase public awareness of 
CKD.95  
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The aim of this study was to develop a web-based training program and evaluate its impact 
on community pharmacists’ knowledge and skills associated with a CKD risk assessment 
service. As a secondary measure, pharmacists’ satisfaction with the training program was 
assessed. 
2.3 Methods 
This study was approved by the Tasmanian Health and Medical Human Research Ethics 
Committee, University of Tasmania (H0014258). 
Four pharmacists (RC, TZ, GP, and LB) and a nephrologist (MJ) designed and developed 
the 60-minute web-based training program. The learning objectives were to: (a) demonstrate 
knowledge on CKD and renally cleared medications; (b) effectively identify from the general 
population people with risk factors of developing CKD; (c) demonstrate skills for the effective 
performance of the CKD risk assessment calculator;55 (d) provide suitable counselling to high 
risk patients on lifestyle management of CKD; and (e) critically review the medication regimen 
of high risk patients for prescribing of renally cleared medications. The program (delivered by 
PG) comprised a lecture presentation (Appendix 2.1) on CKD topics, including:  (a) incidence 
and economic burden; (b) complications, risk factors and primary causes; (c) diagnosis and 
management; (d) quality use of medications in patients with CKD (including drugs that require 
dosage adjustment or are contraindicated in renal impairment);  and (e) a case presentation on 
how to conduct an early CKD detection service using a risk assessment calculator.55 The web-
based training program was reviewed and pre-tested by clinical experts. Following this, 
revisions were made in the lecture presentation before final implementation. 
The CKD risk assessment calculator is a predictive algorithm developed to identify patients 
at increased risk of developing moderate-severe kidney disease over the next five years. The 
algorithm uses risk predictors including age, gender, ethnicity, body mass index, systolic blood 
pressure, smoking status, and clinical conditions (such as Type 1 diabetes, Type 2 diabetes, 
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CVD, treated hypertension, congestive heart failure, peripheral vascular disease, rheumatoid 
arthritis, systemic lupus erythematous, kidney stones and family history of kidney disease), to 
calculate a patient’s percentage risk of developing kidney disease. This calculator thus allows 
pharmacists to perform risk stratification in community patients and enable identification of 
those patients who need further diagnostic testing and regular monitoring of their kidneys.  
A web-based questionnaire was used to evaluate the impact of the training program on 
pharmacists’ knowledge and skills. A thorough literature search identified no existing 
questionnaire to evaluate pharmacists’ CKD screening abilities. Therefore, we reviewed 
questionnaires developed for pharmacist-led interventions in CKD management and quality 
use of renally cleared medications.96-98 We also searched for studies that evaluated the impact 
of continuing education or training programs on pharmacists’ knowledge for other diseases.99-
101 We subsequently developed a questionnaire for evaluation of the training program (for use 
pre- and post-training). Knowledge was evaluated by a set of five multiple-choice questions, 
and skills were evaluated by a clinical vignette (Appendix 2.2). The self-administered 
questionnaires were designed using LimeSurvey (Version 2.05+) and responses were kept 
anonymous. The multiple-choice questions were about general concepts on CKD such as CKD 
complications; renal function markers; renally excreted drugs; CKD signs and symptoms; and 
CKD risk factors. Correct responses were given a score of 1 and incorrect responses were given 
a score of 0. Subsequently, a total score for individual pharmacists and mean total score were 
calculated. For the clinical vignette, pharmacists had to determine the patient’s five-year risk 
of developing CKD using the risk assessment calculator.55 Pharmacists did not have access to 
the calculator at pre-training. During the training, pharmacists were shown how to use the risk 
assessment calculator and at post-training, all pharmacists had access to the calculator. The 
percentage of pharmacists with correct responses to individual multiple-choice questions and 
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the clinical vignette was also calculated. Both questionnaires included a section capturing the 
demographic and professional characteristics of the community pharmacists. 
At the end of the training, pharmacists were asked to complete an online satisfaction survey 
(Appendix 2.3) to assess their reaction towards the various aspects of the training program. The 
survey was generated by identifying similar articles97, 102, 103 and utilising Donald Kirkpatrick’s 
Level 1-Learner satisfaction model.104 This nine-item survey included statements where 
pharmacists indicated their level of agreement with the program on a five-point Likert scale of 
(1) ‘Agree Strongly’ to (5) ‘Disagree Strongly’. Two open-ended questions were also designed 
to provide pharmacists with an opportunity to express their own thoughts on the CKD training 
program. The multiple-choice questions, clinical vignette and satisfaction survey were peer-
reviewed by two experts and trialled on academic pharmacists.  
A letter of invitation explaining the purpose of the study (along with the information sheet 
and consent forms) were mailed to all (a total of 143) community pharmacies across Tasmania 
(Appendix 2.4, 2.5, 2.6, 2.7). To further encourage participation, all pharmacies received a 
telephone invitation after a period of 14 days. Pharmacists who agreed to participate in the 
study were required to complete the pre-training questionnaire. Two reminder phone calls were 
also made at 2-weekly intervals in order to increase the response rate. Subsequently, 
pharmacists (who had completed the pre-questionnaire) were sent web links for the training 
program and post-questionnaire. Follow-up telephone calls were made at an interval of 2 and 
4 weeks as a reminder to complete the training. Pharmacists who had not completed the post-
questionnaire after the phone calls were considered non-respondents. 
Statistical Package for the Social Sciences (SPSS) version 22.0 was used for the analysis. 
Descriptive statistics were used to characterise demographic and professional details of the 
community pharmacists. The Shapiro-Wilk test was used to determine normality and for 
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subsequent selection of the statistical tests. Responses to the web-based questionnaire were 
non-identifiable and therefore, the Mann-Whitney U test was used to compare differences 
between the pre- and post-responses of the pharmacists. A p value < 0.05 was considered 
statistically significant. Reliability of the satisfaction survey was assessed using the Cronbach’s 
alpha measure. The percentage of responses for each Likert scale category was calculated. Both 
open-ended questions were analysed by employing a thematic approach and similar categories 
were then eliminated. 
2.4 Results 
A total of 50 pharmacists from 27 community pharmacies (response rate 19%) agreed to 
participate and were recruited into the study. Twelve pharmacists who completed the pre-
questionnaire withdrew from the study due to time constraints and major business transitions 
occurring at the pharmacy. Overall, 38 pharmacists completed the training program and post-
questionnaire.  
Table 2.1 describes the demographic and professional characteristics of community 
pharmacists who participated in the pre- and post-training questionnaire. The proportion of 
community pharmacists across age groups was similar. Twenty-six percent of the pre-sample 
and 15.8% of the post-sample had undertaken the accreditation process to provide medicines 
review services.  
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Table 2.1 Demographic and professional characteristics of community pharmacists who 
participated in the pre- and post-training questionnaire. 
Characteristics Pre-training  Post-training 
 N % N % 
Total 50 100 38 100 
Age group (years)  
20-29 
30-39 
40-49 
>=50 
14  28 12  31.6 
9  18  6  15.8 
14 28 11 28.9 
13 26  9   23.7 
Gender  
Male 
Female 
24 48 17 44.7 
26 52 21 55.3 
Community pharmacy experience (years)  
<=5 
6-10 
11-15 
16-20 
21-29 
>30 
15 30 12 31.6 
7 14 5  13.2 
4 8 4  10.5 
4 8 3  7.9 
13 26 9  23.7 
7 14 5  13.2 
Highest educational qualification  
Undergraduate 
Honours 
Masters 
Doctorate 
39 78 30 78.9 
5 10 4  10.5 
5 10 3 7.9 
1 2 1 2.6 
Home Medicines Review* Accreditation  
No 
Yes 
37 74 32 84.2 
13 26 6  15.8 
*A Home Medicines Review is a comprehensive clinical review of a patient's medicines in their home by 
an accredited pharmacist on referral from the patient's general practitioner. 
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Knowledge and skills scores of the pharmacists at post-training were statistically 
significantly higher than the same at pre-training (p<0.001, using Mann-Whitney U test). As 
shown in Table 2.2, the median (IQR) knowledge score was 4 (3-4) at pre-training and 4 (4-5) 
at post-training. The median (IQR) skills score was 0 (0-0) at pre-training and 1 (0-1) at post-
training.  
Table 2.2 Knowledge and skills scores of pharmacists, pre and post-training. 
Scores Pre-training Post-training p-value 
Knowledge 
Mean (SD) 3.56 (0.812) 4.29 (0.835) < 0.001 
Median (IQR) 4 (3-4) 4 (4-5)  
Skills 
Mean (SD) 0.08 (0.274) 0.61 (0.495) < 0.001 
Median (IQR) 0 (0-0) 1 (0-1)  
  
Figure 2.1 shows pre- and post-training percentage of community pharmacists with correct 
responses to the individual knowledge questions and clinical vignette. Responses to two 
questions showed significant improvements following training: the signs and symptoms that 
can occur in patients with CKD (pre, 34% vs. post, 58%) and drugs excreted via the renal 
system (pre, 58% vs. post, 87%). Pharmacists’ skills (assessed via the clinical vignette) to 
appropriately use the risk assessment calculator also improved at post-training (pre, 8% vs. 
post, 60.5%).  
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Figure 2.1 Pre- and post-training percentage of community pharmacists with correct responses to the 
individual knowledge questions and clinical vignette 
 
Cronbach’s alpha for the nine-item satisfaction survey was 0.73, suggesting that the scale 
had good internal consistency. Table 2.3 shows the percentage of pharmacists rating the web-
based training program as “Agree strongly” or “Agree somewhat”. The majority of pharmacists 
agreed that the objectives of the training were met, the program content was organised and easy 
to follow, the program content was relevant to them, and the lecturer had good knowledge with 
respect to the training topic.  
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Table 2.3 Percentage of pharmacists rating the individual nine-items of the satisfaction survey 
as ‘Agree strongly’ or ‘Agree somewhat’ (n = 38). 
Survey Item 
Agree 
strongly 
(%) 
Agree 
somewhat 
(%) 
Cumulative 
(%) 
Objectives of the training program were clearly 
defined 
84.2 15.8 100 
The content was organised and easy to follow 68.4 31.6 100 
Content of the training program was relevant to me 84.2 15.8 100 
Time allocated for the training program was sufficient 57.9 34.2 92.1 
This training experience will be useful in my work 60.5 36.8 97.4 
This training program further motivated me to 
participate in the study 
52.6 42.1 94.7 
Learning objectives of the training program were met 60.5 36.8 97.4 
The lecturer has good knowledge with respect to the 
training topic 
81.6 18.4 100 
The lecturer communicated information clearly 71.1 26.3 97.4 
 
Four key themes identified from the analysis of the two open-ended questions were: clarity, 
conciseness, convenience and relevance to the pharmacist. Based on the responses, it was 
determined that the pharmacists were generally satisfied with the web-based delivery of the 
training program. The majority of pharmacists liked that the content and structure of the 
program were clear and succinct. They found the web-based strategy to be highly convenient 
and accessible:  
‘The training program could be completed on-line, at a time and place that suits me’. 
Pharmacists also considered this as an opportunity to utilise their professional expertise in 
terms of CKD screening:  
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‘Information provided was very educational. The program raised awareness on the 
significance of CKD and promotes the professional importance that pharmacists could have in 
the community.’  
‘Good recap on kidney disease. Also, identified potential for pharmacists to be more 
involved in potential diagnosis and disease state awareness.’ 
2.5 Discussion 
With the rising need to decrease the societal burden, high morbidity and mortality associated 
with CKD, detection of CKD in its early stages is vital.88 Community pharmacists’ role in the 
prevention and management of diseases such as asthma, CVD, diabetes, and hypertension is 
well established.89 However, our literature search could not identify any study that used 
community pharmacies as a resource for early identification and prevention of CKD. 
Therefore, prior to determining the feasibility of implementing CKD screening services within 
Australian community pharmacy practice, it was essential to evaluate pharmacists’ knowledge 
of CKD and their ability to screen patients for CKD. This was investigated in the current study. 
 Results of this training program revealed that community pharmacists had overall good 
knowledge of CKD risk factors, complications and renal function markers. Their knowledge 
on CKD signs and symptoms and renally cleared medications was comparatively low, which 
increased notably as a result of the training. Findings of this study further reveal significant 
improvement in pharmacists’ skills to appropriately use the risk assessment calculator. 
However, future training programs should consider implementing more than one clinical 
vignette to further reinforce learning outcomes. 
It is evident from responses of the satisfaction survey that a majority of pharmacists found 
the web-based strategy highly convenient as it allowed them to participate and complete the 
training in their own time over a period of two to four weeks. For community pharmacies which 
employ only one pharmacist, it becomes difficult to attend a training program at a designated 
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venue, particularly if based in a remote or rural area.105 Hence, a web-based approach would 
be highly beneficial and allow pharmacists ease of access for several evidence-based education 
and training programs.  
One of the limitations of this study was that the responses to both questionnaires were kept 
anonymous and non-identifiable. As a result, we could not match the pre-responses of a 
particular pharmacist to their post-responses. Nevertheless, there were no significant 
differences observed between the two groups in terms of demographics, qualifications and 
professional experience. Although the number of participants in our study was low, they had 
reasonably diverse demographic profiles. Therefore, our findings are likely to be significant 
for similar web-based training programs when implemented in a larger population of 
community pharmacists. Finally, future studies could consider periodic reassessment to 
determine how long the pharmacists retain their increased knowledge and skills. 
2.6 Conclusion 
Overall, the pharmacists had a relatively low level of knowledge and skills associated with 
CKD screening, indicating a need for training in order to improve their CKD screening 
abilities. Positive results of this study support further development and widespread 
implementation of this training program, as this has the potential to create awareness and 
facilitate early identification of CKD in a community setting.  However, a larger study is 
needed to evaluate the long-term feasibility and cost-effectiveness of this training program 
when implemented in a community pharmacy setting. 
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PROJECT II (B) 
 
CHAPTER 3.  Evaluation of A Chronic Kidney Disease Risk Assessment 
Service in Community Pharmacies 
 
3.1 Abstract 
3.1.1 Background 
Targeted ‘opportunistic’ screening might be a sustainable approach for the early detection of 
people with undiagnosed CKD. The aim of this study was to implement and evaluate a CKD 
risk assessment service in the community pharmacy setting. 
3.1.2 Methods 
Twenty-four pharmacies in Tasmania, Australia participated in this study. Targeted people 
were aged between 50-74 years, with CKD risk factors (at least one of hypertension, diabetes, 
heart failure, obesity, smoker, history of heart attack, angina, stroke or transient ischaemic 
attack, or family history of kidney disease). The QKidney® risk calculator was used to estimate 
the targeted peoples’ five-year percentage risk of developing moderate-severe CKD. People 
identified with ≥ 3% risk were referred to their general practitioner (GP) and followed-up after 
nine months. Each individual’s risk assessment result was sent to their GP. Laboratory data 
were later collected (with participant consent) from a pathology provider. The main outcome 
measures were rates of GP referral uptake and of participants who underwent eGFR and ACR 
measurement. 
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3.1.3 Results  
We analysed 389 participants, of whom 203 (52.1%) had ≥ 3% 5-year risk of developing 
moderate-severe CKD and were referred to their GP. Follow-up was successful for 126 
participants and showed low (27%) GP referral uptake. GPs not initiating discussion on the 
risk assessment results was identified as a major contributor to the low referral uptake. Analysis 
of the pathology data revealed suboptimal kidney testing in participants with ≥ 3% risk, with 
eGFR and ACR tests performed for only 52.7% and 25.1% of these participants, respectively. 
Also, simultaneous (eGFR + ACR) testing and repeated analysis for abnormal results was 
performed for only 19.7% and 13.3%, respectively. 
3.1.4 Conclusion 
There is significant scope for improving public awareness and early detection of CKD via 
implementation of a community pharmacy-based CKD risk assessment service. However, a 
healthcare system that encourages a close working relationship between community 
pharmacists and GPs, and provides a robust referral pathway to ensure participant follow-up is 
needed to improve the effectiveness of this service. 
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3.2 Introduction 
A systematic analysis indicated that about 497 million adults worldwide in 2010 had CKD, the 
burden of which is fuelled by the epidemics of diabetes and hypertension.1 CKD is a major risk 
factor for end-stage kidney disease (ESKD), CVD and premature death.9 In Australia, data on 
the prevalence of CKD are limited and the best available evidence to estimate the CKD burden 
is drawn from renal replacement therapy (RRT) data.30 At the end of 2014, 959 Australians per 
million population were undergoing RRT,30 and 17% of new patients were referred late to 
nephrologists for the management of ESKD.17 A retrospective study found that despite the 
increasing prevalence of CKD in the state of Tasmania, Australia, testing for kidney disease 
(i.e. SCr and albuminuria) in at-risk people was suboptimal.34 This indicates significant 
evidence-practice gaps and the need to improve early CKD detection. 
Early diagnosis and treatment of CKD has the potential to reduce the risks of CVD and CKD 
progression by up to 50%.5, 6 Worldwide, many targeted screening programs for CKD have 
been conducted106 and an Australian screening program ‘Kidney Evaluation for You (KEY)’ 
found that targeted ‘opportunistic’ screening might prove to be a sustainable approach.36 
Community pharmacy-based screening or risk assessment services have shown potential in 
detecting people at high risk of diabetes and CVD.42, 44, 53, 90 Additionally, pharmacy-based 
screening and health promotion services help to increase public awareness. Pharmacists are 
highly accessible and in a good position to engage people within the community who are not 
aware of their risks and less likely to access general practice care.48 Hence, pharmacists could 
play an important role in the early detection, referral and education of individuals at risk of 
CKD.  
Current literature indicates that various risk assessment tools56, 57, 59, 60, 65 can facilitate the 
early identification of people at risk of developing CKD. One such validated tool recommended 
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by Kidney Health Australia (KHA) is the QKidney® risk calculator.55, 56, 58, 61 This algorithm, 
which estimates a person’s risk of developing moderate-severe CKD (eGFR < 
45mL/min/1.73m2) over the next five years, was derived using the data of over 1.5 million 
primary care patients from 188 general practices across England and Wales.58 
The main aim of this study was to implement and evaluate a CKD risk assessment service, 
using this tool, in Tasmanian community pharmacies. Specific objectives were to (i) identify 
people at risk of developing moderate-severe CKD over the next five years and refer them to 
their general practitioner (GP) for further evaluation, and (ii) document the challenges of 
implementing a CKD risk assessment service within community pharmacy. 
3.3 Methods 
The Tasmanian Health and Medical Human Research Ethics Committee (H0014258) approved 
this prospective cohort study. Written informed consent was obtained from all participants in 
this study. 
Between February 2015 and March 2016, we conducted this study at 24 Tasmanian 
community pharmacies. As per the Pharmacy Access/Remoteness Index of Australia 
(PHARIA), 14 pharmacies were located in highly accessible areas (Category 1, Index 0 – 1), 
eight were located in accessible areas (Category 2-3, Index >1 – 4), and two were located in 
moderately accessible areas (Category 4, Index >4 – 6).107 Geographically, 13 pharmacies were 
located in the south, five were located in the north/north east, and six were located in the north 
west/west of Tasmania. Prior to implementing the CKD risk assessment service, participating 
community pharmacists were provided with online training, and their skills and knowledge 
associated with CKD risk assessment were evaluated. This has been described in detail within 
Project II (A).108 Trained community pharmacists (n = 38), final-year pharmacy students (n = 
2) and a researcher (n = 1) conducted this study. Pharmacists received an incentive of 
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$15/participant recruited (funding was provided by the Tasmanian Community Fund). Patient 
participation was promoted via posters (Appendix 3.1) placed in the pharmacies and by 
pharmacists, directly approaching eligible individuals arriving at the community pharmacy. 
3.3.1 Risk assessment service 
Individuals eligible to participate were aged between 50-74 years, with at least one of the 
following self-reported risk factors: high blood pressure (BP) requiring treatment, diabetes, 
heart failure (HF), obesity (BMI ≥ 30 kg/m2), current smoker, personal history of heart attack, 
angina, stroke or transient ischaemic stroke (TIA), or family history of kidney disease. 
Participants who self-reported having CKD were excluded. The flow diagram for the risk 
assessment protocol is shown in Appendix 3.2. After written consent was obtained, an 
assessment data form was used to collect participant details such as demographic 
characteristics (age, gender, ethnicity, address, contact number), GP details, clinical 
information (smoking status, medical history, family history), and medication history 
(prescription and over the counter (OTC) drugs, complementary and alternative medicine 
(CAM)). Participants were asked to wait for at least 5 minutes before their sitting BP was 
measured using an electronic sphygmomanometer. The first systolic BP reading was recorded 
and classified as per the guidelines for the diagnosis and management of hypertension in adults 
by the National Heart Foundation of Australia.109 Individual participants’ height and weight 
were measured; subsequently, the calculated BMI was recorded and classified.110 All 
supporting documents used to conduct the CKD risk assessment service are shown under 
Appendix 3. 
Collected information was entered into the online QKidney® risk calculator (version 2014 
and 2016).55 Participants were given a detailed explanation of their risk assessment result, 
written education material on kidney disease (Appendix 3.10), and a copy of their results sheet. 
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As per the KHA recommendations,111 participants identified with < 3% “low” risk were not 
referred; participants with 3-15% “moderate” risk were encouraged to discuss the results with 
their GP at the next planned visit; and participants with > 15% “severe” risk were asked to 
discuss the results with their GP within the next two weeks. We also sent a letter to the GP 
(Appendix 3.11) for each participant identified with ≥ 3% risk; the letter included information 
on the study, and a copy of the individual participant’s assessment data form and results sheet. 
3.3.2 Participant follow-up 
All participants with ≥ 3% risk were followed up by telephone after 9 months. We made three 
attempts to contact the participant by telephone, after which we sent the survey via post. The 
survey included questions to establish whether the participant had: a) discussed their risk 
assessment results with their GP and b) undergone a ‘Kidney Health Check’. According to 
KHA, a ‘Kidney Health Check’ consists of three tests: blood test for eGFR, urine test for ACR, 
and BP measurement.5 The survey also included questions to determine if participants had 
made any changes to their lifestyle and disease management strategies as a result of 
participation in this study.  
3.3.3 Pathology data collection 
Written informed consent was obtained from all participants at the beginning of the study to 
collect their laboratory data on eGFR and ACR. These data were collected from a major 
Tasmanian community-based pathology laboratory. Participant data on laboratory tests 
performed within one year after undergoing the risk assessment and repeated within 3 months 
of initial tests for participants with evidence of CKD were included in the final analysis. The 
pathology provider calculated the eGFR by using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula as per the revised recommendations of the Australasian 
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Creatinine Consensus Working Group.112 Evidence of CKD was defined as an eGFR <60 
mL/min/1.73m2 and ACR >3.5 mg/mmol, female or >2.5 mg/mmol, male.6 
3.3.4 Sample size calculation 
Based on the data presented in research that developed and validated the risk assessment 
calculator,58 and extrapolating to an older cohort of individuals with at least one pre-existing 
risk factor for CKD, we estimated that 50% of the sample would have a 5-year risk of moderate-
severe CKD of at least 3% (and therefore require referral). Using a 5% precision and 99% 
confidence level (to be 99% sure that the true percentage of the population aged between 50 
and 74 years with at least one CKD risk factor that has a 5-year risk of moderate-severe CKD 
of at least 3% using the risk assessment calculator, is between 45% and 55%) we needed 384 
eligible individuals.  
3.3.5 Statistical analysis 
We used the Statistical Package for Social Sciences (SPSS) version 23.0 software to perform 
statistical analysis. Participants with 3-15% moderate-risk were sub-categorised into 3-7.9% 
moderate-risk 1 and 8-15% moderate-risk 2. Descriptive statistics were calculated as mean and 
standard deviation (SD) for continuous variables, and percentage for categorical variables. We 
used a thematic approach to analyse all answers to the open-ended questions. 
3.4 Results 
3.4.1 Withdrawal of community pharmacists 
Fourteen of 38 pharmacists withdrew from the study and the most common reason reported for 
withdrawal was lack of time and staff. Several pharmacists mentioned that being the only 
pharmacist on-duty, they were too busy to spend 10-15 minutes per participant to conduct the 
risk assessment effectively.  
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3.4.2 Risk assessment service 
Out of 405 participants initially recruited in the study, we excluded 16 participants because 
either they did not meet the eligibility criteria or we received their data after the follow-up 
timeline had passed. Table 3.1 shows the demographic and clinical characteristics of the 389 
participants included in the final analysis. The mean (± SD) age of participants was 63.3 (± 
6.4) years and 50.4% were female. More than half of our sample had two or more risk factors 
for CKD. Most participants (81.2%) had hypertension, 21.9% had type 2 diabetes, 15.9% had 
a history of heart attack, angina, stroke or TIA, and 6.7% had an immediate family history of 
kidney disease. Of the sample, 14.2% were smokers and 45.2% were obese. More than half of 
the sample (51.7%) were using CAMs, and the most common were vitamin D (21.0%), fish oil 
(15.5%), and magnesium (7.5%); 32.1% were using OTC drugs, and paracetamol (70.7%) was 
the most common of these.  
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Table 3.1 Participant demographics and clinical characteristics 
Characteristics N % 
Total 389 100 
Mean age (mean ± S.D.., range) 63.3 ± 6.4, 50-74 
Gender   
Female 196 50.4 
Male 193 49.6 
Ethnicity   
White or not stated 383 98.5 
Indian 1 0.3 
Other Asian 2 0.5 
Other ethnic group 3 0.8 
Region (n = 381)   
South 205 52.7 
North/north east 89 22.9 
North west/west 87 22.4 
Smoking status 
Non-smoker  218 56.0 
Ex-smoker 116 29.8 
Light smoker (fewer than 10 cigarettes/day) 29 7.5 
Moderate smoker (10 to 19 cigarettes/day) 11 2.8 
Heavy smoker (20 or more cigarettes/day) 15 3.9 
Diabetes 
Type 1 5 1.3 
Type 2 85 21.9 
Heart failure 9 2.3 
High blood pressure requiring treatment 316 81.2 
History of a heart attack, angina, stroke or transient ischaemic attack 62 15.9 
Immediate family* history of kidney disease (*mother, father, brothers or 
sisters) 
26 6.7 
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Characteristics N % 
Total 389 100 
Body mass index (kg/m2) 
Underweight  <18.5 2 0.5 
Healthy  18.5-24.9 56 14.4 
Overweight  25-29.9 155 39.8 
Obese  ≥30 176 45.2 
Systolic blood pressure (mmHg) (n = 386) 
Optimal <120 50 12.9 
Normal 120-129 51 13.1 
High normal 130-139 113 29.0 
Grade 1 (mild) hypertension 140-159 128 32.9 
Grade 2 (moderate) hypertension 160-179 38 9.8 
Grade 3 (severe) hypertension ≥180 6 1.5 
Qkidney risk range (%) 
Risk category Percentage risk   
Low <3 186 47.8 
Moderate 1 3-7.9 130 33.4 
Moderate 2 8-15 45 11.6 
Severe >15 28 7.2 
 
The online QKidney® risk calculator identified 47.8% participants at “low” risk (< 3%), 
33.4% at “moderate” risk 1 (3-7.9%), 11.6% at “moderate” risk 2 (8-15%), and 7.2% at 
“severe” risk (> 15%) of developing CKD in the next 5 years. Almost half (44.6%) of 
participants had a systolic BP ≥140 mmHg (as measured during risk assessment); 47.8% and 
30.6% of participants with and without a reported diagnosis of hypertension, respectively, had 
a systolic BP ≥140mmHg. 
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3.4.3 Participant follow-up 
Of 203 participants with ≥ 3% risk, 28 were excluded from the follow-up analysis because 12 
had forgotten participating in the study, 8 had missing address/contact details and 8 withdrew 
during follow-up. From the remaining 175 participants, follow-up was successful for 126 
(72%). The rate of successful follow-up was similar across moderate-risk 1 (71.4%), moderate-
risk 2 (74.4%) and severe-risk (70.8%) categories. The success rate was highest (75.6%) 
amongst participants between 60-69 years and lowest (60.7%) for the age group 50-59 years. 
Most (70.6%) participants reported that they became aware of the risk assessment service after 
being approached by a pharmacist for participation.  
Of 126 participants with successful follow-up, 120 (95.2%) had subsequently visited their 
GP and 34 (27.0%) had discussed their results. Of participants (n = 41) who provided reasons 
for no discussion of the results, 34% mentioned that their GP did not initiate discussion on the 
risk assessment results and, therefore, they did not. 
 Of 34 participants with follow-up who had discussed results with the GP, blood test, urine 
test and BP check were performed for 26, 17 and 17 participants, respectively. The percentage 
of participants who underwent a complete ‘Kidney Health Check’ was 9 (26.5%). During 
follow-up, 36.4% of participants with hypertension (n = 110) and 48.1% of participants with 
diabetes (n = 54) agreed that they were prompted to take better care of their hypertension and 
diabetes, respectively, as a result of participation. Of 14 participants with follow-up who were 
smokers at the time of risk assessment, 7 reported reducing the number of cigarettes smoked 
per day and 1 had stopped smoking.  
3.4.4 Pathology data analysis 
Within one year following risk assessment, eGFR and ACR testing was performed in 52.7% 
(n = 107) and 25.1% (n = 51), respectively, of ≥ 3% risk participants (n = 203). Simultaneous 
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eGFR and ACR tests were performed for 19.7% (n = 40) participants. Table 3.2 shows the 
stratification of participants’ eGFR and ACR data as per their moderate-severe risk categories. 
Six participants in the moderate-risk 1 category and one in the moderate-risk 2 category had 
eGFR between 45-59 mL/min/1.73m2; however, repeated eGFR testing was performed for only 
one participant who was under the moderate-risk 1 category. Five, two and one participants in 
the moderate-risk 1, moderate-risk 2 and severe-risk category, respectively, had an ACR 
between 3.5-35 mg/mmol, female and 2.5-25 mg/mmol, male. Again, repeated ACR testing 
was performed for a single participant who was in the severe-risk category. 
Table 3.2 Stratification of participants’ estimated glomerular filtration rate and albumin 
creatinine ratio data as per their moderate-severe risk categories 
  Risk categories 
 Total Moderate-risk 1 
(3-7.9%) 
Moderate-risk 2 
(8-15%) 
Severe-risk 
(> 15%) 
 N % N % N % N % 
Estimated glomerular filtration rate (mL/min/1.73m2) (n = 107) 
>90 36 33.6 22 61.1 10 27.8 4 11.1 
60-89 64 59.8 40 62.5 14 21.9 10 15.6 
45-59 7 6.5 6 85.7 1 14.3 - - 
30-44 -  - - - - - - - 
15-30 - - - - - - - - 
<15 - - - - - - - - 
Albumin creatinine ratio (mg/mmol) (n = 51)  
<3.5, female; <2.5, male 43 84.3 26 60.5 9 20.9 8 18.6 
3.5-35, female; 2.5-25, male 8 15.7 5 62.5 2 25 1 12.5 
>35, female; >25, male -  - - - - - - 
 
 
3.5 Discussion  
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The community pharmacy-based CKD risk assessment service, with its targeting, identified a 
high proportion (52.2%) of people at ≥ 3% risk of developing moderate-severe CKD within 5 
years. However, the follow-up analysis revealed that a low proportion (27%) of referred 
participants had discussed their risk results with their GP. The major reason for the low referral 
uptake was GPs not initiating discussion on the risk assessment results. Also, absence of an 
existing medical complaint might have contributed to participants’ reluctance to initiate 
discussion.40 Another contributing factor towards the low referral uptake could be the manner 
in which the results were communicated to the GP. All GPs were sent a referral letter; however, 
it is possible that not all of them had the opportunity to read it before the patient visit.113 On 
the other hand, GPs might not have agreed with the recommendations of the risk assessment 
and chose not to act or deferred investigation in participants who were already overwhelmed 
with their existing comorbidities. Also, GPs might have over-relied on their patients to initiate 
discussion on the risk results.114 In any case, the low referral uptake was a major hindrance to 
the efficacy of the CKD risk assessment service.  
No previous studies have implemented a similar protocol in community pharmacies for 
CKD; hence, direct comparisons could not be made. Upon literature review, we found many 
pharmacy-based screening studies for diabetes,41, 43, 115 asthma,116, 117, bowel symptoms,118 
CVD44 and atrial fibrillation113, which concluded that screening in community pharmacy is 
effective and feasible. However, this seems to have been overstated because the GP referral 
uptake reported in the majority of these studies41, 43, 113, 115, 116, 118 was low and ranged from 9.1-
49%. Only two studies44, 117 reported a high GP referral uptake (92-83%), although the rate of 
referral uptake was self-reported by participants in one study117 and participant loss to follow-
up in another study was high (>50%).44 A recent systematic review investigating the 
effectiveness of pharmacy-based screening services found a significant proportion of screened 
participants do not attend their GPs for follow-up, or GPs often do not act on the referral 
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information.48 Additionally, a qualitative study of Australian GPs showed that most did not 
favour pharmacists’ provision of screening services, as they believed screening to be the role 
of the GP and lacked confidence in the accuracy of screening tests and pharmacists’ 
competence.119 These findings suggest that any pharmacy-based screening services, even with 
a robust in-pharmacy protocol, are likely to have a low success rate unless there are close 
working relationships between community pharmacists and GPs.120-122 More specifically, there 
is a need to develop an innovative referral pathway which can ensure that patients who have 
undergone screening at community pharmacies are subjected to further investigation during 
their routine visit to the GP.119, 122 
A distinctive aspect of our study, compared with other pharmacy-based screening studies, 
was the availability of participant pathology results. The QKidney® algorithm calculates a 
person’s risk of developing moderate-severe CKD over the next five years; however, this study 
identified 15 participants who had evidence of early CKD. For an accurate CKD diagnosis, the 
KHA-CARI guidelines on early CKD detection recommend simultaneous and repeated ACR 
and eGFR measurement; otherwise, an increased incidence of both over- and under-diagnosis 
is likely.6, 51, 123 Our pathology analysis showed that simultaneous testing was performed in 
only 19.7% of ≥ 3% risk participants and, although more than half of these participants had 
undergone eGFR testing, only above one-quarter had their ACR measured. Similarly, in 2007, 
Jose et al. found that only 50.6% and 9.4% of at-risk Tasmanians had serum creatinine and 
albuminuria measured, respectively.34 Also, our study found that repeated ACR or eGFR 
measurement within three months of initial testing was performed for only 2 (13.3%) out of 15 
participants with initial evidence of CKD. This suboptimal kidney testing might be attributed 
to the significant gaps, as identified by the AusHEART study, in Australian GPs’ adherence to 
preventative guidelines and recognition of CKD.12  
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Our pathology analysis revealed that more than half of ≥ 3% risk participants had undergone 
kidney testing (either eGFR or ACR measurement); however, only few were aware of it. 
Similarly, the AusDiab study found relatively low recollection of kidney testing even in 
patients with CKD.124 This suggests that information sharing by providing pharmacists access 
to patients’ medical records and pathology data would help to prevent unnecessary screening,51 
as well as enabling pharmacist review of medication dosing in kidney disease.  
There are two community-based pathology providers in the state of Tasmania. The 
pathology provider from which the data for this study were collected owns approximately 80% 
of the Tasmanian pathology specimen collection centres and has been operating for 
approximately 50 years whereas the other provider has been operating only for the past three 
years. However, it is possible that relevant pathology data for some participants may be 
missing. 
In this study, BP measurement was performed only once. This approach was used because 
the CKD risk assessment protocol was relatively time-consuming as it included several 
components. Generally, community pharmacists do not have more than 10 minutes to spare to 
perform such interventions. Similarly, pharmacy customers won’t generally participate in these 
interventions unless they are brief. Repeating the blood pressure measurements would have 
increased the overall protocol time by at least 5 minutes. Hence, pharmacists were advised to 
take a single sitting blood pressure reading but only after ensuring that the participant was 
properly rested. 
Several barriers restricted pharmacists from continuing participation. Future studies should 
aim to reduce the time required to conduct risk assessment. If pharmacy assistants are trained 
to a) collect participant demographic and clinical data, and b) measure height and weight, then 
this would allow the pharmacists to focus on key aspects, which include 1) BP measurement, 
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2) risk assessment and 3) CKD education. Pharmacists would then need only 5-10 
minutes/participant. Lastly, it is possible that kidney testing by the GP was performed as a 
result of other ongoing comorbidities and not as an outcome of risk assessment. 
3.6 Conclusion 
This study showed considerable scope for improving the awareness and early detection of CKD 
via implementation of a community pharmacy-based CKD risk assessment service. In order to 
improve the referral uptake, we recommend that during CKD risk assessment, community 
pharmacists should put emphasis on the asymptomatic nature of CKD and explain to the 
participant the importance of consulting their GP for a regular ‘Kidney Health Check’. On the 
other hand, a healthcare system that encourages a close working relationship between 
pharmacists and GPs is needed if pharmacy-based risk assessment and screening services are 
to benefit the public. 
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PROJECT II (C) 
 
CHAPTER 4. Community Pharmacists’ Experience of Implementing A 
Chronic Kidney Disease Risk Assessment Service. 
 
4.1 Abstract  
4.1.1 Background  
Community pharmacists are well positioned to deliver chronic kidney disease (CKD) screening 
services. However, little is known about the challenges faced by pharmacists during service 
implementation. The main objective of this study was to explore community pharmacists’ 
experience and barriers of implementing a CKD risk assessment service.  
4.1.2 Methods 
Pharmacists who had implemented a CKD screening service were eligible to participate. A 
purposeful sampling strategy was used for the selection of pharmacists with maximum 
variation. A conventional content analysis approach was used to conduct the qualitative study. 
Data collection was performed using semi-structured, open-ended interview questions. 
Transcripts were thematically analysed. The consolidated criteria for reporting qualitative 
research (COREQ) were followed.  
4.1.3 Results 
Five broad themes emerged from the analysis: contextual fit within community pharmacy; 
perceived scope of pharmacy practice; customer perception towards disease prevention; CKD 
– an underestimated disease; and remuneration for a beneficial service. Pharmacists found the 
Early detection and prevention of CKD 
95 
 
CKD service to be efficient, user-friendly and of significant benefit to their customers. 
However, several pharmacists observed that their customers lacked interest in disease 
prevention, and had limited understanding of CKD. More importantly, pharmacists perceived 
the scope of pharmacy practice to be significantly dependent on inter-professional 
collaboration between pharmacists and general practitioners (GPs), and customer 
acknowledgement of pharmacists’ role in disease prevention.  
4.1.4 Conclusion 
Overall, community pharmacists perceived the CKD service to be worth incorporating within 
pharmacy practice. To increase uptake, future CKD services should aim to improve customer 
awareness about CKD prior to providing risk assessment. Further research investigating 
strategies to enhance GP involvement in pharmacist-initiated disease prevention services is 
also needed.   
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4.2 Introduction 
In Australia and elsewhere, the economic and health burden associated with chronic kidney 
disease (CKD) is high.13 Data from Australia’s dialysis and transplant registry show that the 
prevalence of patients undergoing renal replacement therapies is steadily increasingly;30 this is 
largely fuelled by the ageing population, and rising rates of diabetes and hypertension.1, 17 
Evidence suggests that early diagnosis of CKD allows implementation of preventive measures 
that can reduce the risks of CKD progression and associated cardiovascular disease (CVD) by 
up to 50%.125 Despite this evidence, the availability of clinical practice guidelines,4, 6 and 
development of risk stratification tools,57, 58, 60, 65 numerous people in the community with early 
stages of CKD remain undetected.11 CKD among Australian older adults within primary care 
settings is also common, and under-recognised and under-treated.12 This indicates a large gap 
in clinical practice, and the need to explore ways through which early detection of CKD can be 
improved. 
Screening targeted groups of people with established CKD risk factors was identified as an 
important strategy for early CKD detection.6 Thus, several community-based targeted 
screening programs were conducted;36, 51, 71-75 however, most programs lacked methodological 
rigour and long-term feasibility.106 Instead, implementation of targeted ‘opportunistic’ 
screening within the healthcare system was identified as a more practical and effective 
approach.11, 12, 36 ‘Opportunistic’ screening occurs when a check or test is offered to an 
individual, without symptoms of CKD, when they present to a healthcare system for other 
reasons.11  
Currently, in Australia, routine screening for CKD is not practised.11 Involving community 
pharmacists in the early detection of CKD could be beneficial.126 In recent years, the role of 
pharmacists has extended to the provision of disease prevention services, with patient benefit 
at the core of these services.127, 128 Furthermore, pharmacy screening for diseases such as 
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diabetes,41-43 osteoporosis,45, 46  CVD44 and atrial fibrillation47 has shown potential. Similarly, 
a community pharmacist-initiated targeted CKD risk assessment service could help to alert 
general practitioners (GPs) of at-risk patients who need further diagnostic evaluation. Hence, 
we implemented and evaluated a CKD risk assessment service within 24 community 
pharmacies in the state of Tasmania, Australia. 
To further understand the feasibility of the CKD service, we conducted follow-up qualitative 
research to explore the pharmacists’ experience of implementing this service, with a focus on 
identifying the barriers to service implementation. 
4.3 Methods 
4.3.1 Ethical approval 
The Tasmanian Social Sciences Human Research Ethics Committee (H0015669) approved this 
study.  
4.3.2 CKD risk assessment service  
Prior to implementing the CKD service, online training was provided to participating 
pharmacists, and their skills and knowledge associated with CKD risk assessment were 
evaluated.108 Eligible customers were aged between 50-74 years, with at least one of the 
following risk factors: high blood pressure (BP), diabetes, heart failure, obesity (BMI ≥ 30 
kg/m2), current smoker, personal history of heart attack, angina, stroke or transient ischaemic 
attack, or family history of kidney disease. The online QKidney® risk calculator,55, 56, 58 which 
estimates a person’s 5-year risk of developing moderate-severe CKD, was used by the 
participating pharmacists to identify participants with ≥ 3% risk; these individuals were 
counselled on the results, given educational materials and advised to consult their GP for 
further assessment. These participants were followed-up after 9 months and their laboratory 
data were collected (with consent) from a pathology provider to determine the percentage of 
Early detection and prevention of CKD 
98 
 
participants who underwent estimated glomerular filtration rate (eGFR) and urine albumin 
creatinine ratio (ACR) measurement. Follow-up data analysis showed relatively low GP 
referral uptake (27%), and pathology analysis revealed suboptimal kidney testing in 80% of ≥ 
3% risk participants.  
4.3.3 Study design and participant selection 
Initially, the purpose and design of the study was explained to the pharmacists by researchers 
via mail and/or telephone. Written informed consent was obtained from all 24 pharmacists prior 
to the service implementation. After the intervention, a researcher PG (PhD candidate) 
approached the 8 pharmacists by telephone to organise the face-to-face qualitative interview. 
Pharmacists were selected by purposeful sampling strategy, to provide variation in age and 
geographic location.129 No pharmacists refused to participate in the qualitative interview.  
4.3.4 Data collection 
A conventional approach for content analysis was used to perform the qualitative research.130 
A semi-structured, in-depth interview was conducted with individual pharmacists at their 
respective community pharmacy, four months after completion of the intervention. Interview 
questions were directly related to the study objectives and open-ended (Table 4.1). Prompts 
were also offered to the pharmacists where open-ended questions elicited little response. All 
interviews were audio-recorded and lasted between 15-45 minutes. 
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Table 4.1 Interview guide for pharmacists 
Would you please describe your daily role as a community pharmacist? 
Could you please tell me the demographics of most of the customers that present to your 
pharmacy? 
Do you have a doctor’s surgery nearby? 
What do you think is the current role of community pharmacists in providing health promotion, risk 
assessment and screening services? 
What did you think about the chronic kidney disease risk assessment study? 
Follow-up questions: 
-What did you like most about this service? 
-Was there any aspect of this service that you didn’t like? 
-Was there any aspect you thought could be improved? 
According to you, is the QKidney risk assessment calculator feasible or useful in a community 
pharmacy setting? 
What was it like to recruit participants for this study? 
Follow-up questions: 
-What strategy did you use to recruit participants? 
-How did you find the recruitment process? 
-Did you find it difficult or easy to recruit participants? 
-Could you give me examples of few reasons that participants used for declining to participate in 
this study? 
How did your participants respond to this risk assessment service? Did they seem interested? 
Did your participants know what chronic kidney disease is before participation? 
Follow-up questions: 
-What did your patients think about it? 
-What was their reaction? 
-Did they come back asking about it? 
-Have you received any feedback from participants? 
Did you have your own target in mind that you would recruit at least say X number of participants 
for this study and were you able to accomplish your target? 
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Follow-up questions: 
-What prevented you from achieving your target? 
What do you think stops people in the community from participating in a pharmacist-led chronic 
kidney disease risk assessment service?  
Do you think people in the community need a chronic kidney disease risk assessment service? 
Have you had any feedback from a general practitioner or a nurse with regards to the CKD risk 
assessment service? 
Overall, would you consider the chronic kidney disease risk assessment service to be a success? 
Why? 
Follow-up question 
-I am curious to know whether you would be willing to offer this service in your community 
pharmacy if you had a choice. 
Finally, if there was anything that you would have changed or done differently when it comes to 
implementing similar research projects in your community pharmacy in future, what or how would 
you do it? 
Thank you once again for participating in this study. 
 
4.3.5 Data analysis 
The QSR International’s NVivo 11 software program was used to support each phase of the 
qualitative data analysis. All audio-recordings were transcribed verbatim into Microsoft Word 
documents by Digitype Australasia (a specialist legal and medico-legal transcription service) 
or the author PG, and imported into NVivo. The general inductive approach131 was used to 
identify themes in the documents. The analysis commenced by reading the transcripts several 
times. Initially, a list of free nodes (data categories) was generated and document contents were 
coded exhaustively into relevant nodes. These nodes were then re-grouped and organised 
hierarchically into trees to establish highly conceptualised themes. Initial coding of the raw 
data was performed by PG, with a subsequent discussion with a second author (STZ) to reach 
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an agreement on the themes. These themes were then applied back to the original data. The 
research team met again to further refine the themes, which were reviewed against the original 
transcripts. Feedback from the participants on the results of the analysis was not obtained. The 
consolidated criteria for reporting qualitative research (COREQ) were followed.132 
4.4 Results 
A total of 8 pharmacists were interviewed and data saturation was met. Table 4.2 summarises 
the pharmacists’ characteristics. Five major themes emerged from the analysis: contextual fit 
within community pharmacy; perceived scope of pharmacy practice; customer perception 
towards disease prevention; CKD – an underestimated disease; and remuneration for a 
beneficial service. 
Table 4.2 Characteristics of the interviewed pharmacists 
Pharmacist 
no. 
Age group Gender Years 
worked as a 
community 
pharmacist 
Pharmacy 
location* 
No. of 
participants 
recruited 
P1 56-65 Male 11-15 S >30 
P2 36-45 Male 5-10 S 10-20 
P3 56-65 Female >20 N/NE <10 
P4 26-35 Female <5 N/NE >30 
P5 36-45 Male 5-10 S <10 
P6 26-35 Female <5 S <10 
P7 46-55 Female 16-20 NW/WW <10 
P8 46-55 Male >20 NW/WW <10 
*Location of the pharmacy in the state of Tasmania is described geographically. 
S south; N/NE north/north east; NW/WW north west/western wilderness 
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Contextual fit within community pharmacy  
This theme was defined as the appropriateness of providing the CKD risk assessment service 
within the context of community pharmacy practice as perceived by the pharmacists. 
Most pharmacists in this study agreed that the CKD risk assessment was a well-designed 
and straightforward service that could be incorporated into their routine practice.  
“I thought that it was a good idea as a screening. You know it was nice and simple to go 
through with the patients. It didn’t take too long.” (P5) 
 
Additionally, pharmacists identified the online risk assessment calculator as a user-friendly 
tool. They liked that the online calculator required minimum data that could be easily obtained 
from participants, and provided results immediately.  
“I think it’s definitely a good tool to have and it doesn’t exactly take very long, so it’s not 
like it would take that much time out of your day to do a quick check.” (P4) 
 
Most pharmacists mentioned that the customers who underwent risk assessment appreciated 
the service.  
“Any of them that clipped up (were identified with ≥ 3% risk), they were in the doctors 
straightaway… and they thought that was good… it was just really positively received by 
all the participants.” (P3) 
 
However, several pharmacists mentioned that, given the nature of a community pharmacy 
business, at times it was challenging to recruit participants and carry out risk assessment. Being 
the sole pharmacist on duty or having a busy pharmacy prohibited pharmacists from performing 
risk assessment.  
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“Our time was little bit tricky to squeeze it in. Trying to come out and approach patients 
about this service and that was a little bit of a barrier I guess than trying to fit it between 
prescriptions.” (P2) 
 
Some pharmacists reported that the paperwork required too much time and thinking; and 
further suggested streamlining or computerising the entire process.  
“I think it could be quite easily streamlined so that it becomes easy to do but it does need to 
be a real, simple process for the pharmacist…” (P3) 
 
Several pharmacists found that training staff members to identify eligible customers, recruit 
and perform the initial stages of the risk assessment, was a useful approach to reduce their 
burden.   
“… As soon as we started teaching the staff members, you know make sure that you ask 
them this, then it became a lot easier.” (P4) 
 
Perceived scope of pharmacy practice 
As perceived by pharmacists, the continuing scope of pharmacy practice (especially in the 
provision of disease prevention services) was found to be highly dependent on the inter-
professional collaboration between pharmacists and GPs, and customers’ acknowledgement of 
the role of pharmacist in disease prevention. Pharmacists reported difficulty in engaging GPs 
as a key barrier to the perceived effectiveness of the CKD service. At the beginning of the 
study, a brief discussion on the CKD service occurred between several pharmacists and GPs. 
At that time, pharmacists received mixed reactions; some GPs had a positive view towards risk 
assessment while others did not actively participate. However, most pharmacists said that they 
did not receive any feedback from the GPs, and some wanted to know the outcome of GP 
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referral. Pharmacists expressed that although they can provide such services, having GPs on 
board was crucial. GPs were considered as the final decision makers in the care of patients; 
without their support, pharmacists believed that the scope of the CKD service was limited.  
“We did communicate that (CKD service) to them (GPs) briefly but you know they’re very 
busy. They didn’t take it on board as a big deal.” (P2) 
 
Several pharmacists felt that their professional standing in disease prevention was still 
undervalued, with their customers generally not perceiving this as a role for pharmacists.  
“I think this is an area still to be developed. I am not sure that in a general community our 
credentials as screening people have been developed or promoted… to the point for people 
(to) actually see us as being preventative provider.” (P8) 
 
However, integration of the CKD service with other established pharmacy services, for 
which pharmacists have credibility (e.g. medications review and diabetes management), was 
found to improve the service uptake.  
“What I did is your kidney study was there and then diabetes study we started in the 
pharmacy, so we linked both together and that has been better. So the same person, we can 
sometimes do the both studies.” (P1) 
 
Additionally, to encourage customer participation, some pharmacists used flyers or 
newsletters (other than the promotional poster), and invested more time in directly approaching 
and explaining the service to eligible customers. 
“We went okay once we like started going out and really putting posters up and that sort of 
thing.” (P4) 
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Several pharmacists stated that large-scale promotion through the media could help to create 
awareness and improve the uptake of pharmacy services. 
“It’s probably the fact that we don’t have ads on the radio saying go into pharmacy for this 
and the other… that’s the thing that makes people realise what your scope of business is.” 
(P7) 
 
Customer perception towards disease prevention 
Pharmacists stated that customers were often unwilling to participate, mainly due to their lack 
of interest in disease prevention.  
“… the people who I thought would be good to do really didn’t – they weren’t interested. 
They didn’t have time for their health basically. They weren’t worried enough about it.” (P3) 
 
Pharmacists also found it difficult to engage customers for participation. 
“… A lot of the time they (customers) will come in and they are busy… So they will be like 
aw I have only got enough time to get my scripts while I am here. Even though someone 
could be doing it while they were waiting for the script. But they don’t seem to see to both 
of them together. They just go nope can’t do it, I don’t have enough time….” (P6) 
 
CKD – an underestimated disease 
It was frequently identified that limited CKD awareness campaigns might have contributed 
towards the reduced uptake of the CKD service. Pharmacists perceived CKD to be an important, 
yet often ignored chronic disease in the community. They mentioned that, compared to other 
diseases, such as diabetes, hypertension or CVD, CKD and its screening is not promoted on a 
large-scale within the community. 
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“I think diabetes screening is actually more prominent simply because of the fact that there 
is more funding behind it and Diabetes Tasmania tends to promote it reasonably well in 
terms of people getting screened. So again it’s probably an awareness thing I think that they 
have more awareness than kidney function possibly does.” (P8) 
 
Additionally, pharmacists found that their customers had limited understanding of CKD and 
functions of the kidneys. Due to the lack of any symptoms, customers believed that their 
kidneys were fine; hence, they did not see the need to undergo risk assessment.  
“They didn’t think it was something you know they needed to look out or they felt fine at 
that particular moment, so why would they worry about what their kidneys were doing?” 
(P7) 
 
Remuneration for a beneficial service 
Pharmacists perceived the CKD service to be of significant benefit to their customers. They 
found that the service helped to raise the participant awareness about the kidneys and improved 
their understanding of CKD.  
 “I think the questions (of CKD service) actually (helped) awaken people to the possibility 
that (kidneys) could actually be having influence on their life. A lot of people don’t 
necessarily realise that […] they are likely to have or develop kidney problems… I think 
knowing […] the likelihood of that sort of outcome (CKD) is actually useful information 
once they (patients) have realised the importance of it.” (P8) 
 
Several pharmacists mentioned that they would like to be remunerated for providing the 
CKD service; especially if it was to become an essential component of the pharmacy business. 
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One pharmacist stressed that if the service was funded, then they would be able to allocate 
more of their own and their staff’s time to it.  
 “There had to be some sort of remuneration… so it makes it (CKD service) worth the 
time… At the end of the day, we have to run a business and pay for staff so to be able to 
prioritise time for those different jobs you need to have some sort of income for it.”(P7) 
4.5 Discussion 
Overall, the community pharmacists believed that the CKD risk assessment service was worth 
incorporating within pharmacy practice. Pharmacists perceived that the service would be of 
benefit to their customers and important to raise CKD awareness within the community. 
However, during service implementation, pharmacists experienced several challenges, out of 
which difficulty in engaging GPs was identified as a crucial barrier to the long-term feasibility 
of the service. It is well-recognised that inter-professional collaboration between pharmacists 
and GPs is vital for complete patient care. However, even after initial discussion on the CKD 
service between some of the pharmacists and GPs, the overall GP engagement was minimal. 
One reason could be the extent and mode of discussion that took place between the pharmacists 
and GPs.119 Another reason could be the lack of GPs’ confidence in pharmacists’ clinical 
expertise and capabilities to perform screening services.119, 120 Conversely, a study found that 
GPs were generally supportive of those pharmacy services which they found useful in 
managing patients.119 Prior to implementation, it is important that pharmacists demonstrate 
professional expertise to the GPs, explain the benefits of the CKD service, and establish mutual 
understanding on the referral method.120, 133  
Another barrier towards service implementation was the limited customer perception of 
pharmacists’ scope of practice. Previous studies exploring the customer opinion of community 
pharmacy practice found that most customers viewed dispensing as the primary or only role of 
community pharmacists, and were unaware that pharmacies can offer various public health 
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services.114, 134-138 A systematic review examining customer attitudes found that consumers 
were more receptive towards the availability of medicine-related, rather than health promotion 
or screening, services from community pharmacy.127 Therefore, one important strategy to 
encourage participation in the CKD service would be to incorporate it with other established 
services, which are commonly used by customers. In this study, pharmacists observed an 
improvement in the customers’ response to the CKD service when it was integrated with 
services such as medications review or diabetes management. A similar strategy was 
recommended for future implementation of pharmacy screening services in an atrial fibrillation 
screening study.139  
Another effective strategy would be active participation from pharmacists in offering the 
CKD service. Previous studies have expressed that, in order to improve customer awareness 
and participation in various pharmacy services, pharmacists need to reassess their daily practice 
and ensure that they are not just dispensing prescriptions.138-140 Instead, pharmacists should 
play an active role by directly approaching customers and explaining available services, and 
using prominent flyers.139 Similar strategies were used by pharmacists in this study to improve 
the CKD service implementation. 
This study identified limited customer understanding of CKD and kidneys as a potential 
barrier towards the service uptake. A study exploring how the public decides to undergo health 
checks for CVD prevention found that the decision depends on their perception of being 
vulnerable to the disease and whether they have had any symptoms.141 Similarly, lack of 
symptoms was identified as a barrier towards the CKD service uptake. CKD can be 
asymptomatic until the kidney function declines by up to 90%,11 and lack of this knowledge 
puts a person at increased risk of delayed diagnosis. Hence, providing customers with 
information on CKD, before offering risk assessment, might improve their understanding and 
make them more receptive towards the service.  
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Customers and GPs were not interviewed in this study. Exploring their perceptions of the 
CKD service may help to identify additional barriers, and addressing these could help the 
pharmacists in enhancing the service implementation. Additionally, a small number of 
pharmacists were interviewed in this study; however, it is well-known that for studies with a 
relatively homogenous sample population and narrow objectives, interviews as low as six are 
sufficient to reach saturation, with meaningful themes and valuable interpretation.142  
4.6 Conclusion 
Pharmacists perceived the CKD risk assessment service to be feasible for implementation 
within community pharmacy practice. To encourage customer participation, pharmacists 
should play an active role in promoting and delivering the CKD service. Also, the CKD service 
should aim to improve customer awareness about CKD prior to offering risk assessment. 
Widespread implementation of this service has the potential to improve the understanding of 
CKD within the community, which could lead to enhanced early CKD detection and prevention. 
However, further research exploring effective strategies to enhance GP involvement in 
pharmacist-initiated disease prevention services is needed. 
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PROJECT II (D) 
 
CHAPTER 5. Patient satisfaction with a chronic kidney disease risk 
assessment service in community pharmacies 
 
5.1 Abstract 
5.1.1 Background 
Screening services for some chronic diseases are increasingly being implemented in 
community pharmacy settings. Patient satisfaction is an important determinant of the feasibility 
and sustainability of these services. However, few studies have evaluated this, with no such 
study performed for a chronic kidney disease (CKD) risk assessment service. Therefore, the 
main aim of this study was to determine patient satisfaction with a CKD risk assessment service 
performed in community pharmacies in the state of Tasmania, Australia. 
5.1.2 Methods 
An anonymous nine-item satisfaction survey, with Likert-type scales, was developed following 
a literature review of existing surveys. Patients were asked an additional question on 
willingness to pay, with choices of amount from AUD $5 to $25. The satisfaction survey was 
mailed to all 389 patients who participated in the CKD risk assessment study. The main 
outcome measures were: reliability of the nine-item scale; the percentage of responses to the 
individual nine items of the satisfaction survey; and patient willingness to pay for the CKD 
service. 
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5.1.3 Results  
Responses from 143 participants (effective response rate of 42%) were included in the final 
analysis. The mean (± SD) age of participants was 63.3 (± 6.5) years and 54.5% were female. 
Cronbach’s alpha for the nine-item satisfaction scale was 0.87. The majority of participants 
agreed that the time required to undergo the risk assessment process was justified (90.2%); 
overall, they were satisfied with the CKD risk assessment service (90.0%) and they felt 
comfortable with the pharmacist referring their results to their doctor (88.9%). Of 136 
participants who answered the question on willingness to pay, 62.9% indicated that they would 
pay for the CKD service. Of these, 29.2%, 25.8% and 19.1% were willing to pay $20, $10 and 
$5, respectively.  
5.1.4 Conclusion  
Patient satisfaction with the community pharmacy-based CKD risk assessment service was 
high. These findings provide support for the implementation of the CKD service within 
community pharmacy practice. 
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5.2 Introduction 
In recent years, there has been a noteworthy increase in the number of community pharmacy-
based screening interventions for some chronic diseases.42-47, 143, 144 However, data on patient 
satisfaction with such interventions are limited.145 Patient satisfaction is an important 
determinant of the feasibility and sustainability of community pharmacy services.146, 147 
Moreover, the degree of patient satisfaction is an essential indicator of the quality of pharmacy 
services, and highlights service attributes that may need further reassessment and 
improvement.146 Patient feedback also allows community pharmacists to self-evaluate their 
competence to deliver these services. 
 In Australia, 1 in 10 adults have clinical evidence of chronic kidney disease (CKD) such as 
reduced kidney function and/or albuminuria.3 Interestingly, less than 10% are aware that they 
have this condition. CKD is asymptomatic until kidney function deteriorates by approximately 
90%; this puts a person at an increased risk of kidney failure and death.11 Early diagnosis and 
treatment of CKD in its initial stages (1-3) has the potential to prevent or delay the progression 
of CKD,6 and reduce the likelihood of hospitalisation and mortality.62 Therefore, Kidney 
Health Australia’s Caring for Australasians with Renal Impairment (KHA-CARI) guideline on 
‘Early CKD: Detection, prevention and management’ recommends screening of people with 
CKD risk factors.6 
 Although it has been established that targeted screening may help to reduce the burden of 
CKD,6 no similar strategies within the Australian healthcare model have been explored. 
Therefore, we implemented and evaluated a CKD risk assessment service in the community 
pharmacy setting. Prior to implementation, community pharmacists were trained to deliver the 
CKD service.108 The CKD service was subsequently implemented at 24 pharmacies in the state 
of Tasmania, Australia. Eligible participants were aged between 50-74 years, with at least one 
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of the following CKD risk factors: hypertension, diabetes, heart failure, obesity, current 
smoker, personal history of heart attack, angina, stroke or transient ischaemic attack (TIA), or 
family history of kidney disease.  
 A total of 389 participants underwent CKD risk assessment during 12 months. An online 
QKidney® risk calculator was used to estimate individual participant’s 5-year percentage risk 
of developing moderate-severe CKD.58 Individual participants’ height, weight and blood 
pressure (BP) were also measured during risk assessment. At the end of risk assessment, all 
participants were given written educational material on CKD, a brief explanation on their risk 
assessment results, and a copy of their results sheet. Individual risk assessment took 
approximately 15-20 minutes. Participants identified with ≥ 3% risk (n = 203) of developing 
moderate-severe CKD were advised to consult their general practitioner (GP) for further 
assessment, and followed-up after nine months to determine the outcome of GP referral.  
 To our knowledge, this is the first Australian study to implement a CKD risk assessment 
service in the community pharmacy setting. Hence, it was important to seek patient perceptions 
on the CKD service. The aim of this study was therefore to determine patient satisfaction with 
the CKD risk assessment service within a community pharmacy setting. The specific objectives 
were to identify CKD service attributes which need further improvement, and establish 
patients’ willingness to pay for the CKD service. 
5.3 Method 
A nine-item satisfaction scale (Appendix 4.1), developed by three pharmacists, a nephrologist 
and a researcher, was used to evaluate patient satisfaction with the in-pharmacy CKD risk 
assessment service. A thorough literature search identified one study that evaluated patient 
satisfaction with pharmacy-based screening services.145 Therefore, we identified and reviewed 
scales that were used for other pharmacy services, such as disease management.148-152 
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Subsequently, we developed a nine-item satisfaction scale, informed by the literature. A six-
point Likert-type scale (1 ‘strongly disagree’ to 6 ‘strongly agree’) was used to record 
responses to individual items. The survey included an additional question on willingness to 
pay, providing choices of amount from AUD $5 to $25. Participant opinion of the CKD service 
was also determined via an open-ended question “Are there any comments you would like to 
make regarding the CKD risk assessment service?” at the end of the survey.  
 Written consent for participation in the satisfaction survey was obtained from all participants 
prior to risk assessment within the pharmacies. During telephone follow-up, 13 participants 
were identified who had forgotten participating in the study. These participants were excluded 
and the satisfaction survey was sent to  the remaining 376 participants by mail. Each envelope 
contained an invitation letter, the satisfaction survey and a reply-paid envelope. The invitation 
letter also included brief information on the CKD risk assessment study and the individual 
participant’s risk results, as a reminder. Responses were anonymous. Participants did not 
receive any incentive for completing the satisfaction survey. This study was approved by the 
Tasmanian Health and Medical Human Research Ethics Committee (H0014258). 
 Statistical Package for the Social Sciences (SPSS) version 23.0 was used for the analysis. 
Descriptive statistics were calculated as mean and standard deviation (SD) for continuous 
variables, and percentage for categorical variables. The Shapiro-Wilk test was used to 
determine normality and for subsequent selection of the statistical tests. The percentage of 
responses for each Likert scale category was calculated. The open-ended question was analysed 
by employing a thematic approach and similar categories were eliminated. Cronbach’s alpha 
was used to determine the reliability of the nine-item Likert scale, using responses to individual 
Likert scale categories. Next, the Likert scale categories ‘strongly disagree’, ‘disagree’, 
‘somewhat disagree’ and ‘somewhat agree’ were grouped as 0; and ‘agree’ and ‘strongly agree’ 
were grouped as 1. Chi-square test of independence was then used to explore the relationship 
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between participant characteristics and grouped Likert scale categories. Additionally, the 
relationship between willingness to pay and participant characteristics was evaluated. A p value 
of <0.05 was considered statistically significant.  
5.4 Results 
Of 376 participants, 26 had moved or were uncontactable and 8 withdrew. Hence, the overall 
response rate (146/342) was 42.7%. In addition, 3 were excluded due to unclear responses. 
Thus, a total of 143 participants (41.8%) were included in the final analysis, and Table 5.1 
summarises their characteristics. The mean (± SD) age was 63.3 (± 6.5) years and 54.5% were 
female. More than 70% of participants had two or more risk factors for CKD.  
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Table 5.1 Participant demographics and clinical characteristics 
Characteristics N % 
Total 143 100 
Mean age (years; mean ± S.D., range) 63.6 ± 6.5 (50-74) 
Gender   
Female 78 54.5 
Male 65 45.5 
Region   
South 68 47.6 
North/north east 37 25.9 
North west/west 38 26.6 
Smoking status 
Non-smoker  83 58.0 
Ex-smoker 41 28.7 
Light smoker (less than 10 cigarettes/day) 12 8.4 
Moderate smoker (10 to 19 cigarettes/day) 5 3.5 
Heavy smoker (20 or over cigarettes/day) 2 1.4 
Diabetes 
Type 1 0 0 
Type 2 30 21.0 
Heart failure 1 0.7 
High blood pressure 121 84.6 
History of a heart attack, angina, stroke or transient ischaemic stroke 18 12.6 
Immediate family* history of kidney disease  14 9.8 
Body mass index (kg/m2) 
Underweight  <18.5 0 0 
Healthy  18.5-24.9 21 14.7 
Overweight  25-29.9 55 38.5 
Obese  ≥30 67 46.9 
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Characteristics N % 
Total 143 100 
Qkidney risk range (%) 
Risk category Percentage risk   
Low <3 74 51.7 
Moderate 1 3-7.9 41 28.7 
Moderate 2 8-15 19 13.3 
Severe >15 9 6.3 
*mother, father, brother or sister 
 
 Cronbach’s alpha for the nine-item survey was 0.87, suggesting good internal consistency. 
Table 5.2 shows the percentage of participants rating the individual items on the satisfaction 
survey as ‘agree’ and ‘strongly agree’. The majority of participants agreed that the time 
required to undergo the risk assessment process was justified (90.2%), overall they were 
satisfied with the CKD risk assessment service (90.0%), and they felt comfortable with the 
pharmacist referring their results to their doctor (88.7%). Comparatively, a lower percentage 
(65.8%) of participants agreed that risk assessment raised their awareness of CKD.  
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Table 5.2 Percentage of participants rating the individual items on the satisfaction survey as ‘agree’ and ‘strongly agree’ (n = 143) 1 
Item 
no. 
Survey item Total no.* Agree (%) 
Strongly 
agree (%) 
Total (%) 
1 Risk assessment raised my awareness on chronic kidney disease. 143 41.3 24.5 65.8 
2 Chronic kidney disease risk assessment service is useful. 141 41.1 44.7 85.8 
3 
Community pharmacy is a convenient place to perform chronic kidney disease risk assessment 
service. 
143 40.6 40.6 81.2 
4 The time required to undergo the risk assessment process was justified. 142 47.9 42.3 90.2 
5 Privacy provided during the risk assessment process was acceptable. 141 40.4 37.6 78.0 
6 I feel comfortable with the pharmacist referring my risk assessment results to my doctor. 142 36.6 52.1 88.7 
7 The risk assessment results were clearly explained and understandable. 141 46.1 39.7 85.8 
8 Brochures and leaflets provided on chronic kidney disease were informative. 137 52.6 26.3 78.9 
9 Overall, I was satisfied with the chronic kidney disease risk assessment service. 141 56.0 34.0 90.0 
*The total number of participants does not add up to 143 for several items due to missing data. 2 
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Table 5.3 shows results of the participants’ willingness to pay for the CKD service. Of 136 
participants who answered the question on willingness to pay, 62.9% (n = 90) were willing to 
pay for this service. Of these, 26, 23 and 17 participants were willing to pay $20, $10 and $5, 
respectively.  
Table 5.3 Results of participants’ willingness to pay for the chronic kidney disease risk 
assessment service 
 N % 
Total 143 100 
Willingness to pay for the service (n = 136)   
Yes 90 62.9 
No 46 32.2 
Amount willing to pay for the service (n = 89)   
$ 5 17 19.1 
$ 10 23 25.8 
$ 15 13 14.6 
$ 20 26 29.2 
$ 25 10 11.2 
 
 Of 40 participants who provided comments on the CKD risk assessment service, 13 
provided appreciative comments about the service.  
  “Well done for bringing this kidney screening service to the community.” 
 “…I was very happy with the treatment I received and that it (the CKD service) was very 
informative.” 
 Some participants (n = 8) felt that in order to be able to take advantage of the service, it 
should either be free or the government should compensate for it. 
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 “I feel the government should help out for elderly or anyone over 55 years of age.” 
 “(I) am a pensioner, so I think it should be free." 
 There were no statistically significant associations between participant characteristics and 
either individual items of the satisfaction survey or willingness to pay for the CKD service. 
5.5 Discussion 
Overall, the results showed that participants were highly satisfied with the CKD service. The 
majority of participants were comfortable with pharmacists referring their risk results to their 
doctor, and found that the time required to undergo risk assessment was justified. However, a 
lower percentage of participants agreed that risk assessment increased their awareness of CKD. 
During risk assessment, pharmacists provided participants with a brief explanation of their risk 
assessment results, and written education material on CKD. However, the CKD service did not 
involve a verbal educational component.  
 There was no statistically significant association between participant characteristics and 
level of satisfaction with various aspects of the CKD service. These findings suggest that 
patients generally appreciated the service, regardless of their age, gender, clinical 
characteristics and risk of developing moderate-severe CKD.  
 Our study showed no significant association between various participant characteristics and 
their willingness to pay for the CKD service. Conversely, previous studies153-155 have shown 
factors (other than those assessed in this study) such as higher annual income, patient 
perception of their health status (higher willingness to pay in those with perceived health status 
of average than good or very good), increasing pharmacists’ counselling time, and patients’ 
perception of pharmacists’ abilities, to significantly and positively enhance patients’ 
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willingness to pay for various pharmacy services. Additional investigations are therefore 
needed to determine various influential factors that might further explain patients’ willingness 
to pay for pharmacy screening services.  
 Some participants mentioned that the CKD service should be either free or subsidised by 
the government. This might be because several people in this age category (50-74 years) would 
be living on retirement pension. Currently, in Australia, only diabetes screening is being 
subsidised by the government, and other health services are generally provided free of cost.93 
However, one has to acknowledge that workflow challenges and shortage of time are typically 
the major barriers to pharmacists’ effective implementation of health promotion and disease 
prevention interventions.127, 139 Therefore, if there is no financial return, pharmacists are most 
likely to discontinue these services, even if these provide significant patient benefit.  
 Due to the long follow-up time interval, this study had to be performed nine months after 
the participant underwent CKD risk assessment. This could have adversely influenced the 
response rate. The reliability of our nine-item satisfaction survey was good. Further research is 
needed to test and validate this survey in a larger population. 
5.6 Conclusion  
Overall, patient satisfaction with the community pharmacy-based CKD risk assessment service 
was high. Also, most patients were willing to pay for risk assessment. Thus, from the patient 
perspective, the CKD service is worth incorporating within community pharmacy practice. 
However, to further improve the quality of this service, it should provide additional education 
on CKD.  
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PROJECT III 
 
CHAPTER 6. Knowledge about Chronic Kidney Disease in the Australian 
Public Evaluated Using A New Validated Questionnaire: A Cross-Sectional 
Study 
 
6.1 Abstract 
6.1.1 Background 
Public awareness of chronic kidney disease (CKD) is an important determinant of the uptake 
of screening programs, which may help to address the CKD burden. The aim of this study was 
to determine the CKD knowledge of the Australian public. 
6.1.2 Methods 
A CKD knowledge questionnaire was developed after reviewing the literature and discussions 
with nephrology experts. Content and face validity was performed by nephrologists (n = 3), 
renal nurses (n = 3) and research personnel (n = 4). The questionnaire was piloted in 121 public 
participants. Next, discriminant validation was performed by recruiting two additional groups 
of participants, to add to the public sample: final year undergraduate pharmacy students (n = 
28) and nephrologists (n = 27). Reliability of the questionnaire was assessed by calculating 
Cronbach’s alpha. In phase 2, a cross-sectional survey of the Australian public (n = 943) was 
conducted using the validated questionnaire. It was administered using an online Omnibus 
survey. Quota sampling was used for participant selection and to ensure that the final sample 
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would match the key characteristics of the Australian population. Finally, a standard multiple 
regression analysis was performed to identify predictors of the public knowledge. 
6.1.3 Results 
Phase 1: The median CKD knowledge scores of the public, students and nephrologists were 
12, 19 and 23, respectively, with statistically significant differences in the scores across the 
three groups (p < 0.001; Kruskal-Wallis test). The Cronbach’s alpha for the questionnaire was 
0.88, indicating that the questionnaire had good internal consistency. Phase 2: The online 
survey was closed after one week, during which time 2,173 people accessed the survey and 
1,034 provided complete responses (response rate of 4.2%). A sample of 943 eligible 
participants were included in the final analysis and their mean (SD) age was 47.6 (±16.6) years 
and 51.2% were female. The mean (SD) knowledge score was 10.3 (± 5.0). The multivariate 
analysis showed that participants with a higher level of education; with a family history of 
kidney failure; with a personal history of diabetes; and currently or previously living in a 
relationship had significantly higher knowledge scores. 
6.1.4 Conclusion  
In Australia, the public knowledge about CKD was poor and there is a need to improve their 
knowledge, perhaps through nationwide awareness programs. 
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6.2 Introduction 
The global burden of CKD has increased significantly, causing > 500,000 deaths since 1990.2, 
156 Between 2005 and 2013, the global age-standardised mortality rate for CKD has increased 
by approximately 37%.2 Despite this, CKD has received relatively limited global attention and 
needs effective public health interventions for prevention and management.2 Early detection 
and treatment of CKD in its initial stages may help in the prevention or delaying of disease 
progression.6 Many clinical practice guidelines for CKD, such as Kidney Health Australia 
(KHA) - Caring for Australasians with Renal Impairment (CARI), recommend screening of 
people with risk factors for CKD6, 63, 157 and several screening programs have been conducted 
worldwide to identify people with early stages of CKD within the community.106 
 More generally, health promotion and early detection are important strategies adapted by 
the Australian government within the national health policy to address increasing rates of 
chronic diseases.158 However, there appears to be a lack of understanding amongst the 
Australian community about the preventability of major health conditions.159, 160 An Australian 
survey, which included items to determine the public’s ability to adopt disease preventive 
measures and engage in early detection by understanding health alerts in the media and public 
displays for inoculations and screening, found less than adequate levels of health literacy in 
approximately 60% of participants.161 Limited public knowledge of the particular disease itself 
is another important barrier to the successful implementation of prevention programs.124, 159, 162 
For instance, a cross-sectional survey of Australian adults showed that even amongst subgroups 
of cohorts with the greatest risk of CKD, the knowledge of CKD risk factors and the recall of 
kidney function testing were both limited.124 
 Public awareness of CKD is an important determinant of the uptake of screening 
programs,163, 164 which may help to address the CKD burden. Determining the public 
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knowledge of CKD can also provide guidance to medical health professionals, researchers and 
kidney health organisations when establishing the need for education campaigns. The few 
studies conducted to assess the public knowledge of CKD, used questionnaires that were not 
validated,124, 165-167 with no such study performed in the general Australian population. 
Therefore, the primary aim of this study was to determine the knowledge about CKD in the 
Australian public using a newly developed and validated questionnaire. The secondary aim was 
to determine potential predictors of CKD knowledge in the Australian public. 
6.3 Methods 
The Tasmanian Health and Medical Human Research Ethics Committee (H0015680) approved 
this study, which involved two phases: Phase 1) Development and validation (content and 
discriminant validity) of the CKD knowledge questionnaire, and Phase 2) A cross-sectional 
survey to evaluate the Australian public knowledge of CKD. Written consent was obtained for 
all participants except those who completed the questionnaire online. Completion of the online 
questionnaire by an eligible participant itself implied the consent to participate in this study.  
Phase 1) Development and validation 
The initial draft of the CKD knowledge questionnaire was generated through literature review 
of existing public165-167 and related questionnaires,124, 168-172 following discussions with 
nephrology and research experts. The questionnaire was divided into 5 sections and included a 
total of 35 evidence-based questions on the physiology of the kidneys, ‘Kidney Health Check’,5 
risk factors for CKD173 and signs and symptoms of advanced CKD or kidney failure. Seven 
control items were added to the questionnaire for methodological validity. The questionnaire 
and the correct answers to knowledge questions were reviewed for content and face validity by 
nephrologists (n = 3), renal nurses (n = 3) and research personnel (n = 4). For each section, 
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reviewers were asked to evaluate individual items and highlight those that were deemed 
inappropriate in terms of phrasing and applicability. Consequently, items that would require a 
clinical level of expertise were deleted, and several items were rephrased so that a layperson 
could better understand them. The final draft of the questionnaire is provided as an additional 
file (Appendix 5.1) consisted a total of 24 questions with the multiple-choice options ‘True’, 
‘False’ and ‘I don’t know’. Correct responses were given a score of 1 and incorrect responses 
were given a score of 0. The option ‘I don’t know’ was considered as lack of knowledge and 
given a score of 0.  
Next, the questionnaire was piloted and involved recruitment of eligible people visiting the 
central shopping district and a suburban shopping centre in Hobart, Tasmania. Eligible people 
were adults (≥18 years) who were not registered healthcare professionals, such as a doctor, 
nurse, pharmacist or dietitian, and did not have a personal history of kidney failure. A 
researcher visually determined the eligibility of a potential participant and approached them 
for participation. Those willing to participate (after confirmation of eligibility) were required 
to complete the questionnaire on the spot. The first five participants additionally assessed the 
questionnaire for clarity, formatting and phrasing. Sample size for this pilot phase was 
calculated as per the recommendations made by Viechtbaur et al.174 To be 99% certain that the 
pilot study would detect any unforeseen problems e.g. misinterpretations of the questionnaire 
items with a problem probability of 0.05, at least 90 participants was needed.  
To determine the discriminant validity of the questionnaire, two additional groups of 
participants were recruited: final (fourth) year undergraduate pharmacy students and 
nephrologists. Pharmacy students from the University of Tasmania were invited to answer the 
self-administered questionnaire during their regular university tutorial sessions. Nephrologists 
completed an online questionnaire following recruitment through an advertisement in the 
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Australian and New Zealand Society of Nephrology’s weekly newsletter. No previous data 
(from a pilot study) was available to perform a statistical power analysis for sample size 
estimation. Therefore, choosing a large effect size of 0.40, with an alpha = 0.05 and power = 
0.80, the projected sample size needed was approximately N = 66 (22 per group) for between-
group comparisons.175 It was hypothesised that the mean knowledge score would be highest 
for nephrologists, followed by students and lastly the public. 
Reliability of the questionnaire was measured by calculating the Cronbach’s alpha. Next, 
normality of distributions of the continuous variable was determined using the Shapiro-Wilk 
test. The Kruskal-Wallis test was used to determine if there were any statistically significant 
differences between the knowledge scores of the three groups (i.e. public, students and 
nephrologists). Post-hoc tests were performed using Mann-Whitney U tests to determine which 
groups were significantly different (p < 0.005) from one another.  
Phase 2) Cross-sectional survey 
The above-validated questionnaire was used to evaluate the public knowledge of CKD. Based 
on the Phase 1 data, it was estimated that at least 50% of the sample would have a total score 
of at least 50% of the maximum achievable score on the questionnaire. Using a 5% precision 
and 99% confidence level, to be 99% sure that the true percentage of the public that would 
achieve at least 50% score on the questionnaire was between 45% and 55%, 665 eligible 
participants were needed. The questionnaire was administered using I-view’s (an Australian 
market and social research data collection agency; http://www.iview.com.au/) online Omnibus 
service. 176 The Omnibus is conducted over a period of one week once fortnightly, and provides 
a national sample of 1000 adults (≥18 years). I-view’s online panel ‘MyView’ was used as the 
sampling frame; it consists of approximately 130,000 Australian adults (≥18 years) and 
overseas visitors staying or intending to stay in Australia for 12 months or more. Quotas were 
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set according to age, gender and geographical locations (divided according to state, and by 
metropolitan and rural areas) to ensure that the final sample would match the characteristics of 
the Australian population, as per the Australian Bureau of Statistics (ABS) 2011-census data.  
 The online Omnibus was conducted between 2nd and 6th November 2016. Respondents who 
completed the survey in under half of the median survey length were identified as skimmers 
and excluded. Post-stratification was used to make adjustment to the weights so that the 
resultant weighted estimates from the sample conform to the Australian population values for 
age, gender and location. The sample (cross-sectional survey data) joint distribution and 
population (ABS census 2011 data) joint distribution of all three variables (age range, gender 
and location) was determined. Post-stratification was performed using the rim weighting 
method.177 Rim weighting allows benchmarking sample distributions to that of the population 
distributions. It is an iterative proportional fitting procedure, where all three variables were 
simultaneously weighted until a convergence was reached.  
 After the weighted data were obtained from I-view, participants were excluded if they 
identified themselves as a healthcare professional (such as a doctor, nurse, pharmacist or 
dietitian) or had a personal history of kidney disease. Given the large sample size, the central 
limit theorem holds true, and it was reasonably assumed that the distribution of the total score 
would be approximately normally distributed.178 Next, bivariate analyses was performed using 
one-way ANOVA and independent t-tests, as appropriate, to compare the effect of participants’ 
sociodemographic characteristics on the CKD knowledge score. A multivariable linear 
regression model was then constructed to predict the knowledge score based on potential 
predictor variables (p < 0.10, using bivariate analysis), and a standard multiple regression 
analysis was performed. We confirmed the assumptions of normality, linearity and 
multicollinearity. 
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The software Statistical Package for the Social Sciences (SPSS) version 23.0 and G*Power 
version 3.1 were used to perform the statistical analyses.  
6.4 Results 
Phase 1) Development and validation 
Complete responses were received from 28 students, 27 nephrologists and 121 participants 
from the public, and these were included in the analysis. These corresponded to over 85% of 
the students (n = 31) who attended the university tutorial session and members of the public 
approached, while the nephrologists voluntarily accessed the online questionnaire. Appendix 
5.2 shows the percentage of correct responses to individual items on the questionnaire by all 
three groups. The Cronbach’s alpha was 0.88 (95% CI: 0.86-0.91), indicating that the 
questionnaire had good internal consistency. 
 The p-value for the Shapiro-Wilk test was <0.05, indicating that the data were not normally 
distributed. Therefore, non-parametric statistical tests were used to perform subsequent 
analyses. The Kruskal-Wallis test revealed a statistically significant difference in the total score 
of participants across the three groups (χ2 (2, N = 176) = 109.7, p < 0.001). The median total 
scores of the nephrologists, students and public were 23, 19 and 12, respectively. Post-hoc 
comparisons performed between pairs of groups found statistically significant differences 
between all three groups (p < 0.001). 
Phase 2) Cross-sectional survey 
A total of N = 24,662 people were invited to participate in the online Omnibus survey. The 
survey was closed after one week, during which time 2,173 people accessed the survey and 
1,034 provided complete responses (response rate of 4.2%).  A total of 73 participants were 
identified as a registered healthcare professional or had a personal history of kidney disease, 
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and 18 had unclear sociodemographic characteristics; these were excluded. Thus, a sample of 
943 participants was included in the final analysis, and Table 6.1 shows participant 
characteristics and their comparison with the Australian public. Since this sample was matched 
to only Australian public values for age, gender and location, there are differences in the 
proportions under the categories education and country of birth. More specifically, this sample 
had a higher proportion of Australian-born participants and individuals who were higher 
degree/postgraduate diploma/bachelor degree holders and diploma/vocational holders. 
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Table 6.1 Participant socio-demographic characteristics 
Characteristics Participants  Australian public 
 N % N % 
Total  943 100 16,517,613 100 
Age (Mean ± S.D., range) 47.6 ± 16.6, 18-84   
Age range (years)     
18 – 29 181 19.2 3,533,626 21.4 
30 – 49 347 36.8 6,020,939 36.4 
50 + 415 44.0 6,963,048 42.2 
Gender     
Female 483 51.2 8,446,803 51.1 
Male 460 48.8 8,070,810 48.8 
Country of birth     
Australia 727 77.1 10,674,865 64.6 
Not Australia 216 22.9 5,842,748 35.4 
Education     
Higher degree or postgraduate diploma/Bachelor 
degree 
299 31.7 3,268,574 19.8 
Diploma/Vocational 345 36.6 1,392,191 8.4 
Completed highest level of school 178 18.9 2,639,997 16.0 
Did not complete highest level of school 121 12.8 472,469 2.9 
Occupation     
Professional/Managerial 189 20.0   
Sales/Clerical 147 15.6   
Technical/Skilled 81 8.6   
Unskilled/Labourer 53 5.6   
Other occupations 53 5.6   
Do not work 420 44.5   
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Characteristics Participants  Australian public 
 N % N % 
Total  943 100 16,517,613 100 
Work outside home     
Yes, full-time 331 35.1   
Yes, part-time 192 20.4   
No (Not employed, student, work at home, 
homemaker, retired, etc.) 
420 44.5   
Gross annual income     
Under $50,000 348 36.9   
$50,000 to just under $100,000 281 29.8   
$100,000 and over 208 22.1   
Refused 103 11.2   
Marital status     
Married/Common law, De-facto or Living with a partner 568 60.2   
Single/Never married 227 24.1   
Divorced/Separated/Widowed 148 15.7   
Number of people in the household     
One 186 19.7   
Two 349 37.0   
Three  163 17.3   
Four 172 18.2   
Five or more 73 7.7   
Children under 18 years of age     
Yes 285 30.2   
No 658 69.8   
Area description     
Within a capital city 535 56.7   
Within a major regional city 234 24.8   
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Characteristics Participants  Australian public 
 N % N % 
Total  943 100 16,517,613 100 
Within a rural town or its surrounds 144 15.3   
More than 5km from the nearest town 30 3.2   
State     
New South Wales  296 31.4 5,316,815 32.2 
Victoria 257 27.3 4,149,390 25.1 
Queensland 181 19.2 3,278,855 19.8 
Western Australia 85 9.0 1,709,692 10.4 
South Australia 84 8.9 1,247,852 7.6 
Tasmania 24 2.5 381,299 2.3 
Australian Capital Territory 13 1.4 277,559 1.7 
Northern Territory 3 0.3 153,716 0.9 
Other territories 0 0 2433 0.0 
Aboriginal or Torres Strait Islander descent     
Yes 15 1.6 10,329 0.1 
No 928 98.4 16,507,284 99.9 
Family member working as a registered healthcare professional e.g. doctor, nurse, dietician 
or pharmacist 
Yes 55 5.8   
No 888 94.2   
Family history of kidney failure     
Yes 47 5.0   
No 896 95.0   
Medical condition(s)/illness(es) that require regular medications   
High blood pressure known as hypertension     
Yes 220 23.3   
No 704 74.7   
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Characteristics Participants  Australian public 
 N % N % 
Total  943 100 16,517,613 100 
I don’t know 19 2.0   
Raised blood sugar known as diabetes     
Yes 81 8.6   
No 840 89.1   
I don’t know 22 2.3   
Heart problems such as heart failure or heart attack 
Yes 42 4.5   
No 877 93.0   
I don’t know 24 2.5   
Personal history of stroke     
Yes 18 1.9   
No 900 95.4   
I don’t know 25 2.7   
Blanks indicate that the data for the Australian public was not available. 
*Sample was post-weighted to match only three Australian public characteristics (age, gender and 
state). 
`Variables do not add up to total due to education information inadequately described or not stated by 
the Australian public. 
 
 The mean (SD) knowledge score of the Australian public was 10.34 (± 5.0), with values 
ranging from 0 to 22. The percentage of the public who scored at least 50% on the questionnaire 
was 63.3. As shown in Figure 6.1, 50% of the participants had knowledge scores less than 11. 
Table 6.2 shows the percentage of participants with correct responses to individual items on 
the questionnaire. Most participants knew that kidneys make urine (62.1%) and clean blood 
(69.8%); however, very few identified that kidneys help to maintain blood pressure (BP) 
(26.4%) and keep the bones healthy (14.3%). Many participants identified diabetes (60.6%) as 
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a risk factor, but hypertension (38.3%) was less frequently recognised. Most participants knew 
that urine (76.2%) and blood (68.2%) tests help to determine the kidney health; however, only 
20.3% people knew that BP monitoring also helps in evaluating kidney health. Only 23.4% 
knew that herbal supplements are not effective in treating CKD and just over 50% knew that 
medication could help in delaying the progression of CKD.  
Figure 6.1 Distribution of the chronic kidney disease knowledge scores of the Australian public (n = 
943) 
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Table 6.2 Percentage of correct response to individual items on the questionnaire by the 
Australian general population (N = 943) 
Item 
No 
Question 
Correct response 
(%)  
1* A person can lead a normal life with one healthy kidney. 85.6 
2 
Herbal supplements can be effective in treating chronic kidney 
disease. 
23.4 
3* 
Certain medications can help to slow-down the worsening of chronic 
kidney disease. 
51.2 
What functions do the kidneys perform in the body? 
4* The kidneys make urine.  62.1 
5* The kidneys clean blood.  69.8 
6 The kidneys help to keep blood sugar level normal. 22.6 
7* The kidneys help to maintain blood pressure.  26.4 
8 The kidneys help to breakdown protein in the body. 14.3 
9* The kidneys help to keep the bones healthy. 14.3 
Which of the following are commonly used to determine health of the kidneys? 
10* A blood test.  68.2 
11* A urine test.  76.2 
12 A faecal (poo) test. 45.9 
13* Blood pressure monitoring.  20.3 
What are the risk factors for chronic kidney disease? 
14* Diabetes.  60.6 
15 Being female. 42.4 
16* High blood pressure. 38.3 
17* Heart problems such as heart failure or heart attack. 26.3 
18 Excess stress. 16.4 
19* Obesity. 58.6 
   
Early detection and prevention of CKD 
137 
 
 
 
 
Item 
No 
Question 
Correct response 
(%)  
What are the signs and symptoms that a person might have if they have advanced chronic 
kidney disease or kidney failure? 
20* Water retention. (excess water in the body) 61.1 
21 Fever. 15.2 
22* Nausea/vomiting. 37.6 
23* Loss of appetite. 38.4 
24* Increased fatigue (tiredness).  58.7 
* True items 
 
 The analysis of variance (Appendix 5.3) showed significant associations between the CKD 
knowledge score and socio-demographic variables, such as age, education, occupation, annual 
income and marital status, and a personal history of hypertension, diabetes, heart disease and 
stroke (p < 0.01). There was also a significant difference (p <0.01) in the knowledge scores of 
participants with and without a family history of kidney failure (Appendix 5.4). A multiple 
linear regression was performed to predict the CKD knowledge score based on age, education, 
occupation, marital status, family history of kidney failure, and a personal history of 
hypertension, diabetes, heart disease and stroke. The bivariate analysis showed that participants 
who refused to reveal their annual income had statistically significantly lower knowledge 
scores than the other category participants. This participant characteristic was excluded.  
 Table 6.3 shows the results of the standard multiple regression analysis between CKD 
knowledge score and participant characteristics. A significant regression equation was found 
(F (21,921) = 4.58, p < 0.001), with an R2 of 0.095. The multivariate analysis found higher 
knowledge scores associated with a higher level of education, such as possessing a 
postgraduate diploma or bachelor degree and diploma/vocational certificate. A family history 
of kidney failure was also independently associated with higher knowledge scores, as was a 
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personal history of diabetes. Finally, participants currently or previously within a relationship 
(married, de-facto or living with a partner and divorced/separated/widowed) had significantly 
higher knowledge scores than those who were single/never married.  
Table 6.3 Standard multiple regression analysis between CKD knowledge score and participant 
characteristics 
Characteristics  β coefficient (95% CI) p value 
Age range (years)   
18 – 29*   
30 – 49 -0.06 (-1.56 to 0.25) 0.16 
50 + 0.04 (-0.57 to 1.43) 0.40 
Education   
Did not complete highest level of school*   
Completed highest level of school 0.01 (-0.99 to 1.28) 0.80 
Diploma/Vocational 0.11 (0.10 to 2.14) 0.03 
Higher degree or post graduate diploma/Bachelor degree 0.16 (0.58 to 2.79) 0.003 
Occupation   
Do not work*   
Unskilled/Labourer -0.04 (-2.35 to 0.43) 0.18 
Technical/Skilled -0.01 (-1.27 to 1.10) 0.89 
Sales/Clerical -0.02 (-1.23 to 0.67) 0.57 
Professional/Managerial 0.06 (-0.32 to 1.64) 0.11 
Other occupations 0.05 (-0.39 to 2.43) 0.16 
Marital status   
Single/Never married*   
Married/Common law, De-facto or Living with a partner 0.10 (0.21 to 1.80) 0.01 
Divorced/Separated/Widowed 0.10 (0.28 to 2.48) 0.01 
Family history of kidney failure   
Yes vs No 0.08 (0.39 to 3.24) 0.01 
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Characteristics  β coefficient (95% CI) p value 
Medical condition(s)/illness(es) that require regular medications 
High blood pressure known as hypertension   
Yes*   
No -0.02 (-1.09 to 0.55) 0.52 
I don’t know -0.09 (-6.84 to 0.29) 0.07 
Raised blood sugar known as diabetes   
Yes*   
No -0.09 (-2.54 to -0.22) 0.02 
I don’t know -0.07 (-5.37 to 0.79) 0.15 
Heart problems such as heart failure or heart attack   
Yes*   
No 0.01 (-1.29 to 1.86) 0.73 
I don’t know 0.03 (-2.31 to 4.22) 0.57 
Personal history of stroke   
Yes*   
No -0.09 (-4.32 to 0.27) 0.08 
I don’t know -0.16 (-8.43 to -1.15) 0.01 
*Reference; R2 for the model = 0.095. 
6.5 Discussion 
Overall, the results of this study show poor understanding of CKD amongst the Australian 
public. Participants in this study had limited knowledge of the physiological role of the kidneys, 
especially relating to the regulation of BP, and bone development and metabolism. Participant 
knowledge about CKD risk factors was also limited. Less than half of the participants correctly 
identified hypertension as a risk factor. This percentage was higher, however, than the 2.8% 
reported in a study of 852 Australians by White et al.124 In a public survey of 748 participants 
conducted in Iran,166 only 14.4% selected ‘unmanaged hypertension’ as ‘very likely to result 
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in CKD’; whereas a study of 516 community-dwelling Hong Kong adults reported that 43.8% 
participants knew that hypertension can cause kidney disease.165 Additionally, a cross-sectional 
study of 454 participants conducted in South-West Nigeria found that 54.7% believed that 
hypertension was a CKD risk factor.167 Conversely, the percentage of participants (60.6%) who 
correctly identified diabetes as a risk factor in this study was high as compared to the 8.6%, 
12.7%, 44.0% and 49.0% reported by White et al.,124 Roomizadeh et al.,166 Chow et al.165 and 
Oluyombo et al.,167 respectively.  
 Only half of the participants knew that medications can help to slow the worsening of CKD. 
This suggests that the Australian public’s understanding of the treatment of kidney failure is 
relatively poor. In addition, only 23.4% of participants knew that herbal supplements are 
ineffective in treating CKD. Some herbal supplements have been associated with the 
development of CKD179 and related to acute kidney injury.180 Also, concomitant use of herbs 
and conventional drugs can cause drug toxicity and therapeutic failure via alteration in renal 
function.181 With the increasing availability and use of herbal medicines in high-income 
countries,10 efforts should be made to educate people on their potentially harmful 
repercussions, and their use should be strongly discouraged in people with kidney disease. 
 KHA recommends that people with diabetes or hypertension should undergo a ‘Kidney 
Health Check’ every year.5 A ‘Kidney Health Check’ includes three assessments: a blood test 
to determine the estimated glomerular filtration rate (indicates level of kidney function); a urine 
test to check for albuminuria (marker of kidney damage); and an assessment of BP because 
kidney disease can be an outcome of high BP or cause renal hypertension. More than 65% of 
participants in this study knew that blood and urine tests can be used to determine kidney 
health; however, few correctly identified a BP assessment. Both hypertension and CKD are 
silent diseases, which warrant regular monitoring for prevention and management. There is a 
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need to create improved awareness about BP, its regular monitoring and its association with 
CKD amongst the Australian public.  
 The multivariate analysis showed that CKD knowledge score increased with a higher level 
of education; this is consistent with the findings of other studies.165, 167 Additionally, our 
regression model showed that participants who were single or never married had lower CKD 
knowledge scores. This may be because people who have lived or are living with others are 
more actively involved in acquiring health-related information and implementing healthy 
lifestyles.182-185 Another important predictor variable was a family history of kidney failure. 
This was an expected outcome because knowing a person with kidney failure would be 
anticipated to indirectly raise awareness on the same.  
 White et al.124 and Chow et al.165 found, similar to this study, that participants with a 
personal history of diabetes had better knowledge. Although this predictor variable reached 
statistical significance in the final model, the mean total score of patients with diabetes was 
low (11.8 out of a possible score of 24). This suggests that even though patients with diabetes 
had better knowledge when compared with the public, their overall CKD knowledge was still 
poor. Similarly, even though participants with other existing co-morbidities had comparatively 
higher mean scores, the values were still around half of the maximum achievable on the 
questionnaire. This demonstrates that even amongst the cohorts at highest risk of developing 
CKD, awareness is relatively low.  The KHA-CARI guidelines recommend that physicians 
should provide early CKD education to patients with CKD risk factors as this may prevent 
CKD development and progression.6 A recent Australian study conducted to determine the 
kidney disease health-literacy among new patients referred to specialist nephrology care 
reported that 35.8% patients had received no education and 46.2% had little, but inadequate, 
information on their kidney problem when being referred by their doctor.170 When asked what 
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causes CKD, almost 40% patients answered ‘unsure’ and approximately 30% answered 
‘alcohol’. The reliability of our newly developed and validated questionnaire was good. Hence, 
primary care physicians can use this questionnaire to evaluate CKD knowledge and 
subsequently provide tailored education to patients at risk of developing CKD.  
 Some inconsistencies were found when comparing the questionnaire results of this study 
with those of others. These, in part, may be because of the exploratory nature of the questions 
and non-validated questionnaires used in other studies. Creating a questionnaire that can 
produce valid and reliable data is a complex process, and guidelines are available for 
developing and validating questionnaires before their use in cross-sectional studies.186-188 
Despite this, studies have often used non-validated questionnaires.186 
 Prior to the future use of this questionnaire, several improvements that could be made 
include: 1) Rephrasing section 2 as “What major functions do the kidney perform in our body?” 
(noting that there is some involvement in controlling blood glucose levels) and 2) Addition of 
an item under Section 2 “Kidneys help in the production of red blood cells” (True Item).  
 It is acknowledged that the sample may not have been truly representative of the general 
public. It was weighted to match the Australian population for only age, gender and location, 
and had a relatively high proportion of participants who were higher degree/postgraduate 
diploma/bachelor and diploma/vocational degree holders. Also, more than 20% of the 
participants had a gross annual income of $100,000 and over. Despite this, the mean total score 
of participants was less than 50% of the maximum score achievable on the questionnaire. This 
suggests that everyone should be targeted for CKD education, irrespective of their 
sociodemographic backgrounds. While the regression model was statistically significant, the R 
square value was low. Hence, future studies should explore additional predictors, which can 
further assist in understanding the low CKD knowledge of the public.  
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6.6 Conclusions 
A valid and reliable questionnaire to measure the CKD knowledge of the general population 
was developed and tested in this study. Australian public knowledge of the physiological role 
of the kidneys, and CKD and its risk factors was poor, irrespective of sociodemographic and 
clinical characteristics. Healthcare professionals within primary care settings should evaluate 
the CKD knowledge of patients with CKD risk factors and, if warranted, provide tailored 
education. As for the public, there is a need to increase their understanding of kidneys and 
knowledge of CKD through nationwide awareness programs. These efforts may improve the 
early detection and management of CKD.  
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General Discussion 
Overall, the research described in this thesis highlights some effective strategies, the 
implementation of which could help to improve the early detection and prevention of CKD in 
Australia. A review of the targeted screening interventions for CKD showed that almost all 
interventions inadequately followed the clinical guidelines for initial detection of CKD. The 
analysis further indicated that interventions lacking methodological rigour may result in an 
increased risk of over-diagnosis, inefficient use of resources, and unnecessarily labelling many 
people as diseased within the community. This raises significant concern because the true 
effectiveness of targeted screening cannot be established. We suggest that researchers, 
healthcare professionals, and kidney health organisations, should appropriately use these 
evidence-based clinical guidelines in future interventions, if they are to benefit the public. More 
specifically, the interventions should use simultaneous testing approaches (i.e. eGFR and 
ACR), and perform repeated testing in people identified with positive screening test results. 
The systematic review also highlighted that almost all screening interventions for CKD 
performed in the community settings lacked sufficient evidence to support their long-term 
feasibility. Instead, a better approach would be to incorporate the strategy of targeted screening 
within the healthcare model. Hence, Project II was implemented which evaluated the 
effectiveness of a CKD risk assessment service in community pharmacy settings.  
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Limitations 
Project II showed a considerable scope for improving the public awareness and early detection 
of CKD via implementation of a pharmacy-based CKD risk assessment service. However, 
specific barriers hindered the service from reaching its full potential. An  important one was 
that, in comparison with Canadian community pharmacists,51 Australian pharmacists still do 
not have the authority to order laboratory tests. Hence, participant follow-up for the CKD risk 
assessment was completely dependent on GPs. Additionally, pharmacists faced several 
challenges during service implementation. Therefore, prior to future implementation, several 
steps need to be taken to enhance the CKD service.  
 Two major barriers identified to the effective implementation of the CKD service were:  
1. Inadequate inter-professional collaboration between community pharmacists and GPs, 
and 
2. Suboptimal kidney testing in participants identified at moderate-severe risk of 
developing CKD over the next five years via the online QKidney® risk calculator. 
 The findings of Project II (B) and II (C) suggest that unless there is a close working 
relationship between community pharmacists and GPs, any pharmacy-based screening or risk 
assessment services are likely to have a low success rate. A systematic review evaluating the 
effectiveness of screening for diabetes and CVD in community pharmacies similarly reported 
that although pharmacies are feasible sites for screening, development of inter-professional 
relations between pharmacists and GPs, together with more robust referral pathways, are 
necessary to ensure participant follow-up.48 Thus, identification and implementation of 
strategies to enhance pharmacist-GP collaboration, prior to providing the CKD service, are 
necessary.  
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  In Project II (C), several pharmacists mentioned that they briefly communicated the CKD 
risk assessment service to the GPs once at the beginning of the study. This manner of 
communication could have possibly resulted in limited GP involvement. Previous studies have 
indicated open, face-to-face and high frequency of communication, and combined meetings or 
continuing educational activities as important strategies for improving inter-professional 
collaboration.119, 189-197 One qualitative study showed that GPs highly approve of the home 
medications review service performed by community pharmacists in Australia.119 This is 
mainly because GPs perceived this service valuable for patient care, and important to ensure 
quality use of medicines. Similarly, a review of theoretical models, aimed to understand the 
pharmacist-GP collaboration and identify associated determinants, found that GPs are 
generally receptive towards those pharmacy services which provide patient benefit.120 Hence 
during initial communication, preferably as a scheduled face-to-face meeting, it is necessary 
for pharmacists to provide GPs with detailed information on the CKD risk assessment service. 
More importantly, pharmacists should demonstrate to GPs the patient benefits from undergoing 
CKD risk assessment. These benefits include (i) early identification of initial stages of CKD 
and implementation of measures to prevent disease progression; and (ii) improved patient 
understanding about the functions of the kidneys, their individual risk of developing CKD 
based on their risk factor profile, the asymptomatic nature of CKD, the importance of regular 
‘Kidney Health Checks’, and the significance of managing their existing risk factors, such as 
diabetes and hypertension. 
 GPs often lack confidence in the accuracy of the tests used for screening, and in pharmacists’ 
clinical expertise and capabilities to perform extended professional services.119, 120 A recent 
case study showed that GPs were more willing to advance their collaborative working 
relationship mainly because they were asked to provide input on the testing protocol and 
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training to ensure that they were confident with the pharmacists’ role in providing point-of-
care testing services.198 Hence, pharmacists should demonstrate their professional expertise, 
and provide GPs with comprehensive evidence supporting the validity of the risk assessment 
tool. Also, GPs should be given an opportunity to discuss any queries and make suggestions 
associated with the CKD service and any requisite training. It is particularly important that 
pharmacists and GPs work together to explore and agree on a referral pathway (for e.g. e-mail, 
fax, mail, or telephone), which would be most effective to ensure patient follow-up as per their 
individual pharmacy and general practice environment.  
 Previous studies have shown that pharmacists and GPs have little appreciation and 
understanding of each other’s contribution in patient care.114, 121, 133, 140, 199 It was also 
determined that GPs might not be receptive towards a pharmacy service if they perceive it to 
compromise their patient relationship. Studies have shown trustworthiness and role 
specification as factors significantly responsible for increasing pharmacist-GP 
collaboration.192, 196, 197, 200-202 Therefore, pharmacists should clearly define individual roles in 
providing the CKD service, and highlight sharing of responsibilities for overall patient benefit. 
Lastly, regular meetings between pharmacists and GPs should be organised to review the risk 
assessment and referral process, and implement changes as deemed necessary. This manner of 
communication (i.e. face-to-face, bidirectional decision-making and information sharing, and 
regular meetings) could theoretically lead to enhanced trust and interdependence between 
pharmacists and GPs, which is needed to form a robust collaborative practice.  
 It is possible that absence of a previously established collaborative practice could make 
pharmacists hesitant in approaching GPs, and fear that they might damage their existing 
relations.119 Collaboration with GPs before implementation of a pharmacy screening service 
could prove to be more beneficial as shown by one study where patients were actually referred 
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to the pharmacists for screening and education by GPs.203 Hence, training to improve 
pharmacists’ confidence and communication skills, and providing them with information on 
the above mentioned strategies for enhancing inter-professional collaboration, would ensure 
that pharmacists are proactive in approaching GPs and engaging them in providing the CKD 
service.120, 121, 133, 140, 204 
 Another barrier identified within Project II (B) was the suboptimal kidney testing (i.e. 
measurement of both eGFR and urine ACR) in participants at moderate-severe risk of 
developing CKD. Similarly, the results of a pilot study implementing a CKD early detection 
and management program in Melbourne primary care settings showed that GPs still did not 
perform repeated testing to confirm CKD diagnosis in at-risk patients.35 Currently, in Australia, 
screening for CKD is not routinely practised by any healthcare professional.11 Literature shows 
that owing to the huge patient workload in primary care settings, GPs generally find it difficult 
to effectively perform preventative interventions.37-39 A recent qualitative study conversely 
illustrated that Australian GPs were wary of the financial costs associated with the provision 
of additional non-claimable services, and believed that unfunded services, such as CKD 
screening, were difficult to justify in a private business environment.40 An additional concern 
is the lack of GPs’ adherence to KHA’s recommended algorithm for initial CKD diagnosis,6 
especially for urine ACR testing in at-risk patients.12, 34, 35  
 In any case, the above mentioned barriers raise several important questions (listed below) 
which need to be explored and addressed by future studies in order to improve the efficacy of 
the CKD service.   
1. What are the current clinical practices of GPs for CKD diagnosis and management? 
Under what circumstances do GPs generally perform kidney testing in their patients? 
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2. What are GPs’ views regarding the ‘early CKD detection and prevention’ strategy? 
3. What are the various factors (i.e. patient, disease or health insurance-related) that 
influence GPs’ decision to order kidney tests for their patients?  
4. What are GPs’ perceptions of the pharmacy-based CKD risk assessment service? More 
specifically, what are GPs’ opinions about the online QKidney® risk calculator and the 
recommendations for participant referral? 
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Directions for future research 
Community pharmacists faced several challenges during the CKD service implementation. To 
address these, we recommend some refinements to various aspects of the CKD service. In 
Project II (A), the impact of a web-based training program on pharmacists’ competence to 
deliver the CKD service was evaluated. This study demonstrated that, with appropriate training, 
pharmacists can efficiently perform the CKD service. However, prior to future implementation 
of the pharmacists’ training program, we recommend the addition of four new topics under the 
lecture presentation, as shown in Figure C. These topics are:  
1. Patient education on CKD,  
2. Integration of the CKD service with other established services,  
3. Training of pharmacy staff, and  
4. Training to improve the inter-professional collaboration between pharmacists and GPs.  
 
The revised CKD risk assessment protocol is shown in Figure D. 
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Figure C. The revised community pharmacists’ training program for chronic kidney disease risk 
assessment service. 
 
Pre-training evaluation of pharmacists’ knowledge and skills 
 
 
 
 
 
   
 
 
Post-training evaluation of pharmacists’ knowledge and skills 
Multiple choice questions Clinical vignettes
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prevention, and 
management
Quality use of 
renally cleared 
medications
Revised risk 
assessment 
protocol
QKidney® risk 
calculator
Patient 
counselling on 
risk assessment 
results
Patient 
education on 
CKD
Integration of 
the CKD service 
with other 
services 
Training 
pharmacy staff 
to perform 
initial stages of 
risk assessment
Training to 
improve the 
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professional 
collaboration 
between 
pharmacists 
and GPs
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Figure D. Revised chronic kidney disease risk assessment protocol 
Multiple choice questions Clinical vignettes
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Organise an initial face-to-face meeting with GPs to establish mutual understanding of the CKD 
risk assessment service, identify the most effective referral pathway, and schedule regular 
meetings to review the risk assessment and referral process. 
Collect participant's demographics, clinical information, 
medication history and general practitioner details in 
the assessment data form
Measure and record participant's height, weight and 
blood pressure reading in the results sheet
Calculate participant's percentage risk of developing 
moderate-severe CKD over the next five years using the 
QKidney® risk calculator
QKidney® Risk 
<3%                                      
Referral not required
≥ 3%                                    
Refer to GP
Participant telephone follow-up at 9 months
Pathology data collection
Satisfaction survey
>15%                                        
Discuss results with the GP in 
the next week or two
3-15%                                     
Discuss results with the GP at 
your next planned visit
Provide participants with verbal education 
on CKD, asymptomatic nature, and the 
importance of a regular 'Kidney Health 
Check'
Participant eligibility criteria:                                     
Age range 50-74 years, and at least one of 
the following: High BP requiring treatment, 
diabetes, heart failure, personal history of 
heart attack, angina, stroke or TIA, obesity, 
current smoker, and family History of 
kidney disease.
Pharmacy staff can be 
trained to primarily 
engage customers for 
participation, perform 
data collection, and 
measure height and 
weight. 
CKD service can be 
integrated with other 
established pharmacy 
services, such as 
medication reviews, 
delivered by 
participating 
pharmacies 
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 The qualitative data analysis (Project II (C)) showed that pharmacists perceived their 
customers to have limited understanding of CKD and functions of the kidneys. During follow-
up (Project II (B)), we found that relatively few patients had discussed their risk assessment 
results with their GP. Lastly, the analysis of the satisfaction survey data (Project II (D)) found 
a relatively low percentage of participants who agreed that risk assessment raised their 
awareness on CKD.  A systematic review investigating the effectiveness of several strategies 
to improve diabetes care found interventions that targeted both patients and healthcare 
professionals to be most successful.205 For example, this review found interventions designed 
to promote greater patient understanding of a target disease or to teach specific prevention or 
treatment strategies, in addition to the use of multidisciplinary team, to be more useful in 
reducing the overall patient risk factor profile. 
 A randomised controlled trial, evaluating the effectiveness of a Canadian community 
pharmacist-initiated risk assessment service for osteoporosis, reported a two-fold increase in 
the number of patients who were tested or treated for osteoporosis by their GPs.54 This 
intervention, in addition to providing written educational materials, included a verbal 
educational component. Similarly, a study performed in the United States of America in 
patients with osteoporosis, which involved an educational intervention, showed a statistically 
significant increase in the participant awareness and intention to visit their GP for follow-up.203 
Another Canadian pharmacists’ intervention for cholesterol risk management, where patients 
received education, showed GP referral uptake in 57% of referred participants.206 All the above 
observations indicate the need to include a verbal educational component within the CKD risk 
assessment service. It is crucial that community pharmacists, during their training, are 
instructed on the importance of providing patients with education on several aspects of CKD. 
More specifically, patients need to understand the asymptomatic nature of CKD, and 
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importance of a regular ‘Kidney Health Check’. Consequently, if patients’ understanding is 
improved, then it is possible that more participants would become proactive in initiating a 
discussion on their risk results with their GP, which would lead to an improved GP referral 
uptake and further investigation.  
 During training, pharmacists should also be made aware of the strategy of integrating the 
CKD service with other established pharmacy services. A systematic review examining the 
pharmacy customers’ attitudes towards public health promotion services found that customers 
still perceived the role of community pharmacists to be mainly medicine related and did not 
expect to be offered other extended services.127 However, this review additionally found high 
customer satisfaction in those who had experienced these extended services. In a recent atrial 
fibrillation screening study, pharmacists reported combining services to offer a CVD screening 
package, while performing medications review as a more attractive package for customers.139 
Pharmacists interviewed within Project II (C) similarly observed an increase in the CKD 
service uptake when it was combined with other pharmacy services such as medications review 
and diabetes management, for which pharmacists carry credibility. Hence, if customers are 
offered combined services then it could result in dual advantages: 1. Improved customer 
participation; and 2. Increased uptake of important, less familiar services.  
  Workflow challenges, specifically insufficient time, were identified as another important 
barrier towards effective implementation of the CKD service. Pharmacy staff are often the first 
point of contact, and generally trained to offer several professional services to pharmacy 
customers.127 Up-skilling pharmacy staff to primarily engage customers and perform the initial 
stages of screening could help to reduce the pharmacists’ time burden.139 Increased customer 
response to the CKD service was also observed by few pharmacists within Project II (C) when 
they implemented this strategy. Pharmacists should therefore be instructed to train pharmacy 
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staff to identify eligible customers for recruitment, perform the initial participant demographic 
and clinical data collection, and measure height and weight. This would allow pharmacists to 
focus on key aspects of the risk assessment protocol and educating consumers.  
 Lastly, pharmacists should be self-confident in promoting and delivering the CKD service 
to their customers. This is mainly because findings from Project II (C) and other studies114, 134-
138 have shown that pharmacy customers generally still do not perceive disease prevention to 
be the role of community pharmacists. Also, although not identified as a barrier in our projects, 
a systematic review has shown pharmacists’ confidence in providing public health services as 
being only average to low.127 
 Evaluation of our final (Project III) revealed that the Australian public knowledge of the 
physiological role of the kidneys, CKD and its risk factors was limited, irrespective of 
sociodemographic and clinical characteristics. These findings further suggest that pharmacists 
should not feel intimidated when discussing about CKD with their customers. Evaluation of 
project III results also emphasise the importance of improving the public understanding of 
kidneys and knowledge on CKD through nationwide awareness campaigns. This is particularly 
necessary because limited knowledge about CKD will prevent the public from engaging in any 
CKD associated screening and preventive interventions.  
 The cost of providing each CKD risk assessment is approximately AUD$10, based primarily 
on the pharmacist time required. Approximately 50% of the respondents under Project II (D) 
indicated that they would pay at least this amount for risk assessment. Additionally, integrating 
CKD risk assessment with other services commonly used by pharmacy customers would make 
it more attractive, and consequently, more customers would be willing to pay.  Currently, poor 
awareness of CKD amongst the Australian public also acts as a barrier; however, if this is 
Early detection and prevention of CKD 
157 
 
 
 
 
addressed, then the likelihood of pharmacists being remunerated either by the customer or 
government may improve. 
 
Conclusion 
Despite the significant burden of CKD, at present, healthcare policies and funding to support 
the interventions for ‘Early detection and prevention of CKD’ do not exist in Australia. To our 
knowledge, this is the first study performed in Australia which implemented and evaluated the 
effectiveness of a CKD risk assessment service in the community pharmacy setting. The work 
performed in this thesis shows that community pharmacists possess appropriate knowledge and 
skills to provide a targeted CKD risk assessment service. Also, community pharmacies could 
serve as a useful setting for implementing targeted CKD screening interventions. However, the 
implemented CKD risk assessment protocol had limitations, and requires several refinements. 
Future implementation and evaluation of the refined protocol would help to establish the true 
effectiveness of this service. 
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Appendix 1 PROJECT I  
CHAPTER 1. Effectiveness of Targeted Screening Programs for Detection, 
Prevention and Management of Early Chronic Kidney Disease in community-
settings: A Systematic Review 
Appendix 1.1 Systematic review protocol 
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Available from: 
http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42016037204 
 
Review question(s) 
Can targeted screening effectively identify undiagnosed patients with early stages of chronic kidney disease in the 
community-setting? 
What study characteristics and screening tests should be used to ensure feasibility of a targeted screening program 
for chronic kidney disease? 
 
Searches 
Two search strategies will be used for this systematic review.  
First, an electronic search of four databases: EMBASE, PubMed, Cochrane Central Register of Controlled Trials 
(CENTRAL) and Scopus will be conducted. Three layers of search terms (chronic kidney disease, screening and 
community) will be developed using the thesaurus (Emtree and Medical Subject Headings [MeSH] of EMBASE 
and PubMed, respectively). Wherever possible, the terms will be exploded to broaden the search or searched as a 
keyword in titles and abstracts of articles. Text word searching will also be conducted in order to identify any 
articles that may not have been indexed appropriately. The search terms will be modified for use across individual 
databases, due to the difference in their functionality.  
For the second search strategy, reference lists of included studies or relevant reviews identified through the 
electronic search will be further scanned to identify any potential articles.  
Publication date restrictions will not be applied to identify all relevant studies. Articles in language other than 
English will not be included in this review due to the lack of resources for translation services. 
 
Types of study to be included 
Inclusion criteria: Observational analytical studies (cross-sectional, case-control and prospective cohort) reporting 
the quantitative data and results of the screening tests will be included in this review. 
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Exclusion criteria: Studies that are retrospective in nature and of epidemiological design will be excluded from 
this review. 
 
Condition or domain being studied 
Globally, the incidence and prevalence of chronic kidney disease (CKD) is rising. Major health outcomes of CKD 
include complications of reduced kidney function (hypertension, anaemia, bone disease, electrolyte imbalance), 
end stage kidney disease (ESKD) and, cardiovascular disease (CVD). Evidence suggests that progression and 
adverse outcomes of CKD can be prevented or delayed by detecting and treating the disease in its initial stages 1-
3. Unfortunately, CKD is asymptomatic until kidney function deteriorates by approximately 90%, which makes 
it challenging to detect the disease early. Hence, many clinical practice guidelines recommend that individuals 
with risk factors, such as hypertension, diabetes, CVD and a family history of kidney disease, should be regularly 
tested for 
CKD. Worldwide, screening programs have been implemented in different community settings for high-risk 
patients. 
Specifically, their objectives were to identify patients with evidence of CKD and refer them to healthcare 
professionals for diagnosis and management. The aim of this systematic review is to determine whether the 
targeted screening strategy is effective in identifying adult people with early stages of CKD in the community 
setting. 
 
Participants/ population 
Inclusion criteria: Adults (18 years or above) with one or more of the following medical history: diabetes, 
hypertension, CVD and family history of kidney disease.  
Exclusion criteria: Adolescents (under 18 years of age). 
 
Intervention(s), exposure(s) 
For the purpose of this review, targeted screening program is defined as the implementation of test/s in people 
with risk factors of CKD.  
1. Screening programs for this review are required to have targeted at least two CKD risk factors from the 
following: diabetes, hypertension, CVD and family history of kidney disease.  
2. This review will consider screening programs implemented in any community setting (health centres, 
workplace, community centres, primary health care, outpatient clinics, community pharmacies etc.) by any 
health professional (nurse, pharmacist, physician, interns, residents etc.).  
3. There will be no restrictions based on the length of follow-up of outcomes. 
4. This review will include any screening tests that support early identification of CKD. These include: 
predictive algorithm, risk assessment tool, estimated glomerular filtration rate (eGFR), serum creatinine 
(SCr), proteinuria, albuminuria, albumin creatinine ratio (ACR), haematuria or blood pressure measurement. 
 
Comparator(s)/ control 
This is not applicable to studies included in this systematic review. All studies will be observational, analytical in 
nature. 
 
Outcome(s) 
Primary outcomes 1. Percentage of participants with 
positive screening test results 
2. Participant referral rate 
3. Percentage of participants consequently diagnosed with CKD 
4. Screening tests used to detect evidence of CKD including: predictive algorithm, risk assessment tool, 
estimated glomerular filtration rate (eGFR), serum creatinine (SCr), proteinuria, albuminuria, albumin creatinine 
ratio (ACR), haematuria or blood pressure measurement. 
Secondary outcomes 
None 
 
Data extraction, (selection and coding) 
Screening of titles and abstracts of all articles retained through the search strategy will be performed by two 
reviewers independently. Full-texts of all articles will then be obtained from screened abstracts which appear to 
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be potentially relevant for inclusion. Again, this will be carried out independently by two reviewers and any 
disagreements for article selection will be discussed and resolved through mutual agreement.  
Data extraction will be carried out by using a pre-prepared and pilot-tested data extraction form. The form will be 
developed using “The Cochrane Public Health Group Data Extraction and Assessment Template” as a reference 
and will include: study design type; community setting type; healthcare professional involved; participant 
demographics and characteristics; type of intervention and outcome measures. Where more than one publication 
from one screening program exists, all the results will be grouped together and the most recent or complete data 
set will be used in this systematic review. Disagreement between reviewers will be resolved by discussion; if no 
consensus can be reached, a third reviewer will be approached for assessment. 
 
Risk of bias (quality) assessment 
A Cochrane Risk of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI) 
will be used for assessing the risk of bias of included articles. This tool covers seven domains through which bias 
might be introduced in quantitative studies. The first two domains will assess the risk of bias that can occur before 
initiation of the intervention; the third domain will assess the intervention itself; and the final four domains will 
assess for risk of bias that can arise after the intervention has been initiated. The assessment of risk of bias for all 
included studies will be independently undertaken by two reviewers and any disagreement will be resolved by 
using a third reviewer as an arbitrator. 
Strategy for data synthesis 
Dichotomous data (CKD evidence as indicated by positive screening test results, participant referral rate and CKD) 
will be evaluated using risk ratio (RR) with 95 % confidence interval (CI). Where continuous scales of 
measurement are used, the effects of intervention (tests such as eGFR, SCr, proteinuria, albuminuria, ACR etc.) 
will be analysed using weighted mean difference (with 95% CI) or standardised mean difference (with 95% CI) 
if different measurement scales have been used. 
Data will be pooled only if the studies are of sufficient quality and contain methodologically and clinically 
comparable data. The decision to pool the data will be discussed between reviewers and performed only if 
consensus is reached. Heterogeneity will be analysed by examining the forest plots to detect overlap of CI and by 
using the Chi-square test (statistical significance level: 0.1). The I-squared statistic will be used for quantifying 
inconsistency across studies with values of 30% to 60%, 50% to 90% and 75% to 100% representing moderate, 
substantial and considerable levels of heterogeneity, respectively.  
If quantitative data synthesis is not appropriate, then a systematic narrative synthesis will be provided. 
Characteristics and main findings of the included studies will be presented in the form of texts and/or tables. 
 
Analysis of subgroups or subsets 
None 
 
Dissemination plans 
The results of this systematic review will be published in a peer reviewed journal. 
 
Contact details for further information 
Miss Gheewala 
Tasmanian School of Pharmacy, 
Private Bag 26, Hobart, Tasmania, Australia 7001 
pankti.gheewala@utas.edu.au 
 
Organisational affiliation of the review 
None 
 
Review team 
Miss Pankti Gheewala, Division of Pharmacy, School of Medicine, University of Tasmania, Australia 
Professor Gregory Peterson, Division of Pharmacy, School of Medicine, University of Tasmania, Australia 
Dr Tabish Zaidi, Division of Pharmacy, School of Medicine, University of Tasmania, Australia 
Dr Luke Bereznicki, Division of Pharmacy, School of Medicine, University of Tasmania, Australia 
Professor Matthew Jose, School of Medicine, University of Tasmania, Australia 
Dr Ronald Castelino, Pharmacy, University of Sydney, Australia 
Early detection and prevention of CKD 
184 
 
 
 
 
 
Anticipated or actual start date 04 January 2016  
Anticipated completion date 31 March 2017  
 
Funding sources/sponsors None  
 
Conflicts of interest None known 
 
Language 
English 
Country 
Australia 
Subject index terms status 
Subject indexing assigned by CRD 
Subject index terms 
Early Diagnosis; Humans; Renal Insufficiency, Chronic; Residence Characteristics 
Stage of review 
Ongoing 
Date of registration in PROSPERO 
01 April 2016 
Date of publication of this revision 
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Stage of review at time of this submission Started Completed 
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Appendix 1.2 Systematic review search strategy 
Embase February 2016 
No Query Results 
#1 ‘chronic kidney disease’/exp 43,096 
#2 ('chronic kidney' NEXT/1 (disease* OR disorder* OR function* OR insufficien*)):ab,ti 38,924 
#3 (‘chronic renal’ NEXT/1 (disease* OR insufficienc*)):ab,ti 10,036 
#4 'chronic nephropathy':ab,ti 453 
#5 ‘risk assessment’/exp 372453 
#6 'early diagnosis'/exp 79817 
#7 'early intervention'/exp 14589 
#8 'health promotion'/exp 75951 
#9 'primary prevention'/exp 30918 
#10 ‘screening’/exp 531426 
#11 ‘risk assessment’:ab,ti 49958 
#12 'early diagnosis':ab,ti 81009 
#13 'disease early detection':ab,ti 209 
#14 'early medical intervention':ab,ti 132 
#15 'health promotion':ab,ti 24736 
#16 'wellness program':ab,ti 551 
#17 'primary prevention':ab,ti 19611 
#18 'screening':ab,ti 497460 
#19 'workplace'/exp 28217 
#20 ‘community’/exp 74305 
#21 ('community' NEXT/1 (pharm* OR medicin* OR hospital*)):ab,ti 23675 
#22 ‘community health’ NEXT/1 (program* OR service* OR nurs* OR center* OR worker* OR clinic*) 7201 
#23 'community':ab,ti 403047 
#24 'workplace':ab,ti 30638 
#25 #1 OR #2 OR #3 OR #4 60178 
#26 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18  1328744 
#27 #19 OR #20 OR #21 OR #22 OR #23 OR #24  454734 
#28 #25 AND #26 AND #27 405 
#29 #28 AND ('article'/it OR 'article in press'/it OR 'conference paper'/it) 266 
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PubMed January 2016 
No Query Results 
#1 "Renal Insufficiency, Chronic"[Mesh:NoExp] 9434 
#2 chronic renal insufficienc*[Text Word] 13495 
#3 chronic renal disease*[Text Word] 3263 
#4 chronic kidney disease*[Text Word] 26795 
#5 chronic kidney disorder*[Text Word] 20 
#6 chronic kidney function[Text Word] 6 
#7 chronic kidney insufficienc*[Text Word] 200 
#8 chronic nephropath*[Text Word] 565 
#9 "Risk Assessment"[Mesh] 194168 
#10 "Early Diagnosis"[Mesh:NoExp] 18262 
#11 "Early Medical Intervention"[Mesh] 1273 
#12 "Health Promotion"[Mesh] 59581 
#13 "Primary Prevention"[Mesh:NoExp] 15079 
#14 screening[Text Word] 433232 
#15 risk assessment[Text Word] 213552 
#16 early diagnosis[Text Word] 71412 
#17 disease early detection[Text Word] 16 
#18 early medical intervention*[Text Word] 1398 
#19 health promotion*[Text Word] 69447 
#20 wellness program*[Text Word] 869 
#21 health campaign*[Text Word] 1083 
#22 primary prevention[Text Word] 26107 
#23 "Workplace"[Mesh] 15286 
#24 "Nurses, Community Health"[Mesh] 460 
#25 "Hospitals, Community"[Mesh] 10709 
#26 "Community Pharmacy Services"[Mesh] 3144 
#27 "Community Medicine"[Mesh] 1919 
#28 "Community Health Services"[Mesh] 256423 
#29 "Community Health Nursing"[Mesh] 18845 
#30 "Community Health Centers"[Mesh] 10795 
#31 "Community Health Workers"[Mesh] 3583 
#32 workplace[Text Word] 34686 
#33 community[Text Word] 397345 
#34 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 37096 
#35 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22  784351 
#36 #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 600401 
#37 #34 AND #35 AND #36 260 
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Scopus January, 2016 
No Query Results 
#1 INDEXTERMS ("Renal Insufficiency, Chronic") 8523 
#2 INDEXTERMS ("chronic kidney disease") 29325 
#3 TITLE-ABS-KEY (“chronic renal insufficienc*”) 5452 
#4 TITLE-ABS-KEY (“chronic renal disease”*) 4230 
#5 TITLE-ABS-KEY (“chronic kidney disease*”) 42341 
#6 TITLE-ABS-KEY (“chronic kidney disorder*”) 20 
#7 TITLE-ABS-KEY (“chronic kidney function”) 2129 
#8 TITLE-ABS-KEY (“chronic kidney insufficienc*”) 175 
#9 TITLE-ABS-KEY (“chronic nephropathy*”) 681 
#10 INDEXTERMS ("Risk Assessment") 538457 
#11 INDEXTERMS ("early diagnosis") 76728 
#12 INDEXTERMS ("early medical intervention") 1146 
#13 INDEXTERMS ("health promotion") 87493 
#14 INDEXTERMS ("primary prevention") 32769 
#15 INDEXTERMS ("screening") 505458 
#16 TITLE-ABS-KEY ("Risk Assessment") 570986 
#17 TITLE-ABS-KEY ("early diagnosis") 137481 
#18 TITLE-ABS-KEY ("disease early detection") 344 
#20 TITLE-ABS-KEY ("early medical intervention*") 1310 
#21 TITLE-ABS-KEY ("health promotion*") 102881 
#22 TITLE-ABS-KEY ("wellness program*") 1122 
#23 TITLE-ABS-KEY ("health campaign*") 1518 
#24 TITLE-ABS-KEY ("primary prevention*") 44205 
#25 TITLE-ABS-KEY ("screening") 830060 
#26 INDEXTERMS ("workplace") 32302 
#27 INDEXTERMS ("nurses, community health") 524 
#28 INDEXTERMS ("hospitals, community") 10714 
#29 INDEXTERMS ("community pharmacy services") 3083 
#30 INDEXTERMS ("community medicine") 3120 
#31 INDEXTERMS ("community health services") 27560 
#32 INDEXTERMS ("community health nursing") 21574 
#33 INDEXTERMS ("community health centers") 6058 
#34 INDEXTERMS ("community health workers") 1114 
#35 TITLE-ABS-KEY (workplace) 84912 
#36 TITLE-ABS-KEY (community) 1044850 
#37 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 53460 
#38 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25  1596418 
#39 #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 1124427 
#40 #37 AND #38 AND #39 508 
#41  #40 AND ( LIMIT-TO (DOCTYPE, “ar”) OR LIMIT-TO (DOCTYPE, “cp”) OR LIMIT-TO (DOCTYPE, “ip”)) 407 
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The Cochrane Library January, 2016 
No Query Results 
#1 [Renal Insufficiency, Chronic] MeSH:NoExp 441 
#2 chronic renal insufficienc*:ti,ab,kw 997 
#3 chronic renal disease*:ti,ab,kw 3805 
#4 chronic kidney disease*:ti,ab,kw 4591 
#5 chronic kidney disorder*: ti,ab,kw  370 
#6 chronic kidney function:ti,ab,kw  2192 
#7 chronic kidney insufficienc*:ti,ab,kw  2161 
#8 chronic nephropath*:ti,ab,kw 925 
#9 "Risk Assessment"[Mesh] 7949 
#10 "Early Diagnosis"[Mesh:NoExp] 459 
#11 "Early Medical Intervention"[Mesh] 102 
#12 "Health Promotion"[Mesh] 4249 
#13 "Primary Prevention"[Mesh:NoExp] 3635 
#14 screening:ti,ab,kw 25045 
#15 risk assessment:ti,ab,kw 26078 
#16 early diagnosis:ti,ab,kw 6466 
#17 early detection of disease*:ti,ab,kw 979 
#18 early medical intervention*:ti,ab,kw 1964 
#19 health promotion*:ti,ab,kw  6070 
#20 wellness program*:ti,ab,kw  215 
#21 health campaign*:ti,ab,kw  582 
#22 primary prevention:ti,ab,kw  11035 
#23 "Workplace"[Mesh] 534 
#24 "Nurses, Community Health"[Mesh] 3 
#25 "Hospitals, Community"[Mesh] 192 
#26 "Community Pharmacy Services"[Mesh] 214 
#27 "Community Medicine"[Mesh] 41 
#28 "Community Health Services"[Mesh] 25206 
#29 "Community Health Nursing"[Mesh] 380 
#30 "Community Health Centers"[Mesh] 513 
#31 "Community Health Workers"[Mesh] 242 
#32 workplace:ti,ab,kw  1398 
#33 community:ti,ab,kw  20486 
#34 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 7615 
#35 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22  71906 
#36 #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33  42256 
#37 #34 AND #35 AND #36  62 
#38 #37 (Limit Trials) 43 
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Appendix 2 PROJECT II (A) 
CHAPTER 2. A Web-based Training Program to Support Chronic Kidney 
Disease Screening by Community Pharmacists 
Appendix 2.1 Pharmacists’ online training module 
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Appendix 2.2 Web-based questionnaire for evaluation of pharmacists’ knowledge and skills 
at pre- and post-training  
Pre- and post-training knowledge questions 
Questions 
(1) Which of the following is a possible complication of chronic kidney disease? 
a. Osteodystrophy 
b. Anaemia 
c. Metabolic acidosis 
d. Hyperkalaemia 
e. All of the above 
(2) Which of the following is a good marker of renal function? 
a. Albumin 
b. Nitrogen 
c. Urea 
d. Serum creatinine 
e. None of the above 
(3) Which of the following drugs is not excreted via the renal system? 
a. Baclofen 
b. Codeine 
c. Gabapentin 
d. Metformin 
e. Linagliptin 
(4) The majority of patients with chronic kidney disease have following signs and symptoms 
a. Lethargy 
b. Anorexia 
c. Nocturia 
d. Pruritis 
e. None 
(5) From the following people, who is at the highest risk of developing chronic kidney disease? 
a. 45 years, male, hypertension and smoker 
b. 70 years, female, diabetes and rheumatoid arthritis 
c. 65 years, male, obese, diabetes, high blood pressure, cardiovascular disease and smoker 
d. 50 years, female, family history of kidney disease and hypertension 
e. 62 years, male, high blood pressure, NSAIDS use and obese 
 
Clinical Vignette 
Mr James Moriarty is a 68 year old male with a medical history of hypertension and Type II diabetes. He smokes 
approximately 15 cigarettes/day, is overweight with a height of 170cm and weight of 90kg. He was diagnosed 
with depression 2 months ago and his regular medications are: Glibenclamide 10mg daily; Sitagliptin 50mg 
once daily; Lisinopril 5mg daily; Duloxetine 60mg once daily and; Ibuprofen prn. Mr Moriarty would like to 
undergo the screening service and reveals that he has had kidney stones before. His blood pressure when 
measured was 150/80 mmHg. 
The five-year percentage risk of developing chronic kidney disease in this patient is around: 
a. 58 
b. 30 
c. 45 
d. 18 
e. None of the above 
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Appendix 2.3 Pharmacists’ satisfaction survey 
Survey Item 
Agree 
strongly 
Agree 
somewhat 
Neither agree 
nor disagree 
Disagree 
somewhat 
Disagree 
strongly 
Objectives of the training program were clearly defined □ □ □ □ □ 
The content was organised and easy to follow □ □ □ □ □ 
Content of the training program was relevant to me □ □ □ □ □ 
Time allocated for the training program was sufficient □ □ □ □ □ 
This training experience will be useful in my work □ □ □ □ □ 
This training program further motivated me to participate in the study □ □ □ □ □ 
Learning objectives of the training program were met □ □ □ □ □ 
The lecturer has good knowledge with respect to the training topic □ □ □ □ □ 
The lecturer communicated information clearly □ □ □ □ □ 
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Appendix 2.4 Letter of invitation 
Letter of Invitation 
Dear Sir/Madam, 
The Division of Pharmacy, School of Medicine at the University of Tasmania is conducting a 
screening study funded by the Tasmanian Community Fund (TCF) for early detection of chronic kidney 
disease (CKD) via community pharmacy. This study aims to identify people at high risk of developing 
moderate-severe kidney disease over the next five years using the ‘Qkidney® Risk Assessment’ 
protocol. 
CKD is common amongst the Australian population with less than 1% of people aware that they 
have this condition. 1 in 3 Australians is at an increased risk of developing CKD and adult population 
are at an increased risk of CKD if they have diabetes, high blood pressure, heart problems, obese, 
smoker and have a family history of kidney disease. If detected early, CKD can be managed by 
appropriate lifestyle modifications (such as weight loss, diet changes, physical exercise, smoking 
cessation etc.) and by using drugs such as angiotensin converting enzyme (ACE) inhibitors/angiotensin 
2 receptor blockers (A2RB). These early interventions can reduce the rate of progression of CKD and 
cardiovascular risk by as much as 50% and may also improve quality of life. This screening protocol 
will help identify people at high risk of developing moderate-severe kidney disease over the next five 
years so that they can be referred to their general practitioners for further diagnosis and management. 
You have been invited to participate in the study as your community pharmacy has been recognised 
as one with strong representation of pharmacies within the rural Tasmania state. If your pharmacy 
chooses to participate in the study, then pharmacists are required to recruit approximately 40 
participants and conduct the ‘Qkidney® Risk Assessment’ screening protocol which will 
approximately take 15-20 minutes per participant. Each participating pharmacy will be reimbursed 
with $15 per participant for their time spent on conducting the screening protocol. We invite you to 
read the enclosed information sheet about the screening study. 
We assure you that you are in no way obliged to agree to participate in this study. We will be happy 
to answer any questions you have about the study. You may contact Dr Ronald Castelino via e-mail or 
telephone (Ronald.Castelino@utas.edu.au or +61 3 6226 1032) or Miss Pankti Gheewala via e-mail or 
telephone on (Pankti.Gheewala@utas.edu.au or +61 3 6226 7288) 
Yours Sincerely, 
Dr Ronald L Castelino 
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Appendix 2.5 Pharmacist information sheet 
 
Information Sheet 
 
Invitation 
You are invited to participate in a screening study being conducted to identify people with risk of 
developing moderate-severe kidney disease over the next five years. 
The study is being conducted by 
1. Dr Ronald Castelino, Pharmacy, School of Medicine, University of Tasmania 
2. Professor Gregory Peterson, Pharmacy, School of Medicine, University of Tasmania 
3. Associate Professor Luke Bereznicki, Pharmacy, School of Medicine, University of Tasmania 
4. Dr Tabish Zaidi, Pharmacy, School of Medicine, University of Tasmania 
5. Professor Matthew Jose, School of Medicine, University of Tasmania 
6. Miss Pankti Gheewala, Pharmacy, School of Medicine, University of Tasmania 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why this study is being done and what it will involve.  
Please take the time to read the following information carefully and discuss it with others if you wish. 
 
1. ‘What is the purpose of this study?’ 
The purpose is to investigate whether community pharmacy screening services can help identify people 
at risk of developing moderate-severe kidney disease over the next five years and to determine whether 
this service will help in improving the management and educating participants with kidney disease. 
 
2. ‘Why have I been invited to participate in this study?’ 
You have been invited to participate in the study because your community pharmacy was identified 
as one with strong representation of pharmacies within the rural Tasmania state. 
 
3. ‘What if I don’t want to take part in this study, or if I want to withdraw later?’ 
Participation in this study is voluntary. It is completely up to you whether or not you participate. If you 
decide not to participate, this will not affect your relationship with the University of Tasmania. New 
information about the screening tool being studied may become available during the course of the 
study. You will be kept informed of any significant new findings that may affect your willingness to 
continue in the study. If you wish to withdraw from the study once it has started, you can do so at any 
time without having to give a reason. 
 
4. ‘What does this study involve?’ 
If your community pharmacy decides to participate in the study, then following is involved: 
1. Pharmacists working at your community pharmacy will be provided with an information sheet 
to decide whether they would like to participate in the study. They will also be provided with 
a consent form which they are required to sign if they agree to participate in the study. 
2. An online module to refresh knowledge on chronic kidney disease (CKD) and renally cleared 
medications will be arranged for participating community pharmacists. Pharmacists will also 
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be trained to conduct the screening protocol ‘Qkidney® Risk Assessment’ after the completion 
of which they will be eligible to claim continuing professional development (CPD) points. 
 
3. Screening protocol 
• The screening process will take approximately 15-20 minutes per participant. Screening 
will consists of the following: 
 
o Qkidney® risk assessment data form 
This form will be used to collect information on demographics, medical history, family 
history, prescription medications and over the counter (OTC) drugs of eligible participants 
who are recruited in the study.   
 
o Qkidney® results sheet 
Pharmacists are required to measure participant’s height, weight and blood pressure, 
details of which will be recorded in the Qkidney® results sheet. Participants will also be 
provided with a copy of the results sheet for them to keep. 
 
o Qkidney® risk calculator 
This calculator calculates a person’s risk of developing moderate-severe kidney disease 
over the next five years. The Qkidney® algorithms are based on routinely collected data 
from many thousands of GPs (across United Kingdom) who have freely contributed data 
to the QResearch database for medical research.  
The ‘Qkidney® risk assessment data form’ is designed using the algorithms required 
by the ‘Qkidney® risk calculator’ as a reference and this data collected will be used to 
calculate respective participant’s risk of moderate-severe kidney disease over the next five 
years using the Qkidney® web calculator. The result referred as the ‘Qkidney® Risk’, will 
then be recorded in the ‘Qkidney® Results Sheet’. 
 
o Qkidney® Understanding Your Results 
Participants will then be provided with 1) a detailed explanation of their screening results 
and 2) a written educational material on kidney disease by the pharmacist.  
 
o Qkidney® Health Professional Advice 
Pharmacist will then advise the participants on appropriate action that needs to be taken 
based on their Qkidney® risk. This may or may not involve a comprehensive follow up 
by a GP that includes: blood test (serum creatinine for eGFR), urine test (albumin: 
creatinine ratio) and blood pressure measurement. 
 
4. Pharmacists will be required to demonstrate competency in essential skills and knowledge 
relating to CKD, renally cleared medications and ‘Qkidney® Risk Assessment’ protocol before 
commencing the study. Each pharmacy will be required to recruit approximately 40 eligible 
people in the study by mid-April 2015.  
 
5. For participants identified with at least a 3% risk of developing moderate-severe CKD in the 
next 5 years, who are receiving high risk medications (considered problematic in CKD) and in 
whom a comprehensive follow-up with the GP is advised, pharmacists will be required to 
contact the GP via pre-printed ‘Letter to general practitioners’.  
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These standardised pre-printed ‘Letter to general practitioners’ (modifiable to include 
participant’s name, Qkidney® Assessment Data Form, Qkidney® Results) will be provided to the 
participating community pharmacies. All the supporting documents and promotional 
materials required for the performance of the study will be supplied by the research team. 
 
5. ‘How is this study being paid for?’ 
The study is being sponsored by the Tasmanian Community Fund (TCF) Board and supported by 
Division of Pharmacy, School of Medicine at the University of Tasmania. All of the money being paid 
by the sponsor to run the study will be deposited into an account managed by Division of Pharmacy, 
School of Medicine at the University of Tasmania. No money is paid directly to individual researchers. 
 
6. ‘Are there risks to me in taking part in this study?’ 
There are no known risks associated with this study. 
 
7. ‘Will I benefit from the study?’ 
This study will help to further increase knowledge and create awareness on CKD and may improve 
future intervention and management strategies that can be used in community pharmacies for 
identifying high risk patients. Also, participation in this study will allow the participating pharmacists 
to claim continuing professional development (CPD) points. 
 
8. ‘Will taking part in this study cost me anything, and will I be paid? 
Participation in this study will not cost you anything and each participating pharmacy will be 
reimbursed with $15 per participant for the time spent on conducting the screening protocol. 
Additionally, you may be able to claim for MedsCheck and Diabetes MedsCheck pharmacy program 
incentives for eligible participants as per 5CPA guidelines. 
 
9. ‘What happens with the results?’ 
We plan to publish the results in peer-reviewed journals, presentation at conferences or other 
professional forums. In any publication, information will be provided in de-identified form. Results of 
the study will be provided to you, if you wish. 
 
11. ‘What will happen to the information when this study is over?’ 
All paper based items will be stored in a locked filling cabinet in the office of the chief investigator. 
Databases containing results will be stored on password protected computers at the School of Medicine. 
All the paper based data will be destroyed using a paper shredder and databases deleted 7 years after 
the conclusion of the study. 
 
12. ‘What should I do if I want to discuss this study further before I decide?’ 
If you would like more information or have any more questions at any stage, please do not hesitate to 
contact the researchers: Dr Ronald Castelino via e-mail or telephone (Ronald.Castelino@utas.edu.au or 
+61 3 6226 1032) or Miss Pankti Gheewala via e-mail or telephone on (Pankti.Gheewala@utas.edu.au or 
+61 3 6226 7288) 
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13. ‘Who should I contact if I have concerns about the conduct of this study?’ 
This study has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this study should contact the 
Executive Officer of the HREC (Tasmania) Network on (03) 6226 7479 or email 
human.ethics@utas.edu.au.  The Executive Officer is the person nominated to receive complaints from 
research participants. You will need to quote [H0014258]. 
 
Thank you for taking the time to consider this study. This information sheet is for you to keep.  
If you wish to take part in it, please sign the consent form and post, e-mail or fax it to the address 
indicated on the form. Thank you for taking the time to consider this study. 
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Appendix 2.6 Pharmacy consent form  
 
Consent Form 
 
1. I have read and understood the information sheet for this screening study. 
 
2. I acknowledge that the nature, purpose and contemplated effects of the screening study so far 
as it affects my community pharmacy, have been fully explained to my satisfaction by the 
research worker and my consent is given voluntarily. 
   
3. I understand that my involvement means: 
a. Pharmacists working at my community pharmacy will be asked to participate in the 
study. 
b. Participating community pharmacists will be asked to undergo an online module 
organised to refresh knowledge on chronic kidney disease (CKD) and renally cleared 
medications. 
c. Pharmacists will be trained to conduct the screening protocol ‘Qkidney® Risk 
Assessment’. 
d. My community pharmacy is required to recruit approximately 40 participants for the 
purpose of this study by mid-April 2015. 
e. Pharmacists will be required to contact the GP via pre-printed ‘Letter to general 
practitioners’ for participants identified with at least 3% risk of developing moderate-
severe CKD in the next 5 years, in whom a comprehensive follow-up with the GP is 
advised. These standardised pre-printed ‘Letter to general practitioners’ are modifiable 
to include participant’s name, Qkidney® assessment data form, Qkidney® results. 
 
4. I understand that this study will help to further increase knowledge and create awareness on 
chronic kidney disease and may improve future intervention and management strategies that 
can be used in community pharmacies for identifying high risk patients. Also, participating 
pharmacists will be able to claim continuing professional development (CPD) points. 
 
5. I understand that the community pharmacy will be paid $ 15 per participant recruited and 
additionally the pharmacy will be able to claim for MedsCheck and Diabetes MedsCheck 
pharmacy program incentives for eligible participants as per 5CPA guidelines. 
 
6. I understand that all the research data will be securely stored on the University of Tasmania 
premises for a period of 7 years, and will then be securely destroyed when no longer required. 
 
7. I understand that research data gathered for the study will be published so that the participants 
and the participating pharmacy cannot be identified as participating in this study. 
 
8. I am aware that if I decide to withdraw from the study at any time I can do so without any 
effect and I understand that this will not affect my relationship with the University of 
Tasmania. 
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9. I am aware that I am not giving up my legal rights by signing this consent form.
10. I understand that the study will be conducted in accordance with the latest versions of the
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws.
Name of Community Pharmacy 
Name of Pharmacy Owner 
Signature of Pharmacy Owner   
Contact Number 
Fax Number 
E-mail Address
Date 
11. I have explained this study and the implications of participation in it to this community
pharmacy owner and I believe that the consent is informed and that he/she understands the
implications of participation.
Name of investigator Ronald L Castelino 
Signature of investigator 
Date 6/10/2014 
Please mail your completed Consent Form using the enclosed Reply Paid envelope 
OR 
E-mail your scanned copy to:  
Pankti.Gheewala@utas.edu.au 
OR 
Fax your scanned copy to: 
+61 3 6226 2870
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Appendix 2.7 Pharmacist consent form 
 
Pharmacist Consent Form 
 
1. I have read and understood the information sheet for this screening study. 
 
2. I acknowledge that the nature, purpose and contemplated effects of the screening study so far 
as it affects me, have been fully explained to my satisfaction by the research worker and my 
consent is given voluntarily. 
   
3. I understand that my involvement means: 
a. That I will be asked to undergo an online training module to refresh my knowledge on 
chronic kidney disease (CKD) and renally cleared medications.  
b. I will be trained to conduct the screening protocol ‘Qkidney® Risk Assessment’. 
c. I will be required to demonstrate competency in essential skills and knowledge relating 
to ‘Qkidney® Risk Assessment’ protocol before commencing the screening study and I 
will be eligible to claim ‘Continuing Professional Development’ points on completion 
of the training module.  
d. I will be required to recruit participants for the purpose of this study by mid-April 
2015. 
e. I will be required to contact the GP via pre-printed ‘Letter to general practitioners’, for 
participants identified at high risk of developing moderate-severe CKD in the next 5 
years, in whom a comprehensive follow-up with the GP is advised. These standardised 
pre-printed ‘Letter to general practitioners’ are modifiable to include participant’s 
name, Qkidney® Assessment Data Form, Qkidney® Results. 
  
4. Although I understand that the purpose of this screening study is to improve the quality of 
medical care, it has also been explained that my involvement may not be of any benefit to me.  
 
5. I understand that the survey will be securely destroyed immediately on completion of the 
study and that any information I provide on the questionnaire will be identifiable only by my 
participating pharmacist ID, kept confidential, and viewed only by the researchers. 
 
6. I understand that all the research data will be securely stored on the University of Tasmania 
premises for a period of 7 years, and will then be securely destroyed when no longer required. 
 
7. I understand that research data gathered for the study will be published so that the participants 
and the participating pharmacy cannot be identified as participating in this study. 
 
8. I am aware that if I decide to withdraw from the study at any time I can do so without any 
effect and I understand that this will not affect my relationship with the University of Tasmania 
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9. I am aware that I am not giving up my legal rights by signing this consent form.
10. I understand that the study will be conducted in accordance with the latest versions of the
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws.
Name of Community Pharmacy 
Name of Pharmacist 
Pharmacist ID 
Signature of Pharmacist   
Date 
11. I have explained this study and the implications of participation in it to this community
pharmacy owner and I believe that the consent is informed and that he/she understands the
implications of participation.
Name of investigator Ronald L Castelino 
Signature of investigator 
Date 6/10/2014 
Please mail your completed Consent Form using the enclosed Reply Paid envelope 
OR 
E-mail your scanned copy to:  
Pankti.Gheewala@utas.edu.au 
OR 
Fax your scanned copy to: 
+61 3 6226 2870
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Appendix 3  PROJECT II (B) 
CHAPTER 3.  Evaluation of A Chronic Kidney Disease Risk Assessment 
Service in Community Pharmacies 
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Appendix 3.1 Poster
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Appendix 3.2 Chronic kidney disease risk assessment protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individuals in the age range 50-74 years
Collect participant's demographics, clinical 
information, medication history and general 
practitioner details in the assessment data 
form
Measure and record participant's height, 
weight and blood pressure reading in the 
results sheet
Calculate participant's percentage risk of 
developing moderate-severe CKD over the 
next five years using the QKidney® risk 
calculator
QKidney® Risk 
<3%                           
Referral not required
≥ 3%                                    
Refer to GP
Participant follow-up at 9-10 months
Pathology data collection
Satisfaction survey
>15%
Discuss results with the GP in the next 
week or two
3-15%
Discuss results with the GP at your next 
planned visit
Eligibility criteria 
At least one of the following:
High BP requiring treatment, 
Diabetes, 
Heart failure, 
Personal History of heart attack, 
angina, stroke or TIA
Obesity, 
Current smoker, and
Family History of kidney disease.
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Appendix 3.3 Participant information sheet 
 
Participant Information Sheet 
Invitation 
You are invited to participate in a screening study being conducted to identify people at risk of 
developing moderate-severe kidney disease over the next 5 years. 
This study is being conducted by 
1. Dr Ronald Castelino, Pharmacy, School of Medicine, University of Tasmania 
2. Professor Gregory Peterson, Pharmacy, School of Medicine, University of Tasmania 
3. Associate Professor Luke Bereznicki, Pharmacy, School of Medicine, University of Tasmania 
4. Dr Tabish Zaidi, Pharmacy, School of Medicine, University of Tasmania 
5. Professor Matthew Jose, School of Medicine, University of Tasmania 
6. Miss Pankti Gheewala, Pharmacy, School of Medicine, University of Tasmania 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the screening study is being done and what it will involve. Please take the time to 
read the following information carefully and discuss it with others if you wish. 
 
1. ‘What is the purpose of this study?’  
The purpose is to investigate whether community pharmacy screening services can help identify 
people at risk of developing moderate-severe kidney disease over the next 5 years and to determine 
whether this service will help in improving the management and educating participants with kidney 
disease. 
 
2. ‘Why have I been invited to participate in this study?’ 
You are eligible to participate in this study because:  
• You are between 50-74 years of age. 
• Have at least one of the following risk factors for kidney disease: 
o High blood pressure 
o Diabetes 
o Heart disease (heart failure/past heart attack) and/or have had a stroke 
o Obese (BMI ≥ 30 kg/m2) 
o Smoker 
o Family history of kidney disease 
• You have not been previously diagnosed with kidney disease. 
• You are not pregnant. 
• You are not highly dependent on medical care. 
 
3. ‘What if I don’t want to take part in this study, or if I want to withdraw later?’ 
Participation in this study is voluntary. It is completely up to you whether or not you participate. If 
you decide not to participate, it will not affect the treatment you receive now or in the future. Whatever 
your decision, it will not affect your relationship with the staff caring for you. New information about 
the screening tool being studied may become available during the course of the study. You will be 
kept informed of any significant new findings that may affect your willingness to continue in the 
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study. If you wish to withdraw from the study once it has started, you can do so at any time without 
having to give a reason. However, it may not be possible to withdraw your data from the study results 
if these have already had your identifying details removed. 
 
4. ‘What does this study involve?’ 
Before you participate in the study you have the opportunity to involve a member of your family or a 
friend present while the study is being explained to you. If you agree to participate in this study, you 
will be asked to sign the participant consent form. 
This study will be conducted between January 2015 and April 2015.  
If you agree to participate in this trial, you will then be asked to undergo the following procedures: 
1. Initially, you will be asked to fill out a data form which includes questions related to  
a. Demographics (name, age, gender, date of birth, ethnicity, address, contact number) 
b. General practitioner (GP) details (GP name, general practice name and address) 
c. Clinical information (smoking status, medical history, family history) 
d. Medication history (prescription drugs, over the counter drugs, complimentary and herbal 
medications) 
2. The next step involves measuring and recording your height, weight and blood pressure. 
3. Using the above information, the screening calculator which is known as ‘Qkidney® Risk 
Calculator’ will assess your risk of developing moderate-severe kidney disease over the next 5 
years. 
4. After the assessment, the pharmacist will explain you your screening results in detail. The 
pharmacist will also advise you on the appropriate action that needs to be taken based on your 
results. This may or may not involve a comprehensive follow up with your GP that requires a 
kidney health check. Your GP might ask you to undergo a blood test, urine test and also, 
measure your blood pressure to further investigate kidney disease. 
5. The pharmacist will provide you with a ‘Qkidney® risk results sheet’ for your record and to 
discuss with your GP. Also, the pharmacist will provide educational material on kidney disease 
to you. The entire process mentioned above would approximately take 15-20 minutes. 
6. If you have been identified with at least a 3% 5-year risk of moderate-severe kidney disease in 
the next 5 years, then the pharmacist will send a letter to your GP stating that you have 
undergone the screening study and give details on your screening results. 
7. If your GP requires you to undergo laboratory tests such as urine test or blood test, then this 
information will also be collected from your pathology provider. 
8. The research team will then approach you after a period of 6 months by telephone questionnaire 
to determine whether appropriate action was taken for management of your kidney disease, if 
you were identified with at least a 3% risk of developing moderate-severe kidney disease over 
the next 5 years. 
9. You will also be invited to participate in a survey at the end of the study which will 
approximately take 5 minutes. 
 
5. ‘How is this study being paid for?’ 
The study is being sponsored by the Tasmanian Community Fund (TCF) Board and supported by 
Division of Pharmacy, School of Medicine at the University of Tasmania. All of the money being paid 
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by the sponsor to run the study will be deposited into an account managed by Division of Pharmacy, 
School of Medicine at the University of Tasmania. No money is paid directly to individual researchers. 
 
6. ‘Are there risks to me in taking part in this study?’ 
There are no known risks associated with this study. 
 
7. ‘Will I benefit from the study?’ 
This study aims to further medical knowledge and may improve future intervention and management 
strategies for people at high risk of developing kidney disease. However, it may not directly benefit 
you. 
 
8. ‘Will taking part in this study cost me anything, and will I be paid? 
Participation in this study will not cost you anything.  
 
9. ‘How will my confidentiality be protected?’ 
Of the people treating you, only University researchers, community pharmacist and GP involved in 
your care will know whether or not you are participating in this study. Any identifiable information 
that is collected about you in connection with this study will remain confidential and will be disclosed 
only with your permission, or except as required by law. Only the researchers named above will have 
access to your details and results that will be held securely at the University of Tasmania. 
 
10. ‘What happens with the results?’ 
If you give us your permission by signing the consent form, we plan to publish the results in peer-
reviewed journals, presentation at conferences or other professional forums. 
In any publication, information will be provided in such a way that you cannot be identified. Results 
of the study will be provided to you, if you wish. 
 
11. ‘What should I do if I want to discuss this study further before I decide?’ 
When you have read this information, the community pharmacist will discuss it with you and any 
queries you may have. If you would like to know more at any stage, please do not hesitate to contact 
the researchers: Dr Ronald Castelino via e-mail or telephone (Ronald.Castelino@utas.edu.au or +61 3 
6226 1032) or Miss Pankti Gheewala via e-mail on Pankti.Gheewala@utas.edu.au or +61 3 6226 7288) 
 
15. ‘Who should I contact if I have concerns about the conduct of this study?’ 
This study has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this study you should contact the 
Executive Officer of the HREC (Tasmania) Network on (03) 6226 7479 or email 
human.ethics@utas.edu.au The Executive Officer is the person nominated to receive complaints from 
research participants. You will need to quote [H0014258]. 
 
This information sheet is for you to keep. If you wish to take part in it, please sign the consent 
form. If you decide not to participate in the study, kindly fill out 5 questions at the back of this 
form. Thank you for taking the time to consider this study. 
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Questionnaire for people who chose not to participate in the study 
  
1. Age (years) 
□ 50-59 
□ 60-69 
□ 70-74 
 
2. Gender 
□ Male 
□ Female 
 
3. I came to learn about the study via: 
□ Poster 
□ Pharmacist 
□ Friends/Family 
□ Other 
Please specify 
 
 
4. Medical History: 
□ High blood pressure 
□ Diabetes 
□ Heart disease 
□ Other 
Please specify 
 
 
Please rate your agreement with the statements provided below ranging from strongly disagree to 
strongly agree by ticking the appropriate boxes against the statement 
 Strongly 
disagree 
Disagree Neither 
disagree 
or agree 
Agree Strongly 
agree 
I found that the information sheet 
provided to me regarding the study was 
easy to read 
□1 □2 □3 □4 □5 
I found that the information sheet 
provided to me regarding the study was 
easy to understand 
□1 □2 □3 □4 □5 
 
Please specify below why you chose not to participate in the study 
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Thank you for your time and assistance in completing this questionnaire 
Appendix 3.4 Participant consent form 
 
Participant Consent Form 
 
1. I acknowledge that the nature, purpose and contemplated effects of the screening study so far as it 
affects me, have been fully explained to my satisfaction by the research worker and my consent is 
given voluntarily. 
 
2. I have been given the opportunity to have a member of my family or friend present while the study 
was explained to me. 
 
3. The details of the procedure proposed have also been explained to me, including the anticipated 
length of time it will take, the frequency with which the procedure will be performed, and an 
indication of any discomfort, which may be expected.  
 
4. I understand that my involvement means: 
a. I will be asked to fill out a data form which includes questions related to 
i. Demographics (name, age, gender, date of birth, ethnicity, address, contact number) 
ii. General practitioner (GP) details (GP name, general practice name and address) 
iii. Clinical information (smoking status, medical history, family history) 
iv. Medication history (prescription drugs, over the counter drugs, complimentary and herbal 
medications) 
b. My height, weight and blood pressure will be measured and recorded. 
c. My risk of developing moderate-severe kidney disease over the next 5 years will be determined 
using the screening calculator known as ‘Qkidney® Risk Calculator’ and recorded. 
d. My screening results will be explained to me in detail and I will be advised on appropriate 
action that needs to be taken based on my screening results.  
e. The entire process may take 15-20 minutes. 
f. That the appropriate action advised to me based on my screening results may or may not 
involve a comprehensive follow up with my general practitioner (GP) that requires a kidney 
health check.  
g. My GP might ask me to undergo a blood test, urine test and also, measure my blood pressure 
to further investigate kidney disease.  
h. If I was identified with at least a 3% risk of developing moderate-severe kidney disease over the 
next 5 years, then the pharmacist will send a letter to my GP stating that I have undergone the 
screening study and give details on my screening results. 
i. If I will be asked to undergo the laboratory tests such as urine test or blood test by my GP, then 
this information will be collected by the research team from my pathology provider. 
j. I will be approached by the researchers after a period of 6 months by telephone questionnaire 
to determine whether appropriate action was taken for management of kidney disease, if I was 
identified with at least a 3% 5-year risk of moderate-severe kidney disease.  
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k. I will be invited to participate in a survey by the researchers at the end of the study which will 
approximately take 5 minutes. 
 
5. I understand that there are the following risks or possible discomfort: 
• Possible discomfort due to the underlying medical condition 
• Possible discomfort due to not clearly understanding the scientific reasons for the questions 
being asked. 
• Possible discomfort if I am diagnosed at a risk of developing moderate-severe kidney disease 
in the next 5 years. 
 
6. Although I understand that the purpose of this screening study is to improve the quality of medical 
care, it has also been explained that my involvement may not be of any benefit to me.  
 
7. I understand that the researchers will maintain my confidentiality and that any information I 
supply will be used only for the purposes of research. My data will only be identifiable by a unique 
participant ID. 
 
8. I understand that the questionnaire and survey will be securely destroyed immediately on 
completion of the study and that any information I provide on the questionnaire will be identifiable 
only by my participant ID, kept confidential, and viewed only by the researchers. 
 
9. I understand that all the research data will be securely stored on the University of Tasmania 
premises for a period of 7 years, and will then be securely destroyed when no longer required. 
 
10. I understand that research data gathered from me for the study will be published provided that I 
cannot be identified as a participant. 
 
11. I understand that my involvement in the project will not affect my relationship with my medical 
advisers in their management of my health.  I am aware that if I decide to withdraw from the study 
at any time I can do so without any effect and I may also request to withdraw data that I may have 
supplied for the purpose of the study. My withdrawal will not affect my legal rights, my medical 
care or my relationship with the hospital or my GP. 
 
12. I am aware that I am not giving up my legal rights by signing this consent form.  
 
13. I understand that the study will be conducted in accordance with the latest versions of the National 
Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws. 
 
Name of participant  
Signature of participant  
Date 
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14. I have explained this project and the implications of participation in it to this volunteer and I believe
that the consent is informed and that he/she understands the implications of participation.
Name of investigator Ronald L Castelino
Signature of investigator
Date 5/01/2015
Early detection and prevention of CKD 
239 
 
 
 
 
 
Appendix 3.5 Assessment data form 
Qkidney® Assessment Data Form  
 
Name  Gender  
Date of birth  Age  
Ethnicity 
□ White or not stated 
□ Indian 
□ Pakistani 
□ Bangladeshi 
□ Other Asian 
□ Black Caribbean 
□ Black African 
□ Chinese 
□ Other ethnic group 
Address 
 
 
Contact 
number 
 
 
General Practitioner Details 
Name of your general practitioner  
Name of general practice  
Address  
 
Clinical Information 
Smoking 
Status 
□ Non-smoker 
□ Ex-smoker 
□ Light smoker (less than 10/day) 
□ Moderate smoker (10 to 19 /day) 
□ Heavy smoker (20 or over/day) 
Do you have 
Diabetes 
□ Yes 
□ No □ Type 1 
□ Type 2 
Heart failure □ Yes □ No 
Peripheral vascular disease □ Yes □ No 
High blood pressure requiring treatment □ Yes □ No 
Rheumatoid arthritis (not osteoarthritis/”wear and tear”) □ Yes □ No 
Systemic lupus erythematosis (SLE) □ Yes □ No 
Have you had 
A heart attack, angina, stroke or transient ischaemic 
attack (TIA) 
□ Yes □ No 
Kidney stones □ Yes □ No 
Family history 
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Do immediate family* have kidney disease  
(*mother, father, brother(s) or sister(s)) 
□ Yes □ No 
 
Medication history 
Prescription drugs 
Drug Dose Frequency 
   
   
   
   
   
   
   
   
   
   
Over the counter (OTC) drugs 
Drug Dose Frequency 
   
   
   
Do you use any 
Complementary Medications  
Herbal Medications  
 
 
For Pharmacist Use Only 
 
Pharmacy ID  Participant ID  
Pharmacist ID  Today’s date  
 
 
This study is being conducted by the Division of Pharmacy, School of Medicine at the University of 
Tasmania and funded by the Tasmanian Community Fund  
 
For more information please contact: 
Dr Ronald Castelino           Miss Pankti Gheewala 
Lecturer in Therapeutics and Pharmacy Practice             BPharm (Honours) 
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Ronald.Castelino@utas.edu.au                             Pankti.Gheewala@utas.edu.au 
+61 3 6226 1032                        +61 3 6226 7288 
 
Reference 
1. Kidney Health Australia. QKIDNEY® RISK ASSESSMENT. 2014. 
http://www.kidney.org.au/HealthProfessionals/QKidneyRiskAssessment/tabid/861/Default.aspx. Accessed 18/06/2014. 
Appendix 3.6 Pharmacist results sheet 
Qkidney® results sheet 
(Pharmacist Copy) 
 
Participant ID  
Pharmacist ID  
 
Body measurement Result 
Height (cm)  
Weight (kg)  
Body mass index (kg/m2)  
 
Blood pressure result  
(mmHg) 
 
Qkidney® risk result 
(Moderate or severe kidney disease) 
 
 
 
Speak to your general practitioner about your results  
□ At the first available opportunity 
 
□ In the next week or two  
 
□ At your next planned visit 
 
If you are at an increased risk of developing moderate or severe kidney disease, you should ask your 
general practitioner for a kidney health check which may include: blood test, urine tests and blood 
pressure. 
 
 
This study is being conducted by the Division of Pharmacy, School of Medicine at the University of 
Tasmania and funded by the Tasmanian Community Fund  
 
For more information please contact: 
Dr Ronald Castelino           Miss Pankti 
Gheewala 
Lecturer in Therapeutics and Pharmacy Practice             BPharm (Honours) 
Ronald.Castelino@utas.edu.au                             
Pankti.Gheewala@utas.edu.au 
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+61 3 6226 1032                        +61 3 6226 7288 
 
Reference 
1. Kidney Health Australia. QKIDNEY® RISK ASSESSMENT. 2014. 
http://www.kidney.org.au/HealthProfessionals/QKidneyRiskAssessment/tabid/861/Default.aspx. Accessed 18/06/2014. 
 
Appendix 3.7 Patient results sheet 
Qkidney® results sheet 
 (Patient Copy) 
 
Name  Today’s date  
Date of birth  Age  
 
Body measurement Result 
Height (cm)  
Weight (kg)  
Body mass index (kg/m2)  
 
Blood pressure result 
(mmHg) 
 
Qkidney® risk result 
(Moderate or severe kidney disease) 
 
 
 
Speak to your general practitioner about your results  
□ At the first available opportunity 
 
□ In the next week or two  
 
□ At your next planned visit 
 
If you are at an increased risk of developing moderate or severe kidney disease, you should ask your 
general practitioner for a kidney health check which may include: blood test, urine tests and blood 
pressure. 
 
 
This study is being conducted by the Division of Pharmacy, School of Medicine at the University of 
Tasmania and funded by the Tasmanian Community Fund  
 
For more information please contact: 
Dr Ronald Castelino          Miss Pankti Gheewala 
Lecturer in Therapeutics and Pharmacy Practice             BPharm (Honours) 
Ronald.Castelino@utas.edu.au                            Pankti.Gheewala@utas.edu.au 
+61 3 6226 1032                        +61 3 6226 7288 
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Appendix 3.8 Health professional advise for participants 
Qkidney® Health Professional Advice 
 
The Qkidney® calculator is used to identify a person’s risk of developing moderate-severe kidney 
disease over the next 5 years. Based on the Qkidney® risk and/or blood pressure results, a 
comprehensive follow up by a general practitioner (GP) may be required that includes: blood test 
(serum creatinine for eGFR), urine test (albumin: creatinine ratio) and blood pressure. The tables below 
outline recommendations for referral to a GP based on Qkidney® risk and/or blood pressure results. 
These recommendations are based on the best information available. They are not intended to indicate 
an exclusive course of action. Variations, taking individual circumstances into account, may be 
appropriate. 
Qkidney® Risk Results 
<3% Referral not typically required 
3-15% Requiring attendance at own general practitioner at next planned visit 
>15% Requiring attendance at own general practitioner in next week or two 
 
Blood Pressure Results 
BP<140/90mmHg Referral not typically required 
BP>140/90mmHg Requiring attendance at own general practitioner at next planned visit 
BP>170/110mmHg Requiring attendance at own general practitioner in next week or two 
BP>180/110mmHg See general practitioner at the first available opportunity 
 
General points to remember 
1. Participant should be aged between 50 and 74 years. 
2. Participant should not have a previous diagnosis of CKD. 
3. Participant should be advised on modifiable risk factors such as quit smoking, weight loss, 
physical activity, blood pressure control etc. as appropriate.  
 
 
This study is being conducted by the Division of Pharmacy, School of Medicine at the University of 
Tasmania and funded by the Tasmanian Community Fund  
 
For more information please contact: 
Dr Ronald Castelino          Miss Pankti Gheewala 
Lecturer in Therapeutics and Pharmacy Practice             BPharm (Honours) 
Ronald.Castelino@utas.edu.au                            Pankti.Gheewala@utas.edu.au 
+61 3 6226 1032                        +61 3 6226 7288 
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Appendix 3.9 Understanding your results 
 
Qkidney® Understanding Your Results 
 
Qkidney® risk score 
The Qkidney® risk score provides an estimate of the risk of someone developing moderate-severe 
kidney disease over the next five years. For example, if someone has a Qkidney® risk score of 30%, then 
on average 30 people in a crowd of 100 people like them would develop moderate-severe kidney 
disease over the next 5 years OR they have ‘3 in 10’ chance of getting moderate-severe kidney disease 
over the next 5 years. 
Blood pressure 
Blood pressure is typically recorded as two numbers; systolic and diastolic. These two numbers are 
written in ratio for e.g. 120/80mmHg.  
Systolic: This is the higher number amongst the two numbers and measures the pressure in the arteries 
when the heart beats. 
Diastolic: This is the smaller number amongst the two numbers and measures the pressure in the 
arteries between the heartbeats. 
If you have kidney disease, then it is recommended that your blood pressure is consistently below 
140/90mmHg.  
If you have diabetes or albumin in your urine, it is recommended that your blood pressure stays below 
130/80mmHg. 
Body mass index (BMI) 
BMI is used to give you an idea of whether you are underweight, overweight or an ideal weight for 
your height. BMI is used as a measure of body fat. It is calculated by using your weight (kilograms) and 
height (meters). The normal BMI for most people is between 18.5 and 25 kg/m2. If a person is 
underweight or overweight, then that can lead to health problems. However, for elder people (>74 
years), general health may be more important than being mildly overweight and some researchers have 
suggested a BMI range of 22-26 kg/m2 as acceptable for older Australians. Waist measurement taken 
below the ribs (usually at the level of navel, and while standing) also compares with your BMI and is a 
way of checking your risk of developing chronic disease. Males of Asian or Aboriginal or Torres Strait 
Islander descent should aim for a waist circumference of less than 90cm. All other males should aim 
for less than 102cm. Females of Asian or Aboriginal or Torres Strait Islander descent should aim for a 
waist circumference of less than 80cm. All other females should aim for less than 88cm. 
 
This study is being conducted by the Division of Pharmacy, School of Medicine at the University of 
Tasmania and funded by the Tasmanian Community Fund  
 
For more information please contact: 
Dr Ronald Castelino          Miss Pankti Gheewala 
Lecturer in Therapeutics and Pharmacy Practice             BPharm (Honours) 
Ronald.Castelino@utas.edu.au                            Pankti.Gheewala@utas.edu.au 
+61 3 6226 1032                        +61 3 6226 7288 
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Appendix 3.10 CKD Educational material for participants 
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Appendix 3.11 Letter to the GP 
Letter to General Practitioner 
Dear Doctor, 
Re: ‘Qkidney® Risk Assessment’ screening study 
Your patient …………………………………. participated in the screening study ‘Early 
identification of chronic kidney disease (CKD) via screening by community pharmacy’ and has 
undergone the ‘Qkidney® Risk Assessment’ screening protocol. This study aims to identify people 
at high risk of developing moderate-severe kidney disease over the next 5 years and is being 
conducted by the Division of pharmacy, School of Medicine, at the University of Tasmania. The 
screening protocol uses ‘Qkidney® Risk Calculator’, a web based calculator for determining 5-year 
risk of developing moderate-severe kidney disease and can be accessed from the ‘Kidney Health 
Australia’ website.  
The QKidney® algorithms were developed based on routinely collected data from many 
thousands of general practices across the United Kingdom and these algorithms have the potential 
to identify high risk patients who might benefit from more detailed assessment, closer monitoring 
or interventions to reduce their risk of kidney disease. The calculator requires height, weight and 
systolic blood pressure measures as well as responses to a few questions that relate to risk factors 
for CKD. It is a great educational tool as people also learn what factors increase their risk of 
developing CKD. 
‘Qkidney® Risk Assessment’ screening study is a prospective cohort study and people with risk 
factors for CKD (such as hypertension, diabetes, heart disease, etc.) and who have not been 
previously diagnosed with CKD were screened to identify their 5-year risk of developing moderate-
severe kidney disease. 
Your patient ……………………….. was identified as an eligible participant for this study and 
undertook the screening protocol on.../../…. The participant had a Qkidney® Risk of …….. for 
developing moderate-severe kidney disease over the next 5 years. 
Please find attached with this letter participant’s Qkidney® Assessment Data Form and 
Qkidney® Results Sheet. 
If you have any questions regarding the study, please contact Dr Ronald Castelino via e-mail or 
telephone (Ronald.Castelino@utas.edu.au or +61 3 6226 1032) or Miss Pankti Gheewala via e-mail on 
Pankti.Gheewala@utas.edu.au or +61 3 6226 7288) 
Yours sincerely, 
Dr Ronald Castelino 
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Appendix 3.12 GP results sheet 
Qkidney® results sheet 
(General Practitioner Copy) 
Participant ID  
 
Body measurement Result 
Height (cm)  
Weight (kg)  
Body mass index (kg/m2)  
 
Blood pressure result 
(mmHg) 
 
Qkidney® risk result 
(Moderate or severe kidney disease) 
 
 
 
Speak to your general practitioner about your results  
□ At the first available opportunity 
 
□ In the next week or two  
 
□ At your next planned visit 
 
If you are at an increased risk of developing moderate or severe kidney disease, you should ask your 
general practitioner for a kidney health check which may include: blood test, urine tests and blood 
pressure. 
 
This study is being conducted by the Division of Pharmacy, School of Medicine at the University of 
Tasmania and funded by the Tasmanian Community Fund  
 
For more information please contact: 
Dr Ronald Castelino          Miss Pankti Gheewala 
Lecturer in Therapeutics and Pharmacy Practice             BPharm (Honours) 
Ronald.Castelino@utas.edu.au                            Pankti.Gheewala@utas.edu.au 
+61 3 6226 1032                        +61 3 6226 7288 
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Appendix 4 PROJECT II (D) 
CHAPTER 5. Patient satisfaction with a chronic kidney disease risk assessment 
service in community pharmacies 
 Chronic kidney disease risk assessment satisfaction questionnaire 
For each of the following statements, please tell us your level of agreement with the chronic kidney 
disease risk assessment service. 1 means that you entirely disagree with the statement and 6 means that 
you agree completely.  
 Strongly 
disagree Disagree 
Somewhat 
Disagree 
Somewhat 
Agree Agree 
Strongly 
agree 
1 Risk assessment raised my 
awareness on chronic kidney 
disease 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
2 Chronic kidney disease risk 
assessment service is useful 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
3 Community pharmacy is a 
convenient place to perform 
chronic kidney disease risk 
assessment service. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
4 The time required to undergo the 
risk assessment process was 
justified. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
5 Privacy provided during the risk 
assessment process was 
acceptable. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
6 I feel comfortable with the 
pharmacist referring my risk 
assessment results to my doctor. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
7 The risk assessment results were 
clearly explained and 
understandable. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
8 Brochures and leaflets provided 
on chronic kidney disease were 
informative. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
9 Overall, I was satisfied with the 
chronic kidney disease risk 
assessment service. 
1 
O 
2 
O 
3 
O 
4 
O 
5 
O 
6 
O 
 
Payment 
Would you be willing to pay for this service if it was 
offered on a regular basis? 
□ Yes □ No 
How much would you be prepared to pay for this service? $ 5 O 
$ 10 
O 
$ 15 
O 
$ 20 
O 
>$ 25 
O 
 
 
Are there any comments you would like to make regarding the chronic kidney disease risk assessment service? 
 
 
 
 
Thank you for your cooperation in completing this survey.  
Your involvement in this study is much appreciated. 
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Appendix 5 PROJECT III 
CHAPTER 6. Knowledge about Chronic Kidney Disease (CKD) in the 
Australian Public Evaluated Using A New Validated Questionnaire: A Cross-
Sectional Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Early detection and prevention of CKD 
251 
 
 
 
 
Appendix 5.1 Chronic kidney disease knowledge questionnaire 
For Sections, 1-5, please answer ‘True’, ‘False’ or ‘I don’t know’ to the following questions: 
Section 1 
No Question True False I don’t know 
1 A person can lead a normal life with one healthy kidney. □ □ □ 
2 Herbal supplements can be effective in treating chronic kidney disease. □ □ □ 
3 Certain medications can help to slow-down the worsening of chronic kidney disease. □ □ □ 
 
Section 2 What functions do the kidney perform in our body?  
No Question True False I don’t know 
4 The kidneys make urine. □ □ □ 
5 The kidneys clean blood. □ □ □ 
6 The kidneys help to keep blood sugar level normal. □ □ □ 
7 The kidneys help to maintain blood pressure. □ □ □ 
8 The kidneys help to breakdown protein in the body. □ □ □ 
9 The kidneys help to keep the bones healthy. □ □ □ 
 
Section 3 Which of the following are commonly used to determine the health of your kidneys?  
No Question True False I don’t know 
10 A blood test. □ □ □ 
11 A urine test. □ □ □ 
12 A faecal (poo) test. □ □ □ 
13 Blood pressure monitoring. □ □ □ 
 
Section 4 What are the risk factors for chronic kidney disease? 
No Question True False I don’t know 
14 Diabetes. □ □ □ 
15 Being female. □ □ □ 
16 High blood pressure. □ □ □ 
17 Heart problems such as heart failure or heart attack. □ □ □ 
18 Excess stress. □ □ □ 
19 Obesity.  □ □ □ 
 
Section 5 What are the signs and symptoms that a person might have if they have advanced chronic kidney disease 
or kidney failure? 
No Question True False I don’t know 
20 Water retention (excess water in the body). □ □ □ 
21 Fever. □ □ □ 
22 Nausea/vomiting. □ □ □ 
23  Loss of appetite. □ □ □ 
24 Increased fatigue (tiredness). □ □ □ 
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Appendix 5.2 Percentage of correct response to individual items on the questionnaire 
Item 
No 
Question 
Correct response (%) 
General 
public 
(n=121) 
Student 
(n=28) 
Nephrologist 
(n=27) 
1* 
A person can lead a normal life with one healthy 
kidney. 
94.2 96.4 100.0 
2 
Herbal supplements can be effective in treating 
chronic kidney disease. 
27.3 82.1 77.8 
3* 
Certain medications can help to slow-down the 
worsening of chronic kidney disease. 
71.9 96.4 100.0 
What functions do the kidneys perform in the body? 
4* The kidneys make urine.  57.0 96.4 100.0 
5* The kidneys clean blood.  68.6 82.1 100.0 
6 
The kidneys help to keep blood sugar level 
normal. 
18.2 50.0 85.2 
7* The kidneys help to maintain blood pressure.  24.8 100.0 100.0 
8 
The kidneys help to breakdown protein in the 
body. 
17.4 57.1 81.5 
9* The kidneys help to keep the bones healthy. 15.7 64.3 100.0 
Which of the following are commonly used to determine health of the kidneys? 
10* A blood test.  77.7 96.4 100.0 
11* A urine test.  82.6 96.4 100.0 
12 A faecal (poo) test. 49.6 89.3 96.3 
13* Blood pressure monitoring.  26.4 57.1 92.6 
What are the risk factors for chronic kidney disease? 
14* Diabetes.  71.9 100.0 100.0 
15 Being female. 39.7 57.1 88.9 
16* High blood pressure. 52.9 100.0 100.0 
17* 
Heart problems such as heart failure or heart 
attack. 
28.9 89.3 81.5 
18 Excess stress. 13.2 35.7 81.5 
19* Obesity. 74.4 89.3 96.3 
What are the signs and symptoms that a person might have if they have advanced chronic 
kidney disease or kidney failure? 
20* Water retention. (excess water in the body) 72.7 82.1 96.3 
21 Fever. 16.5 53.6 100.0 
22* Nausea/vomiting. 49.6 64.3 96.3 
23* Loss of appetite. 43.0 89.3 96.3 
24* Increased fatigue (tiredness).  76.0 100.0 100.0 
*True items. 
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Appendix 5.3 Results of the bivariate analysis performed using one-way ANOVA test 
between individual participant characteristics and total score 
 Total score mean (SD) Df
a F p-value Eta-squaredc 
Post-hoc 
comparison b 
Total 10.34 (5.0)      
Age range (years)  2, 940 6.7 <0.005 0.01 
50 + > 18 – 
29, 30 – 49 
18 – 29 9.9 (5.5)*     
30 – 49 9.8 (5.1)*     
50 + 11.0 (4.5)*     
Education  3, 939 4.7 <0.005 0.01 Higher degree 
or post 
diploma/Bach
elor degree > 
Completed 
highest level 
of school 
Higher degree or post graduate 
diploma/Bachelor degree 11.0 (5.0)*     
Diploma/Vocational 10.5 (4.8)     
Completed highest level of school 9.4 (5.3)*     
Did not complete highest level of school 9.7 (4.7)     
Occupation  5, 937 3.3 <0.01 0.02 
Professional/ 
Managerial > 
Sales/Clerical, 
Unskilled/Lab
ourer 
Professional/Managerial 11.2 (4.7)*     
Sales/Clerical 9.4 (5.4)*     
Technical/Skilled 10.0 (5.2)     
Unskilled/Labourer 8.9 (5.3)*     
Other occupations 10.8 (5.0)     
Do not work 10.4 (4.8)     
Work outside home  2, 940 0.2 0.815 NA 
NA 
Yes, full-time 10.2 (5.2)     
Yes, part-time 10.3 (5.1)     
No (Not employed, student, work at home, 
homemaker, retired, etc.) 10.4 (4.8)     
Gross annual income  3, 939 5.3 <0.005 0.02 Refused < 
Under 
$50,000, 
$50,000 to 
just under 
$100,000, 
$100,000 and 
over 
Under $50,000 10.3 (4.9)*     
$50,000 to just under $100,000 10.6 (4.9)*     
$100,000 and over 10.9 (5.1)*     
Refused 
8.6 (5.1)*     
Marital status  2, 940 7.0 <0.005 0.01 Single/Never 
married < 
Married/Com
mon law, De-
facto or Living 
with a 
partner, 
Divorced/Sep
arated/Wido
wed  
Married/Common law, De-facto or Living 
with a partner 10.5 (4.7)*     
Single/Never married 9.3 (5.6)*     
Divorced/Separated/Widowed 11.1 (4.7)*     
Number of people in the household  4, 938 1.3 0.265 NA 
NA 
One 10.2 (5.2)     
Two 10.6 (4.9)     
Three  10.8 (4.8)     
Four 10.0 (5.0)     
Five or more 9.4 (4.9)     
Area description  3, 939 1.2 0.306 NA 
NA 
Within a capital city 10.4 (5.0)     
Within a major regional city 10.2 (4.9)     
Within a rural town or its surrounds 10.7 (4.8)     
More than 5km from the nearest town 8.8 (5.4)     
Location  7,935 0.6 0.789 NA NA 
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Victoria 10.3 (4.9)     
Western Australia 10.4 (5.2)     
Tasmania 10.2 (4.3)     
ACT 11.8 (4.1)     
Northern Territory 9.7 (1.5)     
NSW 10.6 (5.1)     
Queensland 10.1 (4.9)     
South Australia 9.8 (4.8)     
Do you have any of the following medical condition(s)/illness (es) that require you to take regular medications? 
High blood pressure known as hypertension  2, 940 12.3 <0.001 0.03 
I don’t know 
< Yes, No 
Yes 11.1 (4.4)*     
No 10.3 (5.1)*     
I don’t know 5.4 (5.6)*     
Raised blood sugar known as diabetes  2, 940 12.0 <0.001 0.02 Yes > I don’t 
know, No; 
No > I don’t 
know 
Yes 11.8 (4.0)*     
No 10.3 (5.0)*     
I don’t know 6.1 (5.6)*     
Heart problems such as heart failure or 
heart attack  2, 940 6.0 <0.005 0.01 
I don’t know 
< Yes, No Yes 10.9 (4.8)*     No 10.4 (4.9)*     
I don’t know 6.9 (5.9)*     
Personal history of stroke  2, 940 11.6 <0.001 0.02 
I don’t know 
< Yes, No 
Yes 12.8 (4.6)*     
No 10.4 (4.9)*     
I don’t know 6.1 (5.6)*     
a df values (Between groups, Within groups) 
b Tukey HSD post hoc comparison (p<0.05) 
*, Bold indicates variable with a statistical significance that will be included in the multiple linear regression model 
c Cohen classifies Eta-squared value of 0.01 as a small effect, 0.06 as a medium effect and 0.14 as a large effect. 
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Appendix 5.4 Results of the bivariate analysis performed using Independent t-test between 
individual participant characteristic and total score. 
 Total score Mean (SD) t df p-value 
Eta-
squareda 
Gender  1.19 941 0.24  
Female 10.5 (4.9)     
Male 10.1 (5.0)     
Country of birth  -1.19 941 0.23  
Australia 10.5 (4.9)     
Not Australia 10.0 (5.1)     
Children under 18 years of age  -0.08 941 0.93  
Yes 10.3 (4.9)     
No 10.4 (5.0)     
Are you of Aboriginal or Torres Strait Islander descent?  -0.56 941 0.56  
Yes 9.6 (5.4)     
No 10.4 (5.0)     
Does anyone in your immediate family work as a 
registered healthcare professional e.g. doctor, nurse, 
dietician or pharmacist? 
 1.32 941 0.19  
Yes 11.2 (4.5)     
No 10.3 (5.0)     
Do you have a family history of kidney failure?  3.23 941 <0.01 0.01 
Yes 12.2 (4.6)     
No 10.2 (5.0)     
Bold indicates variable with a statistical significance that will be included in the multiple linear regression model 
a Cohen classifies Eta-squared value of 0.01 as a small effect, 0.06 as a medium effect and 0.14 as a large effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
